0001493152-18-000410.txt : 20180110 0001493152-18-000410.hdr.sgml : 20180110 20180110155335 ACCESSION NUMBER: 0001493152-18-000410 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20180110 DATE AS OF CHANGE: 20180110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Algae Dynamics Corp. CENTRAL INDEX KEY: 0001607679 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-199612 FILM NUMBER: 18521513 BUSINESS ADDRESS: STREET 1: 4120 RIDGEWAY DRIVE, UNIT 37 CITY: MISSISSAUGA STATE: A6 ZIP: L5L 5S9 BUSINESS PHONE: 416-704-3040 MAIL ADDRESS: STREET 1: 4120 RIDGEWAY DRIVE, UNIT 37 CITY: MISSISSAUGA STATE: A6 ZIP: L5L 5S9 FORMER COMPANY: FORMER CONFORMED NAME: Converted Carbon Technologies Corp. DATE OF NAME CHANGE: 20140509 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:
   
  For the quarterly period ended June 30, 2017
   
[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:
   
  For the transition period from ________ to ________

 

Commission File Number: 333-199612

 

Algae Dynamics Corp.

(Exact name of registrant as specified in its charter)

 

Canada   N/A
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

4120 Ridgeway Drive, Unit 37, Mississauga, ON L5L 5S9 Canada
(Address of principal executive offices) (Zip Code)

 

(289) – 997- 6740
(Registrant’s Telephone Number, including area code)

 

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [  ] Yes [ X ] No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [  ] Yes [X] No

 

Indicate by check mark whether the registrant is a large accelerated file, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ]   Accelerated filer [  ]
Non-accelerated filer [  ] (Do not check if a smaller reporting company) Smaller reporting company [X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ]Yes [X] No

 

As of January 2, 2018 there were 13,337,521 shares of the issuer’s non-par value common shares issued and outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
     
  PART I FINANCIAL INFORMATION  
     
Item 1. Financial Statements 3
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 30
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 50
     
Item 4. Controls and Procedures 50
     
  PART II OTHER INFORMATION  
     
Item 1. Legal Proceedings 52
     
Item 1A. Risk Factors 52
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52
     
Item 3. Defaults Upon Senior Securities 53
     
Item 4. Mine Safety Disclosures 53
     
Item 5. Other Information 53
     
Item 6. Exhibits 53

 

 2 

 

 

PART 1 - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

ALGAE DYNAMICS CORP.

Condensed Interim Balance Sheets

(Stated in Canadian Dollars)

(Unaudited)

 

    As at June 30,     As at March 31,  
    2017     2017  
             
ASSETS                
                 
Current Assets                
Cash   $ 1,553     $ 87  
Prepaid expenses     74,745       32,878  
Amounts receivable, net     13,335       11,963  
Total Current Assets     89,633       44,928  
                 
Equipment and leasehold improvements, net (Note 3)     43,901       47,828  
                 
Total Assets   $ 133,534     $ 92,756  
                 
LIABILITIES                
                 
Current Liabilities                
Accounts payable and accrued liabilities   $ 416,035     $ 286,792  
Advances from shareholders and related parties (Note 4)     29,122       22,347  
Promissory note (Note 6a)     48,899       16,456  
Term loan (Note 5)     50,796       48,894  
Convertible notes (Note 6b and 6c)     67,953       26,076  
Derivative liability (Note 7)     217,762       260,677  
Warrant liability (Note 8b)     115,555       236,200  
Total Current Liabilities     946,122       897,442  
                 
Going Concern (Note 1)                
Commitments and Contingencies (Note 10)                
                 
STOCKHOLDERS’ (DEFICIENCY)                
                 
Common stock (Note 8a), no par value, unlimited amount authorized, 13,337,521 issued and outstanding as of June 30, 2017, (March 31, 2017 - 13,337,521)    

4,313,931

      4,313,931  
Additional paid in capital (Notes 8b and 8c)    

1,018,406

      1,016,324  
Equity to be issued (Note 8a)     86,372       -  
Accumulated deficit     (6,231,297 )     (6,134,941 )
Total Stockholders’ (Deficiency)     (812,588 )     (804,686 )
                 
Total Liabilities and Stockholders’ (Deficiency)   $ 133,534     $ 92,756  

 

These condensed interim financial statements are approved by the Directors:

 

signed “Cameron McDonald”   signed “Blair Mullin”
Director   Director

 

The accompanying notes are an integral part of these condensed interim financial statements

 

 3 

 

 

ALGAE DYNAMICS CORP.

Condensed Interim Statements of Operations

(Stated in Canadian Dollars)

(Unaudited)

 

 

   For the   For the 
   Three Month   Three Month 
   Period Ended   Period Ended 
   June 30,   June 30, 
   2017   2016 
         
OPERATING EXPENSES          
Accretion expenses (Notes 5 and 6)  $

73,042

   $5,897 
Application and membership fees   3,406    3,247 
Amortization expense (Note 3)   3,927    4,356 
Bad debt recovery (Note 11)   (3,270)   - 
Business development   422    2,486 
Fair value change in derivative liability (Note 7)   (61,047)   - 
Foreign exchange gain   (5,056)   - 
Interest   2,039    1,045 

Management fee (recovery)

   (8,125)   - 
Occupancy costs   8,315    7,982 
Office and general   2,936    1,607 

Professional fees (recovery) (Notes 8a, 8b, 8c and 12e)

   (16,504)   154,755 
Research and development   85,000    1,075 
Stock based compensation (Note 8c)   18,192    151,105 
Telephone and internet services   3,791    2,857 
Travel   5,398    5,025 
Total Operating Expenses   

112,466

    341,437 
           
Net loss before income taxes   

112,466

    341,437 
Deferred income tax recovery   -    - 
Net Loss for the Period  $

112,466

   $341,437 
           
Net loss per common share - basic and diluted  $0.01   $0.04 
           
Weighted average common shares outstanding - basic and diluted   13,337,521    9,728,634 

 

The accompanying notes are an integral part of these condensed interim financial statements

 

 4 

 

 

ALGAE DYNAMICS CORP.

Condensed Interim Statements of Stockholders’ Equity (Deficiency)

(Stated in Canadian Dollars)

(Unaudited)

 

    Common     Common     Additional                    
    Shares     Shares     Paid in     Equity to     Accumulated     Stockholders’  
    Number     Amount     Capital     be Issued     Deficit     (Deficiency)  
                                     
March 31, 2017     13,337,521     $ 4,313,931     $ 1,016,324     $ -     $ (6,134,941 )   $ (804,686 )
                                                 
Warrants expired (Note 8b)     -       -       (16,110 )     -       16,110       -  
Stock based compensation (Notes 8c)     -       -       18,192       -             18,192  
Shares issued to consultants as compensation for services (Note 8a)     -       -       -       86,372               86,372  
Net loss for the period     -       -       -               (112,466 )     (112,466 )
June 30, 2017    

13,337,521

    $

4,313,931

    $

1,018,406

    $ 86,372     $ (6,231,297 )   $ (812,588 )

 

The accompanying notes are an integral part of these condensed interim financial statements

 

 5 

 

 

ALGAE DYNAMICS CORP.

Condensed Interim Statements of Cash Flows

(Stated in Canadian Dollars)

(Unaudited)

 

   For the   For the 
   Three Month   Three Month 
   Period Ended   Period Ended 
   June 30,   June 30, 
   2017   2016 
         
Cash flows from operating activities          
           
Net loss for the period  $(112,466)  $(341,437)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization   3,927    4,356 
Stock based compensation (Note 8c)   18,192    151,105 
Change in warrant liability (Note 8b)   (179,358)   21,783 
Shares issued and to be issued for services (Note 8a)   86,372    48,651 
Accretion expense   

73,042

    5,897 
Foreign exchange gain   (5,056)   - 
Professional fees   (13,898)   - 
           
Change in operating assets and liabilities          
Prepaid expenses   (41,867)   3,651 
Amounts receivable   (1,372)   254 
Accounts payable and accrued liabilities   129,243    15,294 
Net cash flows used in operating activities   (43,241)   (90,446)
           
Cash flows from financing activities          
Advances from shareholders   6,775    50,855 
Term loan proceeds   -    40,000 
Convertible notes   37,932    - 
Warrant exercise proceeds   -    2,318 
Net cash flows from financing activities   44,707    93,173 
           
Net change in cash   1,466    2,727 
Cash position - beginning of period   87    173 
           
Cash position - end of period  $1,553   $2,900 
           
Supplemental Information:          
           
Income taxes paid  $-   $- 
Interest paid   -    - 
    -    - 

 

The accompanying notes are an integral part of these condensed interim financial statements

 

 6 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

1.) Nature of the Business and Going Concern

 

Algae Dynamics Corp. (the “Company”) was incorporated under the Canada Business Corporations Act on October 7, 2008 as Converted Carbon of Canada Corp. On November 19, 2010, the Company amended its Articles of Incorporation to change its name to Converted Carbon Technologies Corp. and a further amendment was approved by the shareholders on August 28, 2014 to change the name to Algae Dynamics Corp.

 

The Company is conducting research through sponsored research agreements with two universities to support development of health products utilizing cannabis, hemp and algae oil. The Company’s planned principal operations are the sale of oil extracted from cannabis oils plus the sale of uniquely formulated health products utilizing cannabis oils, algae oils and hemp oils.

 

In May 2016, the Company signed a Letter of Engagement with Midtown Partners & Co, LLC to raise additional equity capital to support the implementation of its business plan; an addendum to this agreement was signed on January 17, 2017 and the agreement was extended for one year in August 2017. See Note 10.

 

On May 8, 2017, the Company signed an additional consulting agreement with Carter, Terry & Company in connection with the proposed capital raise in a combination of equity and/or debt of the Company for a term of two years. See Note 10.

 

In August 2017, the Company signed a Letter of Intent (LOI) with an authorized licensed producer of cannabis for medical purposes. See Note 13

 

The Company’s activities are subject to significant risks and uncertainties, including failing to obtain patents and failing to secure additional funding to operationalize the Company’s current technology before another company develops similar technology.

 

These unaudited condensed interim financial statements have been prepared on the basis of a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Company is in the development stage and has not yet realized profitable operations and has relied on non-operational sources to fund operations. The Company has suffered recurring losses and additional future losses are anticipated as the Company has not yet been able to generate revenue. In addition, as of June 30, 2017, the Company has a working capital deficiency of $856,489 (March 31, 2017 - $852,514) and an accumulated deficit of $6,231,297 (March 31, 2017 - $6,134,941). The Company’s ability to continue as a going concern is dependent on successfully executing its business plan, which includes the raising of additional funds. The Company will continue to seek additional forms of debt or equity financing, but it cannot provide assurances that it will be successful in doing so. These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Such adjustments could be material.

 

 7 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

2.) Presentation of Financial Statements

 

Basis of Presentation

 

These unaudited condensed interim financial statements should be read in conjunction with the financial statements for the Company’s most recently completed fiscal year ended March 31, 2017. These unaudited condensed interim financial statements do not include all disclosures required in annual financial statements, but rather are prepared in accordance with recommendations for interim financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These unaudited condensed interim financial statements have been prepared using the same accounting policies, and methods as those used by the Company in the annual financial statements for the year ended March 31, 2017, except when disclosed below.

 

The unaudited condensed interim financial statements contain all adjustments (consisting of only normal recurring adjustments) which are necessary to present fairly the financial position of the Company as at June 30, 2017, and the results of its operations for the three month periods ended June 30, 2017 and 2016 and its cash flows for the three month periods ended June 30, 2017 and 2016. Note disclosures have been presented for material updates to the information previously reported in the annual financial statements.

 

Estimates

 

The preparation of these unaudited condensed interim financial statements has required management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of the revenues and expenses during the reporting period.

 

On an ongoing basis, the Company evaluates its estimates, including those related to provision for doubtful accounts, accrued liabilities and contingencies, and the valuation of income taxes, stock based compensation, warrants, convertible debt and intangible assets. The Company bases its estimates on historical experiences and on various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates. As adjustments become necessary, they are reported in earnings in the period in which they become known.

 

New Accounting Pronouncements

 

ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, was issued to simplify the classification of deferred taxes on the balance sheet. The new guidance would require that deferred taxes be classified as non-current assets and liabilities based on the tax paying jurisdiction. Application of the standard, which can be applied prospectively or retrospectively, is required for fiscal years beginning on or after December 15, 2016 and for interim periods within that year. The adoption of the amended guidance does not have a material impact on the Company’s consolidated financial statements.

 

ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU includes multiple provisions intended to simplify various aspects of the accounting for share-based payments. The areas of simplification in the update involve several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows, however, some of the areas for simplification apply only to non-public entities. This guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The guidance does not have a material impact on the Company’s financial statements.

 

 8 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

3.) Equipment and Leasehold Improvements

 

   June 30, 2017   March 31, 2017 
       Accumulated       Accumulated 
   Cost   Depreciation   Cost   Depreciation 
Computer equipment  $3,558   $2,607   $3,558   $2,530 
Production equipment   67,367    37,249    67,367    35,663 
Leasehold improvements   42,290    

29,458

    42,290    27,194 
Total  $113,215   $69,314   $113,215   $65,387 
Net carrying amount       $43,901        $47,828 

 

During the three month period ended June 30, 2017, the Company recorded total depreciation of $3,927 (2016 - $4,356) which was recorded to depreciation expense on the condensed interim statements of operations.

 

4.) Advances from Shareholders

 

As at June 30, 2017, the Company had received cumulative net working capital advances in the amount of $29,122 (March 31, 2017 - $22,347) from two shareholders who are also officers and directors of the Company. The advances from shareholders are unsecured, non-interest bearing and payable upon demand.

 

5.) Term Loan

 

On May 4, 2016, the Company agreed to a term loan of $40,000 for bridge financing with a relative of one of the officers of the Company. The loan matured on November 30, 2017 and the terms specified a 30% premium to be paid at that time. The 30% premium is recognized as an expense over the term of the loan and is amortized on the statements of operations. During the period ended June 30, 2017 the Company recorded accretion expense of $1,902 (2016 - $5,897). The loan was initially scheduled to mature on August 28, 2016 but an extension of three months, followed by a second extension of three months and followed by a further extension to February 28, 2018 was agreed to with the same terms.

 

6.)

Convertible Notes

   
(a) Promissory Note

 

On February 14, 2017, the Company issued a promissory note to Salamon Partners LLC (“Salamon”), an arm’s length organization, for a principal amount of USD$50,000 ($65,350) at 12% per annum. The net proceeds were USD$47,500 which consisted of the principal amount, net of transaction cost of US$2,500. The principal amount became due on August 15, 2017. The outstanding amount may be prepaid at any time at the option of the Company. In the event of a prepayment the penalty rate shall be assessed as follows:

 

 9 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

6.)

Convertible Notes (continued)

   
(a) Promissory Note (continued)

 

i.) if the prepayment occurs within 60 days of the loan issuance, the prepayment penalty will equal twenty-five (25%) of the principal amount prepaid

 

ii.) If the prepayment occurs within 60 to 90 days of the loan issuance, the prepayment penalty will equal thirty percent (30%) of the principal amount prepaid

 

iii.) If the prepayment occurs within 90 to 120 days of the loan, the prepayment penalty will equal thirty-five (35%) of the principal amount.

 

The holder of the note may, after a period of 180 days, at its sole option, convert the outstanding principal balance and accrued interest of 12% per annum, into the Company’s common shares at a market closing bid discount of 50% if converting at less than 5 days of the average trading volume, 60% if converting at more than 5 days of the average trading volume and 65% if converting at more than 10 days of the average trading volume at maturity.

 

Due to the variable conversion price associated with this promissory note and the fact that the conversion price is denominated in US dollars whereas the functional currency is the Canadian dollar, the Company has determined that the conversion feature is a derivative liability. The value of the embedded conversion feature at the date of issuance was estimated to be $135,510 (2016 - $Nil), which was recorded as a derivative liability as of the date of issuance. The debt discount is being amortized over the term of the promissory note.

 

 10 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

6.) Convertible Notes (continued)
   
(a) Promissory Note (continued)

 

The discount to the carrying value of the promissory note is being amortized as a non-cash interest expense over the term of the promissory note using the effective interest rate method, at a rate of 213%. During the period ended June 30, 2017, the Company accreted $33,623 (2016 - $Nil) in non-cash accretion expense in connection with the promissory note, which is included in accretion expense on the statements of operations.

 

Subsequent to the end of the quarter, the promissory note was fully paid at maturity, August 15, 2017. See Note 13.

 

(b) Securities Purchase Agreement and Convertible Note

 

On November 18, 2016, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with GHS Investments, LLC (“GHS”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, GHS shall purchase from the Company a senior convertible note with a principal amount of USD$56,500 ($76,382) for a purchase price of USD$50,000 ($67,595).

 

The convertible note matures upon the earlier of successfully raising of at least USD$200,000 or August 18, 2017 and accrues interest at the rate of 10% per annum. The convertible note is convertible following ninety (90) days of the execution of the note, in whole or in part, at GHS’ option into common shares of the Company’s capital stock at a variable conversion price equal to a 38% discount from the lowest trading price in the twenty (20) trading days prior to the day that GHS requests conversion. At no time will GHS be entitled to convert any portion of the convertible note to the extent that after such conversion, GHS (together with its affiliates) would beneficially own more than 4.99% of the outstanding common shares, although GHS can modify this limit to 9.99% of the outstanding common shares.

 

The convertible note includes customary event of default provisions, and provides for a default interest rate of 20%. The Company had the right at any time prior to May 18, 2017 to redeem all, but not less than all, of the total outstanding amount then remaining under the convertible note in cash at a price ranging from 125% to 135% of the total amount of the convertible note then outstanding.

 

Due to the variable conversion price associated with this convertible note, the Company has determined that the conversion feature is considered a derivative liability. The embedded conversion feature at the date of issuance was estimated to be $117,807 (2016 - $Nil), which was recorded as a derivative liability as of the date of issuance. The debt discount is being amortized over the term of the convertible note.

 

 11 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

6.) Convertible Notes (continued)
   
(b) Securities Purchase Agreement and Convertible Note (continued)

 

The discount to the carrying value of the convertible note is being amortized as a non-cash interest expense over the term of the convertible note using the effective interest rate method, at a rate of 144%. During the period ended June 30, 2017, the Company accreted $35,776 (2016 - $Nil) in non-cash accretion expense in connection with the convertible note, which is included in accretion expense on the statements of operations.

 

Subsequent to June 30, 2017 the note was fully paid. See Note 13.

 

(c) Convertible Note

 

On June 21, 2017, the Company commenced a financing of up to USD$500,000 of one-year 12% convertible notes. The notes are convertible at the option of the holder into common shares of the Company at a price of USD$0.25 per share, and are subject to mandatory conversion if the volume-weighted trading price of the common shares is greater than USD$1.00 per share for twenty consecutive trading days so long as the underlying shares may be resold in compliance with the registration requirements of the Securities Act of 1933, as amended. In addition, the Company shall issue pro rata to the purchasers of the first USD$100,000 of notes an aggregate of 200,000 common shares as a commitment fee. To June 30, 2017, the Company issued USD$50,000 ($66,451) of these notes. The Company also granted 200,000 common share purchase warrants to the holders of the USD$50,000 notes. Each warrant is exercisable into one common share at USD$0.50 ($0.65) for a period of five years.

 

 12 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

6.) Convertible Notes (continued)

 

(c) Convertible Note (continued)

 

Due to the fact that the conversion price and the warrant exercise price are denominated in US dollars whereas the functional currency is the Canadian dollar, the Company has determined that the conversion feature and the warrant are derivative liabilities. The value of the embedded conversion feature at the date of issuance was estimated to be $19,166, which was recorded as a derivative liability as of the date of issuance. The value of the warrant at the date of the issuance was estimated at $27,152, which was recorded as a warrant liability as of the date of issuance. The debt discount is being amortized over the term of the note.

 

The Company used the Black-Scholes option pricing model with the following assumptions to estimate the fair value of the derivative liability at the date of issuance:

 

    June 21, 2017
Stock price  

USD$0.11

Risk free rate  

0.91%

Expected volatility  

251%

Conversion/Exercise price  

USD$0.25

Expected dividend rate   0%
Expected term (in years)  

1.0

 

The Company’s computation of expected volatility is based on the quoted market close price of the Company’s shares over the period equal to the expected life of the convertible note. The Company’s computation of expected life is calculated using the contractual life.

 

The discount to the carrying value of the convertible note is being amortized as a non-cash interest expense over the term of the convertible note using the effective interest rate method, at a rate of 103%. During the period ended June 30, 2017, the Company accreted $1,741 in non-cash accretion expense in connection with the convertible note, which is included in accretion expense on the statements of operations.

 

 13 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

7.) Derivative Liability

 

The convertible notes discussed in Note 6 have variable conversion prices which results in the conversion feature being recorded as derivative liabilities.

 

The fair value of the derivative liabilities are recorded and shown separately under current liabilities. Changes in the fair value of the derivative liabilities are recorded in the statement of operations.

 

The Company used the Black-Scholes option pricing model with the following weighted average assumptions to estimate the fair value of the derivative liability at June 30, 2017:

 

    June 30, 2017
Stock price   USD$0.10
Risk free rate   1.09%
Expected volatility  

186%

Conversion price  

USD$0.06

Expected dividend rate   0%
Expected life (in years)  

0.20

 

The Company’s computation of expected volatility used to estimate the fair value of the derivative liability as at June 30, 2017 is based on the quoted market close price of the Company’s shares over the period equal to the expected term of the conversion feature.

 

The following table represents the Company’s derivative liabilities activity for the period ended June 30, 2017:

 

   Three months     
   ended   Year ended 
   June 30, 2017   March 31, 2017 
         
Derivative liabilities balance, beginning of period  $260,677   $- 
Issuance of derivative liabilities during the period   19,166    253,318 
Change in derivative liabilities during the period   (62,081)   7,359 
Derivative liabilities balance, end of period  $217,762   $260,677 

 

 14 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

8.) Capital Stock

 

(a) Common Shares

 

Authorized

 

The Company is authorized to issue an unlimited number of common shares with no par value.

 

Issued and Outstanding

  

Equity to be issued

 

On April 9, 2017 the Company signed a 12 month consulting agreement. The terms of the agreement include the provision of 100,000 restricted common shares on signing valued at USD$20,390 ($27,186). See Note10.

 

On May 8, 2017, the Company signed a consulting agreement with Carter, Terry & Company. The terms of the agreement include a non-refundable equity retainer on signing of 150,000 restricted common shares valued at USD$33,000 ($45,197). See Note 10. 

 

Under the terms of convertible notes issued on June 21, 2017 the Company agreed to issue 100,000 restricted common shares as a commitment fee. See Note 6 (c). This commitment was valued at $13,989 based on the estimated fair market value of the shares as of the date of commitment.

 

 15 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

8.)  Capital Stock (continued)

 

(a) Common Shares (continued)

 

Equity to be issued (continued)

 

Equity Purchase Agreement (“EPA”)

 

On September 10, 2015, the Company entered into the EPA. The holder of the EPA was committed to purchase up to USD$750,000 worth of the Company’s common shares (the “Put Shares”) over the 12-month term of the EPA. The Company paid to the holder of the EPA a commitment fee for entering into the EPA equal to 50,000 restricted common shares of the Company, valued at $67,195, based on the stock price in the most recent private placement as the Company’s shares had not yet begun to trade on a public market.

 

On June 23, 2016, the Company agreed in conjunction with RY Capital Group, LLC and GHS Investments, LLC to assign the EPA to GHS Investments, LLC.

 

The Company has notified the holder of the EPA that the facility will not be utilized.

 

 16 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

8.)  Capital Stock (continued)
   

(b) Warrants

 

As at June 30, 2017, the following warrants were outstanding:

 

                          Fair Value at  
          Number of     Weighted         June 30, 2017  
Expiration Date   Number of
Warrants
    Warrants
Exercisable
    Average
Exercise Price
        of Vested Warrants – Liability  
December 31, 2017     275,000       50,000     USD$    0.04              
                    $ (0.05 )       $ 5,050  
January 17, 2022     900,000       900,000     USD$    0.65              
                    $ (0.87 )       $ 82,800  
June 21, 2017     200,000       200,000     USD$   0.50              
                    $ (0.65 )       $ 27,705  
      1,375,000       1,150,000     $ 0.67         $ 115,555  

 

 17 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

8.) Capital Stock (continued)

 

(b) Warrants (continued)

 

During the period ended June 30, 2017, the Company issued 200,000 warrants of the Company valued at $27,152 (USD$20,400), pursuant to the financing described in Note 6 (c). Each warrant entitles the holder to purchase one common share at an issue price of USD$0.50 ($0.65) for a period of 5 years after the date of issuance. The fair value of the warrants at the date of grant of $27,152 was estimated using the Black-Scholes option pricing model, based on the following weighted average assumptions: stock price of USD$0.11; expected dividend yield of 0%; risk free interest rate of 1.13%; expected volatility of 221%; and expected term of 5 years. The Company’s computation of expected volatility used to estimate the fair value of the warrants as at June 30, 2017 is based on the market close price of comparable public entities over the period equal to the expected remaining life of the warrants.

 

ASC 815 “Derivatives and Hedging” indicates that warrants with exercise prices denominated in a currency other than an entity’s functional currency should not be classified as equity. As a result, warrants with a USD exercise price have been treated as derivatives and recorded as liabilities carried at their fair value, with period-to-period changes in the fair value recorded as a gain or loss in the statements of operations.

 

The continuity of warrants for the period ended June 30, 2017 as follows:

 

    Number     Weighted Average  
    of Warrants     Exercise Price  
Balance, March 31, 2017     1,197,500     $ 0.68  
Issued     200,000     $ 0.65  
Expired, unexercised     (22,500 )   $ 1.12  
Balance, June 30, 2017     1,375,000     $ 0.67  

 

As at June 30, 2017, the fair value of the 1,375,000 (March 31, 2017 – 1,175,000) warrants exercisable in US dollars was $139,180 (March 31, 2017 - $298,700) which was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:

 

   June 30, 2017   March 31, 2017 
Expected dividend yield   0%   0%
Expected volatility   175%   229%
Risk free interest rate   1.33%   1.03%
Expected term   3.97 years    3.85 years 

 

 18 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

8.) Capital Stock (continued)

 

(b) Warrants (continued)

 

Of this amount, $115,555 (March 31, 2017 - $236,200) was reflected as a liability as at June 30, 2017, representing the percentage of the fair value of the warrants that is equal to the percentage of the requisite service that has been rendered at June 30, 2017.

 

The warrant liability is classified as Level 3 within the fair value hierarchy (See Note 12). The Company’s computation of expected volatility during the three months ended June 30, 2017 and 2016 is based on the market close price of comparable public entities over the period equal to the expected life of the warrants. The Company’s computation of expected life is calculated using the contractual life.

 

(c) Stock-based compensation

 

The Company’s stock-based compensation program (the “Plan”) includes stock options in which some options vest based on continuous service. For those equity awards that vest based on continuous service, compensation expense is recorded over the service period from the date of grant.

 

The total number of options outstanding as at June 30, 2017 was 695,000 (2016 – 930,000). No options were granted during the three months ended June 30, 2017. The maximum number of options that may be issued under the plan is floating at an amount equivalent to 15% of the issued and outstanding common shares, or 2,000,628 as at June 30, 2017 (March 31, 2017 – 2,000,628).

 

The activities in options outstanding are as noted below:

   Number of   Weighted Average 
   Options   Exercise Price 
Balance, March 31, 2017   695,000   $0.99 
Granted   -   $- 
Balance, June 30, 2017   695,000   $0.99 

 

 19 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

8.) Capita Stock (continued)

 

(c) Stock-based compensation (continued)

 

The following table presents information relating to stock options outstanding and exercisable at June 30, 2017.

 

    Options Outstanding   Options Exercisable 
        Weighted           Weighted 
        Average       Weighted   Average 
        Remaining       Average   Remaining 
    Number of   Contractual   Number of   Exercise   Contractual 
Exercise Price   Options   Life (Years)   Options   Price   Life (Years) 
$1.73    185,000    2.46    185,000   $1.73    2.46 
$2.43    85,000    3.52    85,000   $2.43    3.52 
$0.38    425,000    4.33    

155,833

   $0.38    4.33 
$0.99    695,000    

3.44

    

425,833

   $

1.38

    

3.35

 

 

9.) Income Taxes

 

The Company has no taxable income under Canadian Federal and provincial tax laws for the three month periods ended June 30, 2017 and 2016. The Company has non-capital loss carryforwards at June 30, 2017 totally approximately $3,702,500, which may be offset against future taxable income. If not used, the loss carryforwards will expire between 2019 and 2037.

 

10.) Commitments and Contingencies

 

The Company entered into a five year operating lease for office and production facilities. The lease commenced on December 1, 2013 and expires on November 30, 2018. The base monthly rental is $1,390 plus the Company’s estimated portion of property taxes and operating expenses which are currently $847 per month. The future commitments pursuant to this lease arrangement, including property taxes and operating expenses for the fiscal periods ending March 31 are:

 

2018 (remaining)   $ 20,133  
2019   $ 17,896  

 

For the three month period ended June 30, 2017, occupancy costs related to this lease were $6,711 (2016 – $6,525).

 

 20 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

10.) Commitments and Contingencies (continued)

 

On March 11, 2014, and as amended on July 18, September 3, 2014, September 5, 2014, December 31, 2015 and again on December 20, 2016, the Company entered into a consulting agreement with Connectus, Inc. (“Connectus”) to assist and advise the Company in matters concerning corporate finance and the Company’s current and proposed financing activities for the period commencing April 1, 2014 and ending December 31, 2014. Pursuant to this agreement, the Company agreed to issue to Connectus, 625,000 warrants of the Company. Each warrant is exercisable at USD$0.04 ($0.054) per share for a period of three years. Of the warrants granted, 300,000 vested on September 3, 2014 with the unvested portion vesting pro-rata for each USD$250,000 ($335,675) raised in an offering, fully vesting upon USD$1,500,000 ($2,014,050) being raised. During the year ended March 31, 2015, the President of Connectus became a director of the Company. On December 31, 2015, the Company extended the contract to December 31, 2016. In consideration of the contract extension, the Company issued 93,000 common shares to Connectus as compensation, which has been recorded as professional fees on the statements of operations during the year ended March 31, 2016. On December 27, 2016, the Company extended the contract and expiry date of the warrants to December 31, 2017. On January 23, 2017 the Company approved the vesting of 100,000 warrants. Connectus assigned the warrants to Apollo Marketing, LLC.

 

On April 23, 2014, the Company entered into employment agreements with three officers of the Company effective July 1, 2014. The initial contracts contain minimum aggregate commitments of approximately $427,000 per year for three years and additional contingent payments of up to approximately $600,000 in aggregate upon the occurrence of a change of control. The employment agreements were amended whereby any salary from the commencement of the employment agreements has been waived until such a time when the Company is able to raise additional financing. Salaries will be earned and paid at the discretion of the Board.

 

On May 19, 2016, the Company signed a consulting agreement with an agent in connection with proposed placements of up to USD$10,000,000 ($13,427,000) in a combination of equity and or debt of the Company for a term of one year. Consideration payable under the consulting agreement include a non-refundable equity retainer of 100,000 common shares of the Company , a placement fee equal to 8% of the gross purchase price paid for equity of the Company, an administrative fee of 4% of the gross purchase price paid for equity, a placement fee of 4% of the gross purchase price paid for non-convertible debt and warrants to purchase common shares of the Company equal to 8% of the number of shares of common stock issuable by the Company upon exercise or conversion of any and all securities issued at each closing. On January 10, 2017, the Company entered into an addendum to the agreement signed on May 19, 2016 which provided for a grant of 900,000 warrants at an exercise price of USD$0.65 ($0.86) for a period of five years with a cashless exercise option. On August 15, 2017 the Company extended the contract for an additional year.

 

 21 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

10.) Commitments and Contingencies (continued)

 

On February 23, 2017, the Company entered into a three year sponsored research contract with the University of Waterloo commencing on April 1, 2017. Under the terms of the agreement the Company will contribute $130,000 upon start date of the project, $130,000 on completion of Year 1 and $130,000 on completion of Year 2, plus the Company will make an in-kind contribution valued at $70,000 in each of the 3 years. Any patents initiated by the Company from the sponsored research will be assigned to the Company and in return the Company will pay the researcher $10,000 per patent filed, $40,000 per patent issued by the U.S. patent office, $50,000 per product after the first commercial sale and $50,000 per product once the gross sales exceed $1,000,000. As of June 30, 2017, the Company has not made any payments pursuant to this agreement. The payment schedule has been amended to match the cash flow from the capital raise being undertaken by the Company.

 

On March 13, 2017, the Company entered into a four year sponsored research contract with the University of Western Ontario commencing on April 1, 2017. Under the terms of the agreement the Company will contribute $210,000 upon execution of the agreement, $210,000 on completion of Year 1, $210,000 on completion of Year 2 and $210,000 on completion of Year 3, plus the Company will make an in-kind contribution valued at $62,500 in each of the 4 years. Any patents initiated by the Company from the sponsored research will be assigned to the Company and in return the Company will pay the researcher $10,000 per patent filed, $40,000 per patent issued by the U.S. patent office, $50,000 per product after the first commercial sale and $50,000 per product once the gross sales exceed $1,000,000. As of June 30, 2017, the Company has not made any payments pursuant to this agreement. A payment of $50,000 was made on July 28, 2017. The payment schedule has been amended to match the cash flow from the capital raise being undertaken by the Company.

 

On March 27, 2017, the Company entered into a one year agreement with Questrade, Inc. an Investment Dealer to provide guidance on the trading of the Company’s securities and guidance with respect to the promotion of the Company. The Company shall pay Questrade a monthly fee in an amount equal to USD$5,500 for consulting services rendered each month of the term. See Note 13.

 

On April 9, 2017, the Company signed a 12 month consulting agreement effective April 15, 2017 with an arm’s length organization, The Eversull Group Inc, to provide financial public relations, investor, shareholder, press relations and capital search consulting services. Terms of the agreement include the provision of 100,000 restricted shares annually, a minimum monthly retainer of USD$ 2,000 plus a 3% introduction fee for all sources of funding introduced by The Eversull Group, Inc. and accepted by the Company.

 

On May 8, 2017, the Company signed a consulting agreement with Carter, Terry & Company in connection with the proposed raising of capital in a combination of equity and/or debt of the Company for a term of two years. Terms of the agreement include the issuance of 150,000 restricted common shares on signing (see Note 8(a)) plus future consideration payable under the consulting agreement including a placement fee equal to 10% of the gross proceeds raised less than USD$1,000,000 and 8% for gross funds raised in excess of USD$1,000,000, plus the equivalent amount of restricted shares equal to 4% of the capital raised divided by the closing price of the stock on the date of close for a period of two years.

 

See also Note 13 with respect to the Questrade, Inc. claim.

 

 22 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

11.) Related Party Transactions

 

Amounts receivable from an officer in the amount of $3,270 was recovered during the three month period ended June 30, 2017, from an amount of $17,656 previously offset by an allowance for doubtful accounts, leaving a remaining balance in the doubtful account of $14,386.

 

12.) Financial Instruments

 

(a) Liquidity risk

 

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company’s liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company generates cash flow primarily from its financing activities and advances from shareholders. As at June 30, 2017, the Company had cash of $1,553 (March 31, 2017 - $87) to settle current liabilities of $946,122 (March 31, 2017 - $897,442). All of the Company’s financial liabilities other than the warrant liability of $115,555 (March 31, 2017 - $236,200), the term loan of $50,796 (March 31, 2017 - $48,894), the convertible notes of $67,952 (March 31, 2017 - $26,076) a promissory note of $48,899 (March 31, 2017 - $16,456), and derivative liability of $217,763 (March 31, 2017 - $260,677) have contractual maturities of less than 30 days and are subject to normal trade terms. The Company regularly evaluates its cash position to ensure preservation and security of capital as well as liquidity.

 

In the normal course of business, management considers various alternatives to ensure that the Company can meet some of its operating cash flow requirements through financing activities, such as private placements of common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. Management may also consider strategic alternatives, including strategic investments and divestitures. As future operations may be financed out of funds generated from financing activities, the ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the cannabis industry and the Company’s securities in particular. Should the Company elect to satisfy its cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that the efforts to obtain such additional funding will be successful, or achieved on terms favorable to the Company or its existing shareholders. If adequate funds are not available on favorable terms, the Company may have to reduce substantially or eliminate expenditures or obtain funds through other sources such as divestiture or monetization of certain assets or sublicensing (where permitted) of certain rights to certain of the Company’s technologies or products.

 

 23 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

12.) Financial Instruments (continued)

 

(b) Concentration of credit risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits. Cash deposits with a major Canadian chartered bank are insured by the Canadian Deposit Insurance Corporation up to $100,000. As at June 30, 2017, the Company held $1,553 (March 31, 2017 - $87) with a major Canadian chartered bank.

 

(c) Foreign exchange risk

 

The Company principally operates within Canada. The Company’s functional currency is the Canadian dollar and major purchases are transacted in Canadian dollars. Certain of the Company’s debt obligations are denominated in U.S. dollars. Management does not hedge its foreign exchange risk.

 

(d) Interest rate risk

 

As at June 30, 2017, the Company does not have any non-fixed interest-bearing debt. Management believes that the interest rate risk concentration with respect to financial instruments included in assets and liabilities has been reduced to the extent presently practicable.

 

(e) Derivative liability – warrant liability

 

In connection with consulting agreements, the Company granted warrants to purchase up to 1,175,000 common shares of the Company as disclosed in Note 8(b). The warrants have an exercise price of USD$0.04 ($0.052) for Connectus warrants, USD$0.65 ($0.85) for Midtown warrants and USD$0.50 ($0.65) for the investment place in June 2017. The Connectus warrants are exercisable at any time prior to December 31, 2017, the Midtown warrants are exercisable at any time prior to January 16, 2022 and the warrants for the investment undertaken in June are exerciseable prior to June 21, 2022. The warrants are accounted for as derivative liabilities because the exercise price is denominated in a currency other than the Company’s functional currency.

 

      Fair Value at       Fair Value Measurement Using
      June 30, 2017       Level 1       Level 2       Level 3  
Derivative liability – Warrants   $

115,555

    $ -     $ -     $ 115,555  

 

 24 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

12.) Financial Instruments (continued)

 

(e) Derivative liability – warrant liability (continued)

 

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (warrant derivative liability) for the periods ended June 30, 2017 and March 31, 2017:

 

    Three months        
    ended     Year ended  
    June 30, 2017     March 31, 2017  
Balance at beginning of year   $ 236,200     $ 27,479  
Derivative instruments granted or vested     27,152       633,000  
Derivative instruments exercised     -       (55,321 )
Change in fair market value, recognized in operations as professional fees     (147,797 )     (368,958 )
Balance at end of period   $ 115,555     $ 236,200  

 

See Note 8 (b)

 

 25 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

12.) Financial Instruments (continued)

 

(f) Derivative liability – conversion options

 

In connection with the Salamon promissory note and the convertible notes (Notes 6(a), (b) and (c)), the Company has determined that the conversion features are considered derivative liabilities due to the variable conversion prices associated with the notes and the fact that the conversion price is denominated in US dollars whereas the functional currency of the Company is the Canadian dollar. See Note 7.

 

      Fair Value at       Fair Value Measurement Using  
      June 30, 2017       Level 1       Level 2       Level 3  
Derivative liability – conversion options   $

217,762

    $ -     $ -     $

217,762

 

 

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (convertible note derivative liability) for the periods ended June 30, 2017 and March 31, 2017:

 

    Three months ended     Year ended
    June 30, 2017     March 31, 2017
Balance at beginning of period   $ 260,677       $ Nil  
Derivative instruments issued     19,166         253,318  
Change in fair market value, recognized in operations as fair value change in derivative liability     (62,081 )       7,359  
Balance at end of period   $ 217,762       $ 260,677  

 

 26 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

13.) Subsequent Events

 

On April 19, 2017, the Company announced plans to form a joint venture corporation with Avanti Rx Analytics Inc. (ARA). The Company would own 96% of the joint venture and ARA would own 4%. As a result of signing the letter of Intent with Bonify on August 10, 2017 (details provided below) the Company will not be proceeding with the joint venture.

 

During the quarter ended June 30, 2017, the Company commenced a financing of up to USD$500,000, see Note 6 (c). The convertible notes include a provision that if the Company raises additional funds under more favourable terms during the life of the convertible note, then the more favourable terms will apply. The Company did raise $358,000 under more favourable terms, see details below, convertible notes.

 

 27 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

13.) Subsequent Events (continued)

 

On August 8, 2017, the Company signed a non-binding Letter of Intent (LOI) with 6779264 Manitoba Ltd dba Bonify (“Bonify”). Bonify is a licensed producer, pursuant to the Access to Cannabis for Medical Purposes Regulations in Canada. In the LOI the Company and Bonify have outlined the following:

 

i)

The purchase and installation of cannabis oil extraction equipment with an estimated cost of $1,450,000 to be jointly agreed upon by the Company and Bonify with the equipment being located in Bonify’s facility. At the end of the agreement, full right and title to the equipment would be assigned to Bonify;

   
ii) The processing of cannabis material supplied by Bonify and other licensed producers in the oil extraction facility;
   
iii) The supply of cannabis oil and algae omega-3 oils to The University of Waterloo and University of Western Ontario to support the sponsored research agreements that the Company has in place with the two universities (See Note 10);
   
iv)

The sharing of direct expenses, and, after adjustment for the market value of cannabis material supplied by Bonify and third parties, sharing of revenues from the sale of cannabis oil and algae-cannabis oil products; and

   
v) The negotiation of a definitive agreement no later than September 30, 2017. The definitive agreement is still being negotiated.

 

Convertible Notes

 

Subsequent to June 30, 2017, the Company raised a total of USD$408,000 ($520,160) through the issue of convertible notes. The convertible notes, totalling USD$358,000 have a maturity of 60 days, an interest rate of 10%, a conversion price of USD$0.07 per share if the price on or around 15 days before maturity is less than US$0.10 or USD$0.10 per share if the closing price per share is USD$0.10 or above at the conversion dates. For the initial convertible note issued on July 25, 2017, of USD$50,000, the Company committed to issue 100,000 common shares as a commitment fee, the maturity is twelve months from the issue date, the interest rate is 12%, plus the Company granted 200,000 common share purchase warrants. . Each warrant is exercisable into one common share at USD$0.50 ($0.65) for a period of five years. See Note 6(c).

 

Part of the proceeds from the convertible notes has been used to repay the convertible notes payable to Salamon Partners LLC and GHS Investments. See Notes 6(a) and (b).

 

See Note 10 for the $50,000 payment made to the University of Western Ontario. 

 

 28 

 

 

Algae Dynamics Corp.

Notes to the Condensed Interim Financial Statements

(Stated in Canadian Dollars)

(Unaudited)

June 30, 2017 and 2016

 

13.) Subsequent Events (continued)

 

On August 15, 2017, the Company engaged a Canadian firm, Kernaghan and Partners Ltd. (the Agent) a fully regulated full service brokerage firm to conduct a capital raise in the Canadian market. In consideration of the services to be rendered the Agents shall receive on the closing date of the offering;

 

i) a work fee of $25,000;
   
ii) cash commission (the Agency Fee”) of 6% of the gross proceeds from the sale of common shares pursuant to the offering, except for sales to persons on the “President’s List”, in respect of which the commission shall be reduced to 2% of the gross proceeds received from such persons;
   
iii) broker warrants entitling the Agent to purchase, equal to the issue price, the number of common shares that is equal to 6% of the number of common shares sold pursuant to the offering, except for sales to persons on the “President’s List”, in respect of which the broker warrants shall entitle the Agent to purchase the number of common shares that is equal to 2% of the number of common shares sold to such persons. The broker warrants shall have a term of 2 years and an exercise price equal to the offering price of the common shares.

 

On October 24, 2017, the Company was named in Small Claims Court entitled Questrade, Inc. versus Algae Dynamics Corp. (the “Claim”).  The Claim seeks payment of $25,000 for payments allegedly owed under a Consulting Agreement with the Company in which Questrade was to provide certain financial advisory services.  The Company has filed a general denial of liability on the basis that services were not provided or alternately disputing the amount claimed. A hearing date of February 6, 2018 has been set.

 

Grant award

 

The Company, as the industry partner, is a participant in a Project Grant of up to $400,000 from the Mitacs Accelerate program, that will be delivered directly by Western University through eligible internships. The financial contribution by the Company which is $180,000 for this grant is part of the funding included in the research agreement the Company signed with the university and announced on March 13, 2017. To-date the Company has paid the initial of six installments to Mitacs, with the remaining installments being invoiced throughout the duration of the project. The balance of the $400,000 award ($220,000) will be provided by Mitacs. The project started on December 1, 2017 and is scheduled to operate for two (2) years. The extent of the announced award from Mitacs of $400,000 to be paid directly to the university is dependent on the funding provided by the Company and on the number of interns actually employed in the project.

 

On November 8, 2017, the Board approved the grant of 850,000 stock options for common shares to directors and officers of the Company (800,000) and external counsel (50,000). In addition, the Board approved the award of an aggregate of 1,050,000 common shares to three management personnel for services rendered, plus the Board cancelled an aggregate of 600,000 common shares awarded in a prior period to the three management personnel.

 

 29 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Caution Regarding Forward-Looking Information

 

This following information specifies certain forward-looking statements of management of Algae Dynamics Corp. (the “Company”). Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may,” “shall,” “could,” “expect,” “estimate,” “anticipate,” “predict,” “probable,” “possible,” “should,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

 

The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. We cannot guaranty that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and, except as required by law, we assume no obligation to update any such forward-looking statements.

 

This Form 10-Q should be read in conjunction with the audited financial statements of the Company included in its Annual Report on Form 10-K for the year ended March 31, 2017, including the notes thereto and the risk factors identified therein. Quarterly results are not necessarily indicative of full-year results.

 

Company Overview

 

Algae Dynamics Corp (ADYNF) is focused on the development of proprietary research and products utilizing cannabis oil and algae oil. The original core of our product development strategy is the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, we have developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

 

Collaborating with prominent Canadian universities is a core part of our plan to bolster cannabis extraction expertise, develop premium products and add to our portfolio of intellectual property. Through our agreements with the University of Waterloo and the University of Western Ontario, the Company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

 

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. The Company also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has relevant experience ranging from public company management and process experience to successful fund raising and commercialization.

 

The Company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. With this strong foundation, we are positioned to execute on our plan to build a revenue-generating, sustainable opportunity in a rapidly expanding market.

 

Sponsored Research Programs

 

In order to support our new mission, we engaged two prominent Canadian universities to provide research and product development in the use of extracts from cannabis oil and algae oil in the context of cancer, and the development of novel pharmacotherapies for mental health, as follows:

 

 30 

 

 

  Dr. Jonathan Blay, PhD, FRSB, FIBMS, Csci, CBiol (Professor of Pharmacy, University of Waterloo, Professor of Pathology, Dalhousie University), the University of Waterloo – to perform research and product development on cannabis oil and its constituents in the context of the development and treatment of the colorectum, pancreas, breast and prostate cancers.
     
Dr. Steven Laviolette, BSc, PhD (Addiction Research Group, Dept. of Anatomy & Cell Biology, Dept. of Psychiatry, Canadian Institute for Military and Veterans Health Research), University of Western Ontario - to perform research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

 

Each research program is a sponsored research program in which the Company pays an agreed amount to each university and in return receives the benefits of the research and the right to acquire the associated intellectual property, based on an agreed fixed payment with no ongoing royalties. The sponsored programs run for three years at the University of Waterloo, at a cost of $600,000 over the three-year life, and for four years at University of Western Ontario, at a cost of $1,000,000 over the life of the program.

 

Collaboration and Supply Agreement

 

We have entered into a letter of intent with 6779264 Manitoba Ltd dba Bonify (“Bonify”) that will provide the Company with several important benefits. We and Bonify have agreed to work together in good faith to finalize definitive documents in a timely manner. Bonify currently holds a Cultivation License pursuant to the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) in Canada with the capability to grow multiple strains of cannabis in its state of the art 320,000 square foot facility. In the letter of intent, we and Bonify agree as follows:

 

The purchase and installation of cannabis oil extraction equipment with an estimated cost of $1,450,000 to be jointly agreed upon by the Company and Bonify with the equipment being located in Bonify’s facility. At the end of the agreement, full right and title to the equipment would be assigned to Bonify;
   
The processing of cannabis material supplied by Bonify and other licensed producers in the oil extraction facility;
   
The supply of cannabis oil and algae omega-3 oils to The University of Waterloo and University of Western Ontario to support the sponsored research agreements that the Company has in place with the two universities (See Note 10);
   
The sharing of direct expenses, and, after adjustment for the market value of cannabis material supplied by Bonify and third parties, sharing of revenues from the sale of cannabis oil and algae-cannabis oil products; and
   
The negotiation of a definitive agreement no later than September 30, 2017. The definitive agreement is still be negotiated.

 

We believe that this relationship is the fastest and surest path to revenues and profits for the Company as the Company will be installing and operating the equipment at the Bonify facility. The term of the agreement is for 3 years from commencement of operations and may be extended by mutual agreement. Should the agreement not be extended we agree to transfer title to the equipment to Bonify. Bonify is currently in the process of obtaining its Sales License to sell cannabis-related products such as cannabis oil. The key benefits of the agreement to the Company are 1) the ability to supply cannabis oil to The University of Waterloo and University of Western Ontario for research purposes, and 2) the potential for a pathway to revenues much faster than if we simply applied for our own licenses. Our current target for commencement of operations is the fourth quarter after completion of necessary financing.

 

 31 

 

 

Achievement of revenue for the Company under the licensing regime of Health Canada

 

Stage 1- Collaboration with an authorized Licensed Producer

 

While we believe that our agreement with Bonify, when fully operational, provides us with a pathway to revenues in the near-term, we also intend to apply for our own licenses – both a Cultivation License and a Sales License.

 

The Cultivation License allows the holder to:

 

  possess, produce, provide, ship, deliver, transport and destroy dried cannabis or cannabis oil;
     
  possess, produce, and destroy cannabis in its natural form, other than marijuana or cannabis oil, for the purpose of producing cannabis oil; and
     
  possess and destroy cannabis, other than marijuana or cannabis oil, for the purpose of conducting in vitro testing that is necessary to determine the cannabinoid content of marijuana or cannabis oil.

 

The Sales License allows the holder to sell dried marijuana and cannabis oil to:

 

  a client of the Company or an individual who is responsible for the client;
     
  a hospital employee, if the purpose is in connection with their employment;
     
  another Licensed Producer;
     
  a Licensed Dealer;
     
  the Minister of Health; and
     
  a person to whom an exemption relating to the substance has been granted under section 56 of the Controlled Drugs and Substances Act (CDSA).

 

The Cultivation Licence will also allow the Licensed holder to apply for an import permit to import dried marijuana cannabis as described by the ACMPR. The Cultivation Licence will also allow the Licensed holder to apply for an export permit to export dried marijuana or cannabis other than marijuana or cannabis oil, for the purpose of conducting in vitro testing that is necessary to determine the cannabinoid content of marijuana or cannabis oil. Last, the Cultivation Licence will allow the Licensed holder to ship dried marijuana or cannabis oil to a health care practitioner in the case referred to in subparagraph 130(1)(f)(iii) of the ACMPR.

 

The ACMPR also provide for licenses and import permits relating to fresh marijuana. The Licences, if received, will not include this permission until applied for separately and approved by Health Canada.

 

 32 

 

 

The ACMPR provides that cannabis in its natural form, other than marijuana or cannabis oil, for the purpose of producing cannabis oil, may be provided, shipped, delivered or transported if it was obtained or produced for that purpose.

 

We do not require similar special licensing with respect to the extraction of Omega-3 oils from algae biomass and related sales.

 

Capital Requirement

 

In order to execute on our strategy as described above, we estimate an initial capital requirement of US$2.5 million to support activities over the following twelve months, including the following:

 

  Payment to the universities to support the sponsored research programs;
     
  Application to Health Canada for licensing under the ACPMR;
     
  Purchase and installation of oil extraction equipment at Bonify’s facility; and
     
  Working capital to support ongoing operations.

 

We have engaged Kernaghan and Partners, a registered full service brokerage firm in Toronto, and Midtown Partners & Co LLC, a registered broker/dealer in New York, to assist with raising the required capital.

 

Stage 2- Achievement of Licensed Producer status.

 

As part of the longer term strategy the Company will be submitting an application to become an Authorized Licensed Producer of Cannabis for Medical Purposes.

 

The ACMPR Licensing Process

 

The market for cannabis (including Medical Marijuana) in Canada is regulated by the Controlled Drugs and Substances Act (CDSA), the ACMPR, the Narcotic Control Regulations, and other applicable law. Health Canada is the primary regulator of the industry as a whole. The ACMPR aims to treat cannabis like any other narcotic used for medical purposes by creating conditions for a new commercial industry that is responsible for its production and distribution.

 

The table below provides a general overview of the licensing process as described by Health Canada:

 

  Summary
   
Step 1 Preliminary Screening: When Health Canada receives an application, preliminary screening is conducted to ensure that the application is complete. Any incomplete applications will be returned to the applicant, and complete applications are assigned an application numbers. The assignment of an application number indicates that the application has completed the preliminary screening stage.
   
Step 2

Enhanced Screening: After being assigned an application number, a more thorough review of the application is conducted to ensure that there is sufficient information to assess whether the requirement of the regulations are met. Specific elements given initial consideration include: the location of the proposed site; risks to public health, safety and security; the proposed security measures; and the credentials of the proposed quality assurance person to meet the good production requirements outlined in Subdivision D of the ACMPR. Health Canada will verify that the applicant has provided notice of the application to the senior official with the local government in the jurisdiction of the proposed site.

 

The applicant is responsible for ensuring that they are in compliance with all applicable provincial, territorial, and municipal legislation, regulations, and bylaws, including zoning restrictions, fire and electrical safety requirements, and waste management requirements.

 

At this step, Health Canada may request additional information that is relevant to the application.

 

 33 

 

 

Step 3 Security Clearance: Once the screening of an application is complete, the security clearance forms for key personnel will be sent for processing. At this point, the Minister for Health will conduct criminal record checks and will review the relevant background of key personnel to assess whether the applicant poses a risk to the integrity of the control of the production and distribution of cannabis under the CDSA. The amount of time required to conduct mandatory security checks varies with each application.
   

Step 4

 

Review: Once all security clearances are obtained, an application will be thoroughly reviewed to validate the information provided. Given the extensive review process, applicants are generally required to communicate with Health Canada multiple times to clarify elements of their application. Health Canada may also request additional information.

 

A detailed review and assessment of physical security plans will be conducted at this stage. Applicants must meet a minimum of a level 7 (as defined in the Directive on Physical Security Requirements for Controlled Substances - Licensed Dealers Security Requirements for the Storage Of Controlled Substances) to be considered for a licence. It is a requirement that physical security comply with the Directive.

 

  Once Health Canada is satisfied that an application is ready for a pre-licence inspection, they will contact the applicant and identify information that needs to be confirmed before a pre- licence inspection can be scheduled. This includes, but may not be limited to, confirming how the applicant has indicated in their application that they would comply with Part 1, Division 1, Subdivision C (Security Measures) of the ACMPR.
   

Step 5

 

Pre-Licence Inspection: When Health Canada is satisfied of the prior steps and when the applicant has confirmed that the site has been fully built and security measures are in place, a Pre-Licence Inspection will be scheduled. The inspection may cover, but is not limited to: Security Measures, Good Production Practices, Packaging, Labelling and Shipping, Registration, and Record Keeping. The purpose of the inspection is to verify that the information submitted to Health Canada is accurate and to assess compliance with the applicable sections of the ACMPR prior to licence approval. Any identified deficiencies will be communicated to the applicant and must be addressed prior to a licence being issued.
   
Step 6

Licensing: Next, the results of the Pre-Licence Inspection are reviewed along with all of the information submitted by the applicant and any other additional relevant information. If it is determined that the issuance of the licence is not likely to create risks to public health, safety or security, including the risk of cannabis being diverted to an illicit market or use, and there are no other grounds for refusing the application, a licence will be issued.

 

Health Canada has introduced a graduated licensing process. Upon approval, applicants will first be issued a production licence. This will enable Health Canada inspectors to confirm that the first batch of marijuana produced meets the production standards and requirements outlined in the ACMPR.

 

The Licensed Producer’s first crop of marijuana will be inspected to establish whether the marijuana meets the Licensed Producer’s specified quality control standards and the Good Production Practices set out in Subdivision D of the ACMPR. Only once Health Canada is satisfied the Licensed Producer meets the requirements of the ACMPR will a licence be amended to allow sale to the public.

 

 34 

 

 

Statutory Reporting Requirements

 

With respect to the management and administration of the Company, the ACMPR will require that:

 

  (a) In order to confirm any information submitted in support of an application for a licence or an amendment or renewal of a licence, an inspector may, at a time during normal business hours and with the reasonable assistance of the Company, inspect the site in respect of which the application was made.
     
  (b) If the Company experiences a theft of cannabis or an unusual waste or disappearance of cannabis that cannot be explained on the basis of normally accepted business activities, the Company must report the occurrence to a member of a police force within 24 hours after becoming aware of it and provide a written report to the Minister within 10 days after becoming aware of the occurrence.
     
  (c) The Company apply for and obtain the Minister’s approval before making a change involving the replacement or the addition of (i) the senior person in charge, (ii) the responsible person in charge and, if applicable, the alternate responsible person in charge, (iii) an officer or director, or (iv) an individual authorized to place an order for cannabis on behalf of the licensed producer.
     
  (d) The Minister be notified not later than five days after the event, if a person ceases to be an officer or director of the Company.
     
  (e) The Minister be notified not later than the next business day if the responsible person in charge of the Company ceases to carry out their duties and there is no person designated as an alternate responsible person in charge.
     
  (f) The Company notify the Minister, within five days after such change, of any change to the method used for keeping records or the telephone number, the facsimile number, or the email address for the Company’s site or each building within the site where the activities are conducted under the Cultivation Licence or the Sales Licence.

 

With respect to future clients of the Company and proposed products sold by the Company if granted the Licences, the ACMPR requires that:

 

  (a) In respect of fresh or dried marijuana or cannabis oil sold by the Company, the Minister be provided with a case report for each serious adverse reaction to the substance within 15 days after the day on which the Licensed Producer becomes aware of the reaction.
     
  (b) The Company annually prepare and maintain a summary report that contains a concise and critical analysis of all adverse reactions to fresh or dried marijuana or cannabis oil sold by the Company that have occurred during the previous 12 months (the serious adverse reaction reports and annual summary reports must be retained for a period of 25 years after the day on which they were made).
     
  (c) The Company report any new dried marijuana equivalency factor determined under section 79 of the ACMPR, and the method used to determine it, at least 10 days before the Company sells fresh cannabis, dried marijuana or cannabis oil, in respect of which the label referred to in section 84 or 88 of the ACMPR indicates the new factor, to a client.
     
  (d) The Company, if provided with the given name, surname, date of birth and gender of an individual by a member of a Canadian police force who requests information in the course of an investigation under the CDSA or the ACMPR, verify in a reasonable manner that the person requesting the information is a member of a Canadian police force. If the person is verified as a member of a Canadian police force, the Company must provide as soon as feasible, within 72 hours after receiving the request, the following information to that Canadian police force:

 

 35 

 

 

  an indication of whether or not the individual is one of the Company’s clients or an individual who is responsible for one of the Company’s clients,
     
  in the case of a Company client, whether the client is registered with the Minister under Part 2 of the ACMPR and, if so, whether the client’s registration with the producer is for the purpose of obtaining an interim supply of fresh or dried marijuana or cannabis oil, marijuana plants or seeds, or both, and
     
  the daily quantity of dried marijuana that is specified in the medical document supporting the client’s registration or that is specified in that individual’s registration with the Minister made under Part 2 of the ACMPR.

 

  (e) The Company provide the Minister with any information that the Minister may require in respect of the records, documents and information referred to in Division 2 of the ACMPR, in the form and at the times that the Minister specifies.

 

Reporting Requirements from the Licences

 

In addition to the above general reporting requirements of the ACMPR, the Licences, if received, will require that the Company report the following additional information to the Office of Controlled Substances of Health Canada on a monthly basis, unless otherwise stated:

 

  (a) The total amount of dried marijuana (kg) tested, approved and ready for sale, produced by the Company during the reporting period.
     
  (b) The total amount of dried marijuana (kg) transferred to the Company from other Licensed Producers during the reporting period.
     
  (c) The total amount of dried marijuana (kg) sold by the Company during the reporting period to (i) registered clients, (ii) other Licensed Producers, (iii) Licensed Dealers, and (iv) other clients.
     
  (d) The total number of marijuana plants sold during the reporting period.
     
  (e) The number of clients of the Company at the end of the reporting period, including only those clients whose registrations were valid on the last day of the reporting period, and the total number new clients of the Company registered during the reporting period.
     
  (f) The number of clients who attempted to register with the Company during the reporting period, but could not be registered, regardless of the reason.
     
  (g) The number of clients who placed orders or tried to place orders with the Company that could not be filled during the reporting period, regardless of the reason.
     
  (h) The total amount of the following that the Company has in stock on the final day of the reporting period (i) number of harvested plants in the drying process, (ii) cannabis (kg) that has been dried but not tested, (iii) cannabis (kg) that has been dried and tested but not approved for sale, (iv) cannabis (kg) that has been dried, tested, approved and ready for sale, (v) cannabis (kg) held as samples, (vi) number of marijuana plants identified as ready to be destroyed, (vii) dried marijuana (kg) identified as ready to be destroyed, and (ix) number of live marijuana plants.

 

  (i) The total amount of dried marijuana (kg) that the Company imported and exported during the reporting period.

 

 36 

 

 

  (j) The total amount of dried marijuana (g) lost and/or stolen during the reporting period.
     
  (k) The total amount of dried marijuana (g) destroyed during the reporting period, specifying the reason(s) and amount(s) of each (e.g., contaminated, past expiration date, recalled).
     
  (l) The total amount of waste marijuana (e.g., plants, leaves, twigs) destroyed during the reporting period (g).
     
  (m) The total number of shipments from the Company to the following in each province or territory during the reporting period (i) registered clients, (ii) other Licensed Producers, (iii) Licensed Dealers, and (iv) other clients.
     
  (n) The average and median daily amounts of dried marijuana (g) supported by healthcare practitioners to be used by the Company’s registered clients during the reporting period for all clients whose registrations were valid on the last day of the reporting period.
     
  (o) The average and median amounts of dried marijuana (g) shipped to the Company’s registered clients during the reporting period.
     
  (p) The 10 highest and ten lowest amounts of dried marijuana shipped to registered clients during the reporting period.
     
  (q) The total number of shipments of dried marijuana to registered clients categorized into 10-gram ranges increasing in size from 0 to 10 g to 141 to 150 g.
     
  (r) A list of all healthcare practitioners who provided a medical document for a registered client in the reporting period, the location of the healthcare practitioner and the number of medical documents the healthcare practitioner signed during the reporting period.
     
  (s) The amount of dried marijuana (kg) that the Company expects to produce during each month of the upcoming three months.
     
  (t) The amount of dried marijuana (kg) that the Company expects to have in inventory during each month of the upcoming three months.

 

Legal and Business Context

 

The Company’s business of the development of unique health products and pharmaceuticals that utilize hemp and cannabis oils is rigorously regulated.

 

Legal access to medicinal cannabis or medical marijuana has been a gradual and regulated process in Canada, which started as early as 1999 with the granting of exemptions under the Controlled Drugs and Substances Act (Canada). Following successful court actions in which patients reliant on medical marihuana won legal recognition of their rights to access marihuana as a medicine, the Federal Government implemented the Marihuana Medical Access Regulations (MMAR) in 2001. The MMAR created an initial regime for individuals with a prescription from their health care practitioner in the required form, to possess and use medical marihuana which they grew themselves, or which they purchased from designated producers or a Health Canada supplier.

 

In general, this regime of supply was restrictive, and faced continuing court challenges from users, eventually leading to the implementation of the Marihuana for Medical Purposes Regulations (MMPR) in June 2013, providing for an expansion of supply based on a regulated private industry of licensed producers of medical marihuana.

 

Over time, court challenges were also mounted to the restrictions in the MMPR, which initially restricted the products made available by Licensed Producers to only dried marihuana. In 2015, the Supreme Court of Canada held that the restriction making only dried medicinal marihuana available to patients was unconstitutional. In response, the Federal Government broadened the scope of available licenses for Licensed Producers to include the production and sale of cannabis oils as well as fresh marihuana leaves and buds.

 

The current ACMPR provides a more advanced and rigorous regulatory regime for the production, distribution and sale of medical marihuana in Canada, and regulates and contemplates the sale of medical marihuana by Licensed Producers to jurisdictions outside of Canada where the use and sale of medical marihuana and derivatives thereof are legally sanctioned.

 

 37 

 

 

Liberalizing Regulatory Environment and Competitive Conditions

 

The ACMPR, like prior regulations, requires patients seeking medical marihuana to obtain medical approval from their health care practitioner and to provide a medical document to a Licensed Producer. However, the ACMPR provisions have simplified the requirements of the MMPR, offering easier access to medical marihuana in Canada.

 

According to Health Canada, more than 167,000 patients had enrolled with Licensed Producers under the ACMPR regime by March 31, 2017. Health Canada also indicates that, as of March 31, 2017, the average amount of dried marihuana for medical purposes authorized per client was 2.4 grams per day. For further information, see the Health Canada website at:

 

http://www.hc-sc.gc.ca/dhpmps/marihuana/info/market-marche-eng.php.

 

Further information has recently been released by Canada’s Parliamentary Budget Officer (the “PBO”) in its November 1, 2016 report, which estimates that, in 2018, an estimated 4.6 million individuals aged 15 and over will use cannabis at least once, representing 655 metric tons of cannabis. This number could rise to 5.2 million individuals by 2021, representing 734 metric tons of cannabis. The PBO stated that the pre-tax price of legal cannabis is projected to be between $6.67 and $8.33 per gram, with a mid-point estimate of $7.50. For further information, see “Legalized Cannabis: Fiscal Considerations”, authored by the Office of the PBO and dated November 1, 2016.

 

Recent Canadian developments on the process for the legalization of cannabis.

 

Task Force Report

 

The Task Force on Cannabis Legalization and Regulation (the “Task Force”) appointed by the Federal Government recently released its report entitled “A Framework for the Legalization and Regulation of Cannabis”, dated November 30, 2016 (the “Report”). The Task Force makes a number of recommendations in the Report that are relevant to the market for recreational marihuana and, in particular, recommends that the legislation and regulations ultimately put in place by the Federal Government, among other things, do the following:

 

  set a national minimum age of purchase of 18;
     
  apply comprehensive restrictions to the advertising and promotion of cannabis and related merchandise;
     
  allow limited promotion in areas accessible by adults, similar to those restrictions under the Tobacco Act (Canada);
     
  require plain packaging for cannabis products that only display the producer company name, strain name, price, amounts of THC and cannabidiol (CBD), and warnings and other labelling requirements;
     
  impose strict sanctions on false or misleading promotion as well as promotion that encourages excessive consumption, where promotion is allowed;

 

 38 

 

 

  impose requirements to protect children;
     
  impose a price and tax scheme based on potency to discourage purchase of high-potency products;
     
  prohibit mixed products, for example cannabis-infused alcoholic beverages or cannabis products with tobacco, nicotine or caffeine; and
     
  allow for personal cultivation for non-medicinal purposes of up to four plants per residence subject to additional local and safety requirements.

 

Of particular importance, the Task Force recommended that the Federal Government:

 

  continue to regulate the production of cannabis and its derivatives, drawing on the current medicinal marihuana production regime;
     
  use licensing and production controls to encourage a competitive market; and
     
  implement a tracking system to prevent diversion and to allow for product recalls.

 

A full copy of the Report can be found at: http://healthycanadians.gc.ca/task-force-marijuana-groupeetude/framework-cadre/index-eng.php.

 

Legislation introduced to Parliament by the Government of Canada in April 2017

 

The Government of Canada has introduced Bill-45 (Cannabis Act) which is an Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts.

 

The proposed Cannabis Act would create a strict legal framework for controlling the production, distribution, sale and possession of cannabis across Canada.

 

The Act seeks to:

 

  restrict youth access to cannabis
     
  protect young people from promotion or enticements to use cannabis
     
  deter and reduce criminal activity by imposing serious criminal penalties for those breaking the law, especially those who import, export or provide cannabis to youth
     
  protect public health through strict product safety and quality requirements

 

 39 

 

 

  reduce the burden on the criminal justice system
     
  provide for the legal production of cannabis to reduce illegal activities
     
  allow adults to possess and access regulated, quality controlled legal cannabis
     
  enhance public awareness of the health risks associated with cannabis

 

The current program for accessing cannabis for medical purposes would continue under the new Act. Cannabis will remain illegal as the bill moves through the legislative process. If it is approved by Parliament, the bill could become law with a target date of no later than July 2018.

 

Current Status of the legislation

 

In a statement by Prime Minister Justin Trudeau reported by the Toronto Star on Monday June 19, 2017, the Prime Minister stated - The federal government is staying firm on its plan to legalize marijuana by next summer, even if it has to “backstop” provinces that aren’t ready to distribute cannabis or tax it. Worries about the readiness for legalization were aired Monday when a meeting of federal and provincial finance ministers ended with no clear agreement on a coordinated strategy to tax cannabis or even on the principles to guide how it should be taxed. Indeed, behind the scenes several provinces appealed to Ottawa to delay legalization to provide more time to prepare the myriad law enforcement and health moves required by the change. But Ottawa won’t budge on its deadline to legalize marijuana by July 2018, a fact Prime Minister Justin Trudeau made clear Monday. “We gave everyone lots of time,” Trudeau said on Parliament Hill. “We’ve been working for a long time with all the provinces, with municipalities. It is time to move on.” Federal Finance Minister Bill Morneau says the approaching deadline to legalization should spur the work necessary to make it a reality. “We know that to get things done, we need to set a timeline. That’s exactly what we’ve done,” Morneau told reporters after the meeting.

 

Markets

 

We believe that our focus on development of product formulations that utilize both cannabis oil and algae is a niche strategy that will give us a unique market position. While we believe that this strategy is a natural extension of existing, rapidly growing markets, there is limited data available to measure the market opportunity. With that in mind, what follows is a discussion about the cannabis oil market and the algae oil market.

 

While we are aware of developments in the United States regarding the liberalization in certain states regarding recreational and medicinal marijuana, continuing legal uncertainty has led management to focus exclusively on the Canadian market.

 

Market for Cannabis Oil

 

The Canadian oil extraction marketplace is forecast to grow from C$1 million in 2015 to C$1.7 billion in 2020, assuming full legalization in 2018. In terms of conversion from dried marijuana to extracts/oil, due diligence has been conducted on the Colorado market, finding that 45% of dried marijuana users would eventually convert to marijuana extracts/oil. The Company assumes the market would gradually reach an approximate 45% conversion rate by 2018. Source: Mackie Research Capital Corporation, April 8, 2016 – MRCC Estimates

 

CIBC World Markets issued a report in January 2016 that provided some early estimates of the size of the Canadian recreational marihuana market (to be legalized by July 1, 2018). Using the legalized markets in the States of Colorado and Washington as a comparison, it estimated the Canadian recreational marihuana market is in the broad range of $5 billion to $10 billion per year. This compares with estimated annual Canadian liquor sales of between $5 billion and 8.7 billion according to Deloittes. Canaccord Genuity estimates that the number of marihuana users in the first year following the legalization of marihuana will be approximately 4,000,000. Even as an early estimate, this indicates a recreational market size in the order of 4 to 8 times the size of the medical marihuana market in Canada. (please, see the link for complete report)

 

http://research.cibcwm.com//economic_public/download/eijan16.pdf.

 

 40 

 

 

Market for Algae Oil

 

The market data for algae oil presented below is brief since our plan is to utilize algae oil in our products largely to the extent that it complements our products that contain cannabis oil. Whereas until recently, our intention was to commercialize our BioSilo® algae cultivation system for the purpose of selling bulk algae oil, as well as algae biomass, to global markets, our current intention is to utilize the BioSilo system to the extent required to support our internal needs for cannabis/algae oil blends. Any algae oil that is surplus to our mission would be made available to other markets.

 

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain omega-3 fatty acids. Studies have shown that EPA and DHA are important for proper fetal development, including neuronal, retinal, and immune function. EPA and DHA may affect many aspects of cardiovascular function including inflammation, peripheral artery disease, major coronary events, and anticoagulation. EPA and DHA have been linked to promising results in prevention, weight management, and cognitive function in those with very mild Alzheimer’s disease. Source: Advances in Nutrition -An International Review Journal January 2012.

 

(DHA) Algae oil prices currently trade in the range of $60 to $90 per kilogram today depending on DHA concentration and country of origin, however, algae oil typically sells for $70 to $75 per kilogram. (source: F & S May 24th. 2016).

 

The opportunity in the global algae market stood at US$608.0 million in 2015 and is projected to be worth US$1.1 billion by 2024, growing at an annual rate of 7.39% therein. By volume, the market is poised to expand at a 5.32% CAGR between 2016 and 2024. Source: Transparency Market Research (TMR) Sept 20, 2016

 

Algae Used Extensively for DHA Production in Healthcare and F&B Sectors

 

Based on application, DHA production takes the lead in the global algae market and is expected to retain its lead throughout the forecast period. Algal biomass is most extensively used in the production of DHA, which is used in the healthcare, pharmaceutical, and food and beverages sectors. Within this segment, the pharmaceutical application sub-segment held a larger share of just under 28% in 2016, which is expected to decline over the coming years to make room for the protein sales sub-segment.

 

Sales and Distribution

 

We intend to develop marketing channels including but not limited to website promotion, medical doctors, product distributors, as appropriate and in compliance with the regulatory requirements.

 

Initially, we intend to sell our product formulations mainly through Bonify, our collaboration and raw material supply partner. When we have received our Sales License from Health Canada, we expect to broaden our sales and distribution channels to include patients, medical doctors, and product distributors.

 

The Company intends to build brand awareness by working with brand/marketing management professionals, specializing in the medical health market, to have packaged products available for sale to customers.

 

Marketing Strategies and Competition

 

Advertising and marketing of medical marihuana in Canada is regulated by the Food and Drugs Act (Canada) and the Narcotic Control Regulations issued under the Controlled Drugs and Substances Act (Canada). Licensed Producers are strictly prohibited from advertising marihuana products or promoting their use.

 

 41 

 

 

Our marketing activities will be focused on the promotion of the Company and increasing its visibility within the marketplace. Those efforts will include working with numerous client education centers (patient aggregators), which will review the available research data provided by the universities on medical cannabis oils and products available to clients. We believe this scientific data will help clients make educated decisions.

 

We believe we will have significant advantages in the market that will include multiple strain selection and consistently-produced cannabis oil products backed by scientific research that supports the improved effectiveness of each treatment.

 

We are actively preparing to respond to increased market demand that is expected to occur following the coming into force of proposed legislation to legalize and regulate recreational marihuana. We intend to participate fully in the legalized recreational marihuana marketplace, subject to compliance with applicable regulatory requirements.

 

According to Health Canada, there are currently 54 Licensed Producers in total and of these, just over 30 hold Sales Licenses. For further information, see the Health Canada website at: http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/list-eng.php

 

Cannabinoids and Omega-3

 

Cannabis by itself has long been used for medical purposes and in recent decades has gained significant traction in becoming a common and preferred treatment for specific ailments. Cannabis is one of the fastest growing industries in North America. The Company’s new strategic initiative will seek product development and formulation opportunities that combine the benefits of algae and cannabis oils.

 

The Company’s core product development strategy has been the production of high volume specific algae species and extraction of Essential Fatty Acids (EFAs) which is the foundation of the endocannabinoid system (ECS). The ECS is a group of endogenous cannabinoid receptors located in the mammalian brain and throughout the central and peripheral nervous systems, consisting of neuromodulatory lipids and their receptors. The extracted algae Omega 3 oil with high concentrations of DHA is used as a health supplement product. In light of the potential synergies, the Company has developed its strategy which is aimed at developing new products and formulations that combine the health benefits of algae and cannabis oils.

 

Health Benefits of Algae Omega-3 and Cannabis

 

The following are some of the health benefits of algae and cannabis that the Company intends to research further to potentially combine into synergistic products:

 

Algae Omega-3   Cannabis
Detoxes heavy metals and toxins   Reduces stress and anxiety
Supports immune system   Reduces glaucoma and prevents macular degeneration
Fights cancer   Prevents certain cancers
Detoxifies radiation and chemotherapy   Relives pain
Lowers cholesterol and blood glucose levels   Increases appetite
Improves cardiovascular function   Stimulates antioxidant processes
Improves cognitive functioning   Fights multiple sclerosis and schizophrenia
Fights Alzheimer’s disease   Fights neurodegenerative disorders
Reduces antiplatelet effects   Reduces migraines and headaches
Reduces major coronary events   Fights epilepsy
Acts as an anti-inflammatory agent   Fights obesity and metabolic syndrome
Improves memory   Fights anorexia and osteoporosis

 

Research and Product Development Relationships and Scientific Advisors

 

Dr. Jonathan Blay, PhD, FRSB, FIBMS, Csci, CBiol (Professor of Pharmacy, University of Waterloo, Professor of Pathology, Dalhousie University), the University of Waterloo - performs research and product development on cannabis oil and its constituents in the context of the development and treatment of the colorectum, pancreas, breast and prostate cancers.

 

 42 

 

Research/Expertise:

 

  Tumour microenvironment of solid cancers (colorectal carcinoma);
     
  Mechanisms of metastasis and its regulation by proteins at the cell surface; and
     
  Development of drugs (both synthetic and natural product-derived) that interfere with cancer metastasis.

 

Dr. Blay’s research group applies a range of techniques in molecular and cellular biology to understand how cell behavior and the action of existing anticancer drugs are affected by the unique physiology of the cancer. This research involves investigations of chemokine pathways, and tumor-initiating cells; as well as the capacity of both synthetic and natural product-derived agents to interfere with the steps that favor metastasis. Researchers in the group identify novel pathways that may be the targets for future anticancer drugs, both derived from natural products and synthesized with the aid of colleagues through molecular design. The goal is to perform fundamental cancer-related research on botanical oils and their constituents which will carry out studies relating to the cellular safety and known cancer-related potential of components within the oils.

 

His full profile may be seen on the University of Waterloo, website at

 

https://uwaterloo.ca/:https://uwaterloo.ca/pharmacy/people-profiles/jonathan-blay

 

Dr. Steven Laviolette, BSc, PhD (Addiction Research Group, Dept. of Anatomy & Cell Biology, Dept. of Psychiatry, Canadian Institute for Military and Veterans Health Research), University of Western Ontario - performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

 

Research/Expertise:

 

Dr. Laviolette’s research interests explore the interface between neurobiology, psychology and emotion by using an integrative combination of in vivo neuronal electrophysiology and behavioral neuropharmacology. At the general level, Dr. Laviolette is interested in exploring the neurobiological mechanisms that control how the brain processes emotionally salient information and how disturbances in these basic neural processes may lead to disorders such as addiction and schizophrenia

Dr. Laviolette’s investigations into the neurobiology of addiction have focused on nicotine and opiates, both of which represent highly addictive substances and act on pathways in the brain that control reward, motivation and learning. Dr. Laviolette’s research group has characterized and identified specific regions in the mammalian brain that control the ‘switch’ from the non-addicted state, to the addicted state following exposure to drugs of abuse. Their ongoing research seeks to precisely define and identify the neurobiological mechanisms that control the addiction process at the behavioral, molecular and single neuron levels of analysis.

In addition, Dr. Laviolette’s research group is interested in exploring the neuronal mechanisms of emotional associative learning both in single neurons and in specific brain circuits. They have focused on the roles of the endocannabinoid system and specific dopamine receptor populations in the processing of emotionally salient information. Their ongoing research seeks to examine how disturbances in these brain receptor substrates may underlie the distorted sensory processing and emotional associative learning observed in individuals with schizophrenia.

 

 43 

 

 

His full profile may be seen on the University of Western Ontario, website:

 

www.uwo.ca:http://www.schulich.uwo.ca/anatomy/people/bios/faculty/laviolette_steve.html

 

Dr. Kirsten Muller (PhD) – Lead Phycologist

 

Over 10 years’ experience researching and cultivating algae. Currently Associate Professor at the University of Waterloo and Associate Director of the Canadian Phycology Culture Centre (CPCC), which is housed within her laboratory at the University of Waterloo (500 species). She has authored over 25 papers in leading phycology journals and has received many national and international research awards. Dr. Muller won The Luigi Provasoli Award in recognition of authoring the outstanding paper published in the Journal of Phycology (Phycological Society of America) during 2011.

 

Dr. Brendan McConkey (PhD) – Oil Analysis

 

Over 7 years’ research experience as Associate Professor at the University of Waterloo. His areas of expertise include proteomics, biochemistry, toxicology, and computational biology. Research emphasis has been on interdisciplinary approaches that combine biology, chemical engineering, and computational research.

 

BioSilo®

 

Algae Dynamics has engineered a proprietary algae production technology, the Algae Dynamics BioSilo®, which maximizes growth and purity, while minimizing its footprint through a modular design. It allows us to cultivate a wide variety of algae species tailored to the nutrient and purity requirements of our prospective customers. BioSilo® is a novel method of cultivating algae that combines the positive features of open pond systems with those of enclosed photobioreactor algae production systems. The system produces a continuous supply of ultra-pure algae biomass in high volumes. The design’s small footprint and scalability results in very low maintenance cost. The BioSilo ® is capable of producing a variety of species, including Chlorella and algae suited for Omega-3 rich Algae oil.

 

Intellectual Property

 

Our intellectual property currently pertains to the legacy business plan of commercialization of our BioSilo algae cultivation system. The development of BioSilo is commercially relevant in the context of our missions of developing unique products that contain cannabis and algae oils.

 

The following is our approach to intellectual property protection historically. Firstly, a United States Patent (US 8,800,202 B2) Bioreactor was issued August 12, 2014, a second US patent (US 14/334,909) has been filed and a Patent Application (CA 2,735,635) on the same claims as the U.S. patent has been filed for Canada.

 

The patent abstract is: “Biomass production apparatus is disclosed and comprises a stack of trays, each tray, in use, being in receipt of a respective layer of liquid, the layers being spaced apart from one another such that each layer has associated therewith a respective headspace. Light sources are provided for each layer and are disposed in the headspace associated with said each layer, to illuminate, at least in part, said each layer”.

 

Secondly, significant know-how and proprietary in-house knowledge were acquired during development at the University of Waterloo, with the result that the engineering component of intellectual property related to the BioSilo® is a significant part of the “secret sauce”. As well, the Company has identified proprietary algae species isolated by phycology (the study of algae) scientists at the University of Waterloo, Drs. K. Muller and B. McConkey. Algae Dynamics has exclusive access to these species. These species which are not genetically modified have been selected for their high nutrient values.

 

 44 

 

 

Critical Accounting Policy and Estimates

 

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations section discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. In addition, these accounting policies are described at relevant sections in this discussion and analysis and in the notes to the financial statements included in this Quarterly Report on Form 10-Q for the period ended June 30, 2017.

 

All results are presented in Canadian dollars ($) unless otherwise stated.

 

The following discussion and analysis should be read in connection with the Company’s financial statements and related notes thereto, as included in this quarterly report on Form 10-Q.

 

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying financial statements, as well as information relating to the plans of our current management.

 

Results of Operations and Going Concern

 

We are an early stage company with a limited operating history, and we have not begun s to commercialize our products. As a result, we will need to generate significant revenues to achieve and maintain profitability. If our revenues grow slower than anticipated, or if operating expenses exceed expectations, then we may not be able to achieve profitability in the near future or at all, which may depress our stock price. These circumstances raise substantial doubt as to the ability of the company to meet its obligations as they come due and accordingly, the appropriateness, ultimately, of the use of accounting principles applicable to a going concern. The accompanying financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

 

We continue to rely on advances, sale of equity, short term bridge loans to fund operating shortfalls and do not foresee a change in this situation in the immediate future. There can be no assurances that we will continue to be able to access advances and sell equity, without which we will not be able to continue operations. As a result of the bridge financing that is currently being completed and advances from members of management and their families, the Company has adequate capital resources to fund its operations through to the end of January 2018. The Company is currently undertaking a raise via private placement or direct offering to the public of equity in our Company in order to fund operations going forward.

 

The Company is projecting that $2 to $3 Million is required to implement the first phase of the business plan. The initial funding is expected to be comprised of a combination of debt and equity.

 

The financing will provide working capital for the Company to execute its long term plan as well as the purchase and installation of the oil extraction equipment at the Bonify facility in order to facilitate the generation of revenue.

 

If the funding from the private placement or direct offering is not available in a timely manner then management will continue foregoing salaries and operations will be scaled back to operate within the funds available. In the normal course of business, management considers various alternatives to ensure that the Company can meet some of its operating cash flow requirements through financing activities, such as private placements of common shares, preferred share offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. Management may also consider strategic alternatives, including strategic investments and divestitures. As future operations may be financed out of funds generated from financing activities, the ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the cannabis industry and the Company’s securities in particular. Should the Company elect to satisfy its cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that the efforts to obtain such additional funding will be successful, or achieved on terms favorable to the Company or its existing shareholders. If adequate funds are not available on favorable terms, the Company may have to reduce substantially or eliminate expenditures or obtain funds through other sources such as divestiture or monetization of certain assets or sublicensing (where permitted) of certain rights to certain of the Company’s technologies or products.

 

 45 

 

 

For the three months ended June 30, 2017 and 2016

 

Results of Operations and Going Concern

 

We are an early stage company with a limited operating history, and we have not begun to commercialize our products. We have incurred operating losses since our inception in October 2008, and we expect to continue to incur operating losses for the foreseeable future. At June 30, 2017, we had an accumulated deficit of $6,231,297. For the quarters ended June 30, 2017 and 2016, we had a net loss attributable to common stockholders of $112,466, and $341,437, respectively. The more significant expenditures decreased include professional fees which decreased by $171,259 and stock based compensation which decreased by $132,913 during the 3 month period ended June 30, 2017 compared to June 30, 2016. As a result of the Company being in a loss position, we will need to generate significant revenues to achieve and maintain profitability. If our revenues grow slower than anticipated, or if operating expenses exceed expectations, then we may not be able to achieve profitability in the near future or at all. These conditions create an uncertainty as to our ability to continue as a going concern.

 

Results of Operations

 

Revenues

 

We had no revenues for the three months ended June 30, 2017 and 2016 respectively.

 

Operating Expenses

 

The operating expenses decreased in the three month period ended June 30, 2017 $112,466 compared to the same period of 2016 $341,437. This substantial decrease was a result of decreases in professional fees and stock based compensation and the scaling back of operations pending the receipt of financing to continue the business plan. Upon receipt of financing we expect our operating expenses to increase substantially as operating activities are appropriately funded.

 

Other Expenses

 

Nil

 

Net Loss

 

The Company recognized a net loss of $112,466 for the three month period ended June 30, 2017 as compared to a net loss of $341,437 for the same period of 2016. A number of initiatives have been accomplished during the three month period:

 

 

On April 15, 2017 the Company engaged The Eversull Group to provide assistance with the communication to shareholders.

     
 

On April 19, 2017 the Company signed a joint venture agreement with ARA – Avanti Rx Analytics Inc. (ARA) to provide cannabis extraction services. With the signing of the letter of Intent with Bonify the Company will not be proceeding with the ARA joint venture initiative.

     
 

On May 8, 2017 the Company signed a Memorandum of Understanding (MOU) with Bonify for Strategic Collaboration, Material Supply and Product Marketing. Subsequent to the end of the quarter on August 8, 2017 , the MOU was turned into a Letter of Intent to complete a definitive agreement by September 30, 2017; however, the negotiations are still in process.

 

 46 

 

 

 

On May 8, 2017 the Company engaged Carter, Terry and Company an Atlanta based firm to act as a Financial Advisor and Placement Agent to raise capital. Subsequent to the end of the quarter the Company strategically decided to initiate the process to raise capital in the Canadian market as well the intent is to submit an application to be listed on the Canadian Securities Exchange. In order to facilitate this process the Company engaged a registered Toronto based broker dealer to assist with this this process. On August 15, 2017 the Company signed an engagement letter with Toronto based Kernaghan and Partners Ltd. a registered full service broker dealer to assist with the capital raise in the Canadian market

     
  On June 19, 2017, the Company signed a three month contract with Network News Wire to increase brand awareness, to be more transparent and to educate our shareholders about the benefits of cannabis and algae oils for health.
     
 

During the quarter the Company initiated a capital raise for bridge financing to meet the Company’s immediate cash flow requirements until the longer term capital raise being undertaken by Kernaghan and Partners Ltd. takes place. During the quarter USD$50,000 was raised under a bridge financing program and subsequent to the end of the quarter a further USD$408,000 (C$520,160) has been raised.

     
  Subsequent to the end of the quarter a portion of the bridge financing was utilized to pay the initial $50,000 to Western University under the terms of the sponsorship agreement.

 

Liquidity and Capital Resources

 

Net cash used by operating activities was $43,241 and $90,446 for the three month periods ended June 30, 2017 and 2016, respectively. The Company had a working capital deficiency of $856,489 as of June 30, 2017 compared to $852,514 as of March 31, 2017. While the Company continues to incur substantial operating losses, a substantial portion of the operating losses reflect expenses which have been satisfied through the issuance of shares.

 

Furthermore, given the cash shortages the Company has delayed paying trade creditors and professionals pending receipt of expected funds from financing activities.

 

We do not at present have any material commitments for capital expenditures. However, should we execute our business plan as anticipated, we would incur substantial capital expenditures and require financing in addition to the amount required to fund our present operation. When the agreement is completed with Bonify (as discussed under Item 2 – Management’s Discussion and Analysis of Financial Conditions and Results of Operations subsection Collaboaion and Supply Agreement) there will be a potential commitment up to $1,450,000 for capital purchases. In addition, the Company has a commitment to pay under the terms of the Sponsored Research Programs ($340,000 annually), as referenced under Item 2 – Management Discussion and Analysis of Financial Conditions and Results of Operations. The universities have agreed to match the payments under the sponsored research agreements to the cash flow from the cash flow from the capital raise currently being undertaken by the Company.

 

Convertible Note Issued to Teewinot Life Sciences Corporation

 

 

Effective as of October 27, 2017, the Registrant entered into a definitive Note Purchase Agreement with Teewinot Life Sciences Corporation (“Teewinot”) pursuant to which Teewinot invested USD$250,000 in the Registrant in the form of a 10% Senior Convertible Note (the “Note”). The Note converts into common shares automatically on the 45th day after issuance at USD$0.10 per share; provided that if the closing price of the common shares on December 11, 2017 is less than USD$0.10 the then conversion price is adjusted to USD$0.07 per share. The Notes are part of an offering of USD$500,000 of similar notes. The Registrant had previously issued USD$208,000 of similar notes to other investors.

     
  subsequent to the end of the quarter, the bridge financing raised was used to pay the Promissory Note outstanding to Salamon Partners LLC,maturity USD$50,000 at 12% due August 15, 2017. In addition, the Convertible Note due to GHS Investments, LLC was paid.

 

 47 

 

 

Additional financing

 

We continue to rely on advances and sale of equity to fund operating shortfalls and do not foresee a change in this situation in the immediate future. There can be no assurances that we will continue to be able to access advances and sell equity, without which we will not be able to continue operations. As a result of bridge financing which has been completed to date (USD$50,000, C$66,550 during the quarter and USD$408,000 (C$520,160) subsequent to the quarter ending) and advances from members of management and their families, the Company has adequate capital resources to fund its operations through to the end of February 2018. The Company has commenced the process to raise via private placement or direct offering to the public of equity in our Company as early as feasible in order to fund operations going forward.

 

The execution of the business plan has been slowed until the appropriate commitments have been made for funding. In order to move forward the Company entered into an agency agreement with Midtown Partners LLC, a registered broker/dealer based in New York and with Kernaghan and Partners Ltd., a Toronto based registered full service broker with the objective being to raise up to $3 million. The Company is projecting that $2 to $3 million is required to implement the first phase of the business plan. The initial funding is expected to be comprised of a combination of debt and equity.

 

The financing will provide working capital for the Company to execute its long term plan as well as the funds to implement the purchase and installation of the oil extraction equipment at the Bonify facility in order to facilitate the generation of revenue.

 

If the funding from the private placement or direct offering is not available in a timely manner, then management will continue foregoing salaries and operations will be scaled back to operate within the funds available. In the normal course of business, management considers various alternatives to ensure that the Company can meet some of its operating cash flow requirements through financing activities, such as private placements of common shares, preferred share offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. Management may also consider strategic alternatives, including strategic investments and divestitures. As future operations may be financed out of funds generated from financing activities, the ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the cannabis industry and the Company’s securities in particular. Should the Company elect to satisfy its cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that the efforts to obtain such additional funding will be successful, or achieved on terms favorable to the Company or its existing shareholders. If adequate funds are not available on favorable terms, the Company may have to reduce substantially or eliminate expenditures or obtain funds through other sources such as divestiture or monetization of certain assets or sublicensing (where permitted) of certain rights to certain of the Company’s technologies or products.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Critical Accounting Policies and Recent Accounting Pronouncements

 

Critical Accounting Policies

 

The financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”) applied on a consistent basis. The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods.

 

 48 

 

 

We have identified the policies below as critical to our business operations and the understanding of our financial statements. A complete discussion of our accounting policies is included in Note 3 of the annual audited financial statements for the year ended March 31, 2017.

 

Use of estimates

 

The preparation of financial statements in accordance with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from these estimates.

 

Going Concern

 

These financial statements have been prepared on the basis of a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Company is in the development stage and has not yet realized profitable operations and has relied on non-operational sources to fund operations. The Company has suffered recurring losses and additional future losses are anticipated as the Company has not yet been able to generate revenue. In addition, as of June 30, 2017, the Company has a working capital deficiency of $856,489 (March 31, 2017 - $852,514) and an accumulated deficit of $6,231,297 (March 31, 2017 - $6,134,941). The Company’s ability to continue as a going concern is dependent on successfully executing its business plan, which includes the raising of additional funds. The Company will continue to seek additional forms of debt or equity financing, but it cannot provide assurances that it will be successful in doing so. These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Such adjustments could be material.

 

Recent Accounting Pronouncements

 

ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, was issued to simplify the classification of deferred taxes on the balance sheet. The new guidance would require that deferred taxes be classified as non-current assets and liabilities based on the tax paying jurisdiction. Application of the standard, which can be applied prospectively or retrospectively, is required for fiscal years beginning on or after December 15, 2016 and for interim periods within that year. The adoption of the amended guidance does not have a material impact on the Company’s consolidated financial statements.

 

ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. Most notably, this new guidance requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. This new guidance is effective for annual reporting periods beginning after December 15, 2017. The guidance is not expected to have a material impact on the Company’s financial statements.

 

ASU No. 2016-02, Leases (Topic 842), On February 25, 2016, the FASB issued a new standard which requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The new guidance will require the asset and liability to be initially measured at the present value of the lease payments in the statement of financial position. The new guidance will also require the company to recognize interest expense on the lease liability separately from the amortization of the right-use-asset for finance leases and recognize a single lease cost allocated on a straight-line basis over the lease term for operating leases, in the statement of comprehensive income. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early application permitted. The Company is currently evaluating this guidance to determine the impact it may have on the Company’s financial statements.

 

 49 

 

 

ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU includes multiple provisions intended to simplify various aspects of the accounting for share-based payments. The areas of simplification in the update involve several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows, however, some of the areas for simplification apply only to non-public entities. This guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The guidance does not have a material impact on the Company’s financial statements.

 

ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The ASU provides clarity to preparers on the treatment of eight specific items within an entity’s statement of cash flows. The guidance becomes effective for all public entities in fiscal years beginning after December 15, 2017, including interim periods therein. Early adoption of the guidance, including within an interim period, is permitted. We are currently assessing the impact of this modification on the Company’s financial statements.

 

ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. The ASU amends the scope of modification accounting for share-based arrangements and provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The guidance becomes effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. We are currently assessing the impact of this modification on the Company’s financial statements.

 

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 3 Quantitative and Qualitative Disclosure about Market Risk

 

As a smaller reporting company, the Company is not required to provide this disclosure.

 

Item 4. Controls and Procedures.

 

Evaluation of disclosure controls and procedures.

 

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of June 30, 2017, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities Exchange Commission’s rules and forms, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2017, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described below.

 

Our principal executive officers do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officers have determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

 50 

 

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

Management identified the following three material weaknesses that have caused management to conclude that, as of June 30, 2017, our disclosure controls and procedures, and our internal control over financial reporting, were not effective at the reasonable assurance level:

 

  1. We have developed documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act as of the period ending June 30, 2017. We plan to progressively implement the written policies and procedures commencing in the immediate future. However, until all of the internal controls and procedures are fully implemented there will continue to be some weaknesses in the system.
     
  2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Based on the current magnitude of our operations at the present time, it is impractical to employ sufficient staff to fully address the separation of duties issue. As the business plan is implemented and additional staff is required, we will be able to and intend to address this identified weakness.
     
  3. Effective controls over the control environment have not been fully implemented. Specifically, management has not developed and effectively communicated to employees its accounting policies and procedures. This has resulted in inconsistent practices. Further, our Board of Directors has only one independent member. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness. As the expansion plans are implemented, we intend to communicate our accounting policies and procedures to our employees.
     
  4

We did not maintain sufficient personnel with an appropriate level of technical accounting knowledge, experience and training in the application of GAAP commensurate with our complexity and our financial accounting and reporting requirements. This control deficiency is pervasive in nature. Further, there is a reasonable possibility that material misstatements of the financial statements including disclosures will not be prevented or detected on a timely basis as a result.

 

As a result of the material weaknesses identified above, our internal control over financial reporting was not effective as of June 30, 2017.

 

The Company has initiated a program to address the above weaknesses, specifically the Company has implemented a Code of Business Ethics and Conduct policy, an Equal Opportunity policy, a Freedom from Harassment policy, a Substance Abuse policy, a Whistleblower policy and a Fraud policy. While segregation of duties is very difficult in a small company the Company has an internal policy that all major expenditures are collectively approved by the CEO, President and CFO. In addition, the Company has constituted an Audit Committee, consisting of two non-management directors with the Independent Director as the Chair.

 

 51 

 

 

To address the material weaknesses identified, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

 

As part of the implementation strategy for the expansion of the Company we additionally plan to engage a third-party firm to assist us with the development of any additional systems required. We intend to remedy our material weakness with regard to insufficient segregation of duties by hiring additional employees as funding becomes available to implement the business plan in order to segregate duties in a manner that establishes effective internal controls. All such required remedies are dependent on having the financial resources available to complete them.

 

Changes in internal controls.

 

No change in our system of internal control over financial reporting occurred during the period covered by this report, the period ended June 30, 2017, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

On October 24, 2017 the Company was named in Brampton Small Claims Court entitled Questrade, Inc. v. Algae Dynamics Corp. (the “Claim”).  The Claim seeks payment of Cdn$25,000 for payments allegedly owed under a Consulting Agreement with the Company in which Questrade was to provide certain financial advisory services.  The Company has filed a general denial of liability on the basis that services were not provided or alternately disputing the amount claimed. A hearing date of February 6, 2018 has been set.

 

Item 1A. Risk Factors.

 

See the risk factor identified in the Company’s Form 10-K filed for March 31, 2017 which are incorporated by reference.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Recent Sales of Unregistered Securities

 

Issued and Outstanding

 

Nil

 

Shares to be issued

 

On April 9, 2017 the Company signed a 12 month consulting agreement effective April 15, 2017 with an arm’s length organization, The Eversull Group Inc,. to provide financial public relations, investor, shareholder, press relations and capital search consulting services. Terms of the agreement include the provision of 100,000 restricted shares annually, a minimum monthly retainer of USD$ 2,000 plus a 3% introduction fee for all sources of funding introduced by The Eversull Group Inc. and accepted by the Company.

 

On May 8, 2017, the Company signed a consulting agreement with Carter, Terry & Company in connection with the proposed raising of capital in a combination of equity and/or debt of the Company for a term of two years. Consideration payable under the consulting agreement includes a non-refundable equity retainer of 150,000 restricted shares of the Company, a placement fee equal to 10% of the gross proceeds raised less than USD$1,000,000 and 8% for gross funds raised in excess of USD$1,000,000, plus the equivalent amount of restricted shares equal to 4% of the capital raised divided by the closing price of the stock on the date of close for a period of two years.

 

 52 

 

 

During the quarter Company commenced a private placement of up to USD$500,000 of one-year 12% convertible notes (the “Notes”). The Notes are convertible at the option of the holder into common shares of the Company at a price of USD$0.25 per share, and are subject to mandatory conversion if the volume-weighted trading price of the common shares is greater than USD$1.00 per share for twenty consecutive trading days so long as the underlying shares may be resold in compliance with the registration requirements of the Securities Act of 1933, as amended. In addition to the issuance of the Notes, the Company shall issue to the holders 100,000 five-year common share purchase warrants with an exercise price of USD$0.50 for each USD$25,000 principal amount of Notes purchased. Furthermore, the Company shall issue pro rata to the purchasers of the first USD$100,000 of Notes in the Offering an aggregate of 200,000 common shares as a commitment fee. To the end of the quarter the Company issued USD$50,000 of these Notes and subsequent to the end of the quarter a further USD$408,000 (C$520,160) has been raised. As a consequence, at June 30, 2017 the Company had an obligation to issue 100,000 commitment shares.

 

Each of these issuances was exempt from registration under the Securities Act of 1933, as amended by virtue of Section 4(2) thereunder. No commissions were paid in connection with such issuances.

 

Item 3. Defaults Upon Senior Securities.

 

There was a default on the GHS Investment as the covenant under the agreement for the Company to remain current in its reporting. The Convertible Note including the penalty has now been paid in full.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Securities Purchase Agreement and Convertible Note

 

As noted in the Subsequent events note from the Financial Statements for the period ended June 30, 2017, effective as of October 27, 2017, the Registrant entered into a definitive Note Purchase Agreement with Teewinot Life Sciences Corporation (“Teewinot”) pursuant to which Teewinot invested US$250,000 in the Registrant in the form of a 12% Senior Convertible Note (the “Note”). The Note converts into common shares automatically on the 45th day after issuance at US$0.10 per share; provided that if the closing price of the common shares on December 11, 2017 is less than US$0.10 the then conversion price is adjusted to US$0.07 per share. The Notes are part of an offering of US$500,000 of similar notes. The Registrant had previously issued US$208,000 of similar notes to other investors, and anticipates closing the offering shortly.

 

Grant of Shares under the Stock Incentive Plan

 

Effective as of November 8, 2017, the Registrant issued 350,000 common shares of the Corporation to each of Richard Rusiniak, Paul Ramsay, and Ross Eastley in light of their services during 2017 during which they have received no other compensation. In addition to these share issuances, the Registrant granted options to purchase 240,000 options to Messrs. Rusiniak and Ramsay, 200,000 options to Mr. Eastley, 120,000 options to the outside directors and 50,000 to a consultant, such options to be priced at the close of business on November 10, 2017. These shares and the shares underlying the options were registered under the Securities Act by virtue of the Registrant’s Registration Statement on Form S-8.

 

On November 8, 2017 the Board cancelled an aggregate of 600,000 common shares awarded in a prior period to three management personnel.

 

Item 6. Exhibits.

 

31.a Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
31.b Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
32.a Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
32.b Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 53 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Algae Dynamics Corp.
  a Canadian Corporation
     

Date: January 10, 2018

By: /s/ Ross Eastley
    Ross Eastley
    Chief Financial Officer
    (Chief Financial and Principal Accounting Officer)

 

 54 

 

 

EX-31.A 2 ex31-a.htm

 

Exhibit 31 a

 

Certification of Chief Executive Officer,

pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934

 

I, Richard Rusiniak, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Algae Dynamics Corp.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting , to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 10, 2018

 

/s/ Richard Rusiniak  
Richard Rusiniak  
Chief Executive Officer  

 

 

 

 

 

EX-31.B 3 ex31-b.htm

 

Exhibit 31 b

 

Certification of Chief Financial and Principal Accounting Officer,

pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934

 

I, Ross Eastley, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Algae Dynamics Corp.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting , to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 10, 2018

 

/s/ Ross Eastley  
Ross Eastley  
Chief Financial Officer, Principal Accounting Officer  

 

 

 

 

 

 

EX-32.A 4 ex32-a.htm

 

Exhibit 32 a

 

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Quarterly Report of Algae Dynamics Corp. a Canadian corporation (the “Company”) on Form 10-Q for the period ending June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Richard Rusiniak, Chief Executive Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to Algae Dynamics Corp., and will be retained by Algae Dynamics Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

 

/s/ Richard Rusiniak  
Richard Rusiniak  
Chief Executive Officer  

January 10, 2018

 

 

 

 

 

EX-32.B 5 ex32-b.htm

 

Exhibit 32 b

 

Certification of Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Quarterly Report of Algae Dynamics Corp. a Canadian corporation (the “Company”) on Form 10-Q for the period ending June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ross Eastley, Chief Financial Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to Algae Dynamics Corp.., and will be retained by Algae Dynamics Corp. and furnished to the Securities and Exchange Commission or its s9taff upon request.

 

/s/ Ross Eastley  
Ross Eastley  
Chief Financial Officer  

January 10, 2018

 

 

 

 

 

EX-101.INS 6 adynf-20170630.xml XBRL INSTANCE FILE 0001607679 2017-04-01 2017-06-30 0001607679 2017-03-31 0001607679 us-gaap:CommonStockMember 2017-03-31 0001607679 us-gaap:WarrantMember 2016-04-01 2017-03-31 0001607679 us-gaap:WarrantMember 2017-03-31 0001607679 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0001607679 ADYNF:EquitytobeIssuedMember 2017-03-31 0001607679 us-gaap:RetainedEarningsMember 2017-03-31 0001607679 2017-06-30 0001607679 2016-04-01 2016-06-30 0001607679 us-gaap:ComputerEquipmentMember 2017-03-31 0001607679 ADYNF:ProductionEquipmentMember 2017-03-31 0001607679 us-gaap:LeaseholdImprovementsMember 2017-03-31 0001607679 us-gaap:ComputerEquipmentMember 2017-06-30 0001607679 ADYNF:ProductionEquipmentMember 2017-06-30 0001607679 us-gaap:LeaseholdImprovementsMember 2017-06-30 0001607679 2016-05-04 0001607679 2016-05-03 2016-05-04 0001607679 2013-12-01 2013-12-02 0001607679 us-gaap:WarrantMember 2014-09-02 2014-09-03 0001607679 us-gaap:MaximumMember 2016-04-01 2017-03-31 0001607679 ADYNF:CanadianDepositInsuranceCorporationMember 2017-06-30 0001607679 us-gaap:FairValueInputsLevel1Member 2017-06-30 0001607679 us-gaap:FairValueInputsLevel2Member 2017-06-30 0001607679 us-gaap:FairValueInputsLevel3Member 2017-06-30 0001607679 us-gaap:WarrantMember ADYNF:USDMember 2017-03-31 0001607679 us-gaap:WarrantMember ADYNF:USDMember 2014-09-02 2014-09-03 0001607679 ADYNF:ConsultingAgreementMember ADYNF:AgentMember 2016-05-17 2016-05-19 0001607679 ADYNF:ConsultingAgreementMember ADYNF:AgentMember 2016-05-19 0001607679 ADYNF:ConsultingAgreementMember ADYNF:AgentMember ADYNF:USDMember 2016-05-19 0001607679 ADYNF:EmploymentAgreementsMember 2014-04-20 2014-04-23 0001607679 ADYNF:ConnectusIncMember 2015-04-01 2016-03-31 0001607679 ADYNF:ConsultingAgreementMember 2017-06-30 0001607679 ADYNF:ConsultingAgreementMember ADYNF:USDMember 2017-06-30 0001607679 ADYNF:GHSInvestmentsLLCMember ADYNF:ConvertibleNoteMember 2016-11-18 0001607679 ADYNF:GHSInvestmentsLLCMember ADYNF:ConvertibleNoteMember 2016-11-17 2016-11-18 0001607679 ADYNF:GHSInvestmentsLLCMember ADYNF:SecuritiesPurchaseAgreementMember ADYNF:USDMember 2016-11-18 0001607679 ADYNF:GHSInvestmentsLLCMember ADYNF:SecuritiesPurchaseAgreementMember 2016-11-18 0001607679 ADYNF:GHSInvestmentsLLCMember ADYNF:SecuritiesPurchaseAgreementMember ADYNF:USDMember 2016-11-17 2016-11-18 0001607679 ADYNF:GHSInvestmentsLLCMember ADYNF:SecuritiesPurchaseAgreementMember 2016-11-17 2016-11-18 0001607679 ADYNF:GHSInvestmentsLLCMember us-gaap:MaximumMember 2016-11-18 0001607679 ADYNF:SecuritiesPurchaseAgreementandConvertibleNoteMember 2016-11-18 0001607679 ADYNF:SecuritiesPurchaseAgreementandConvertibleNoteMember us-gaap:MinimumMember 2016-11-18 0001607679 ADYNF:SecuritiesPurchaseAgreementandConvertibleNoteMember us-gaap:MaximumMember 2016-11-18 0001607679 ADYNF:TeamLoanMember 2017-04-01 2017-06-30 0001607679 ADYNF:TeamLoanMember 2016-04-01 2016-06-30 0001607679 ADYNF:PromissoryNoteMember 2017-04-01 2017-06-30 0001607679 ADYNF:SalamonPartnersLLCMember 2017-02-14 0001607679 ADYNF:SalamonPartnersLLCMember ADYNF:USDMember 2017-02-14 0001607679 ADYNF:SalamonPartnersLLCMember ADYNF:USDMember 2017-02-13 2017-02-14 0001607679 ADYNF:SalamonPartnersLLCMember ADYNF:WithInSixtyDaysMember 2017-02-14 0001607679 ADYNF:SalamonPartnersLLCMember ADYNF:WithInSixtyToNinetyDaysMember 2017-02-14 0001607679 ADYNF:SalamonPartnersLLCMember ADYNF:WithInNinetyToOneTwentyDaysMember 2017-02-14 0001607679 2017-02-14 0001607679 ADYNF:PromissoryNoteMember 2016-04-01 2016-06-30 0001607679 ADYNF:WarrantsMember 2017-03-31 0001607679 ADYNF:SalamonPartnersLLCMember 2017-02-13 2017-02-14 0001607679 ADYNF:WarrantLiabilityMember 2017-04-01 2017-06-30 0001607679 ADYNF:DerivativeLiabilityMember ADYNF:USDMember 2017-06-30 0001607679 ADYNF:ConsultingAgreementMember 2017-01-07 2017-01-10 0001607679 ADYNF:ConsultingAgreementMember 2017-01-10 0001607679 ADYNF:ConsultingAgreementMember ADYNF:USDMember 2017-01-10 0001607679 ADYNF:ThreeYearSponsoredResearchContractMember 2017-02-22 2017-02-23 0001607679 ADYNF:ThreeYearSponsoredResearchContractMember ADYNF:YearOneMember 2017-02-22 2017-02-23 0001607679 ADYNF:ThreeYearSponsoredResearchContractMember ADYNF:YearTwoMember 2017-02-22 2017-02-23 0001607679 ADYNF:ThreeYearSponsoredResearchContractMember ADYNF:YearThreeMember 2017-02-22 2017-02-23 0001607679 ADYNF:FourYearSponsoredResearchContractMember 2017-03-12 2017-03-13 0001607679 ADYNF:FourYearSponsoredResearchContractMember ADYNF:YearOneMember 2017-03-12 2017-03-13 0001607679 ADYNF:FourYearSponsoredResearchContractMember ADYNF:YearTwoMember 2017-03-12 2017-03-13 0001607679 ADYNF:FourYearSponsoredResearchContractMember ADYNF:YearThreeMember 2017-03-12 2017-03-13 0001607679 ADYNF:FourYearSponsoredResearchContractMember ADYNF:YearFourMember 2017-03-12 2017-03-13 0001607679 ADYNF:OneYearAgreementMember 2017-03-25 2017-03-27 0001607679 ADYNF:ConsultingAgreementMember ADYNF:MidtownWarrantMember 2017-06-30 0001607679 ADYNF:ConsultingAgreementMember ADYNF:USDMember ADYNF:MidtownWarrantMember 2017-06-30 0001607679 us-gaap:FairValueInputsLevel1Member ADYNF:WarrantLiabilityMember 2017-06-30 0001607679 us-gaap:FairValueInputsLevel2Member ADYNF:WarrantLiabilityMember 2017-06-30 0001607679 us-gaap:FairValueInputsLevel3Member ADYNF:WarrantLiabilityMember 2017-06-30 0001607679 ADYNF:WarrantLiabilityMember 2017-06-30 0001607679 ADYNF:WarrantLiabilityMember 2016-04-01 2017-03-31 0001607679 ADYNF:WarrantLiabilityMember 2016-03-31 0001607679 ADYNF:SecuritiesPurchaseAgreementandConvertibleNoteMember 2017-06-30 0001607679 ADYNF:SecuritiesPurchaseAgreementandConvertibleNoteMember 2017-04-01 2017-06-30 0001607679 ADYNF:SecuritiesPurchaseAgreementandConvertibleNoteMember 2016-04-01 2016-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:JointVentureMember 2017-04-19 0001607679 us-gaap:SubsequentEventMember ADYNF:ARAMember 2017-04-19 0001607679 us-gaap:SubsequentEventMember ADYNF:USDMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:USDMember 2017-04-01 2017-06-30 0001607679 ADYNF:ThreeYearSponsoredResearchContractMember ADYNF:USPatentOfficeMember 2017-02-23 0001607679 ADYNF:ThreeYearSponsoredResearchContractMember ADYNF:AfterFirstCommercialSaleMember 2017-02-23 0001607679 ADYNF:FourYearSponsoredResearchContractMember ADYNF:USPatentOfficeMember 2017-03-13 0001607679 ADYNF:FourYearSponsoredResearchContractMember ADYNF:AfterFirstCommercialSaleMember 2017-03-13 0001607679 ADYNF:FourYearSponsoredResearchContractMember ADYNF:JulyTwentyEightTwoThousandAndSeventeenMember 2017-04-01 2017-06-30 0001607679 2018-01-02 0001607679 2016-03-31 0001607679 2016-06-30 0001607679 ADYNF:JuneTwentyOneTwoThousandAndSeventeenMember 2017-04-01 2017-06-30 0001607679 ADYNF:ConvertibleNoteMember 2017-04-01 2017-06-30 0001607679 ADYNF:USDMember 2017-06-21 0001607679 ADYNF:ConvertibleNoteMember ADYNF:USDMember 2017-06-20 2017-06-21 0001607679 ADYNF:ConvertibleNoteMember ADYNF:USDMember 2017-04-01 2017-06-30 0001607679 ADYNF:PromissoryNoteMember ADYNF:SecuritiesPurchaseAgreementandConvertibleNoteMember ADYNF:USDMember 2017-06-21 0001607679 ADYNF:PromissoryNoteMember ADYNF:SecuritiesPurchaseAgreementandConvertibleNoteMember 2017-06-20 2017-06-21 0001607679 ADYNF:DerivativeLiabilityMember 2017-04-01 2017-06-30 0001607679 2016-04-01 2017-03-31 0001607679 ADYNF:ConsultingAgreementMember 2017-04-08 2017-04-09 0001607679 ADYNF:ConsultingAgreementMember ADYNF:USDMember 2017-04-08 2017-04-09 0001607679 ADYNF:ConsultingAgreementMember us-gaap:RestrictedStockMember 2017-05-07 2017-05-08 0001607679 ADYNF:ConsultingAgreementMember ADYNF:USDMember 2017-05-07 2017-05-08 0001607679 ADYNF:EquityPurchaseAgreementMember ADYNF:USDMember 2015-09-09 2015-09-10 0001607679 us-gaap:WarrantMember 2017-04-01 2017-06-30 0001607679 us-gaap:WarrantMember ADYNF:USDMember 2017-04-01 2017-06-30 0001607679 us-gaap:WarrantMember 2017-06-30 0001607679 us-gaap:WarrantMember ADYNF:USDMember 2017-06-30 0001607679 ADYNF:StockBasedCompensationMember 2017-06-30 0001607679 ADYNF:StockBasedCompensationMember 2016-06-30 0001607679 ADYNF:StockBasedCompensationMember 2017-04-01 2017-06-30 0001607679 ADYNF:StockBasedCompensationMember 2016-04-01 2017-03-31 0001607679 ADYNF:DecemberThirtyOneTwoThousandAndSeventeenMember 2017-06-30 0001607679 ADYNF:DecemberThirtyOneTwoThousandAndSeventeenMember ADYNF:USDMember 2017-06-30 0001607679 ADYNF:DecemberThirtyOneTwoThousandAndSeventeenMember 2017-04-01 2017-06-30 0001607679 ADYNF:JanuarySeventeenTwoThousandTwentyTwoMember 2017-06-30 0001607679 ADYNF:JanuarySeventeenTwoThousandTwentyTwoMember ADYNF:USDMember 2017-06-30 0001607679 ADYNF:JanuarySeventeenTwoThousandTwentyTwoMember 2017-04-01 2017-06-30 0001607679 ADYNF:JuneTwentyOneTwoThousandAndSeventeenMember 2017-06-30 0001607679 ADYNF:JuneTwentyOneTwoThousandAndSeventeenMember ADYNF:USDMember 2017-06-30 0001607679 ADYNF:JuneTwentyOneTwoThousandAndSeventeenMember 2017-04-01 2017-06-30 0001607679 ADYNF:WarrantsMember 2017-04-01 2017-06-30 0001607679 ADYNF:WarrantsMember 2017-06-30 0001607679 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001607679 ADYNF:ExercisePriceOneMember 2017-06-30 0001607679 ADYNF:ExercisePriceOneMember 2017-04-01 2017-06-30 0001607679 ADYNF:ExercisePriceTwoMember 2017-06-30 0001607679 ADYNF:ExercisePriceTwoMember 2017-04-01 2017-06-30 0001607679 ADYNF:ExercisePriceThreeMember 2017-06-30 0001607679 ADYNF:ExercisePriceThreeMember 2017-04-01 2017-06-30 0001607679 ADYNF:ExercisePriceFourMember 2017-06-30 0001607679 ADYNF:ExercisePriceFourMember 2017-04-01 2017-06-30 0001607679 ADYNF:ConsultingAgreementsMember us-gaap:WarrantMember 2017-04-01 2017-06-30 0001607679 us-gaap:WarrantMember ADYNF:ConnectusIncMember 2017-01-22 2017-01-23 0001607679 ADYNF:ThreeYearSponsoredResearchContractMember us-gaap:MaximumMember 2017-02-22 2017-02-23 0001607679 ADYNF:FourYearSponsoredResearchContractMember us-gaap:MaximumMember 2017-03-12 2017-03-13 0001607679 ADYNF:TheEversullGroupIncMember ADYNF:USDMember 2017-04-08 2017-04-09 0001607679 ADYNF:TheEversullGroupIncMember 2017-04-08 2017-04-09 0001607679 ADYNF:CarterTerryAndCompanyMember 2017-05-07 2017-05-08 0001607679 ADYNF:CarterTerryAndCompanyMember 2017-05-08 0001607679 ADYNF:CarterTerryAndCompanyMember ADYNF:USDMember 2017-05-07 2017-05-08 0001607679 ADYNF:CarterTerryAndCompanyMember ADYNF:USDMember us-gaap:MaximumMember 2017-05-07 2017-05-08 0001607679 us-gaap:OfficerMember 2017-06-30 0001607679 ADYNF:CanadianCharteredBankMember 2017-06-30 0001607679 ADYNF:CanadianCharteredBankMember 2017-03-31 0001607679 ADYNF:ConsultingAgreementMember ADYNF:ConnectusWarrantMember 2017-06-30 0001607679 ADYNF:ConsultingAgreementMember ADYNF:USDMember ADYNF:ConnectusWarrantMember 2017-06-30 0001607679 ADYNF:WarrantLiabilityMember 2017-03-31 0001607679 ADYNF:ConvertibleNoteDerivativeLiabilityMember 2017-04-01 2017-06-30 0001607679 ADYNF:ConvertibleNoteDerivativeLiabilityMember 2016-04-01 2017-03-31 0001607679 ADYNF:ConvertibleNoteDerivativeLiabilityMember 2017-06-30 0001607679 ADYNF:ConvertibleNoteDerivativeLiabilityMember 2017-03-31 0001607679 ADYNF:ConvertibleNoteDerivativeLiabilityMember 2016-03-31 0001607679 us-gaap:SubsequentEventMember ADYNF:FixedPriceConvertibleNoteMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:FixedPriceConvertibleNoteMember ADYNF:USDMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:FixedPriceConvertibleNoteMember 2017-04-01 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:FixedPriceConvertibleNoteMember ADYNF:USDMember 2017-04-01 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:FixedPriceConvertibleNoteMember us-gaap:MinimumMember ADYNF:USDMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:FixedPriceConvertibleNoteMember us-gaap:MaximumMember ADYNF:USDMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:KernaghanandPartnersLtdMember 2017-08-14 2017-08-15 0001607679 us-gaap:SubsequentEventMember ADYNF:KernaghanandPartnersLtdMember us-gaap:MinimumMember 2017-08-14 2017-08-15 0001607679 us-gaap:SubsequentEventMember ADYNF:DirectorsAndOfficersMember 2017-11-07 2017-11-08 0001607679 us-gaap:SubsequentEventMember ADYNF:MitacsAccelerateProgramMember 2017-08-14 2017-08-15 0001607679 us-gaap:EmployeeStockOptionMember 2017-03-31 0001607679 us-gaap:EmployeeStockOptionMember 2017-06-30 0001607679 us-gaap:CommonStockMember 2017-04-01 2017-06-30 0001607679 us-gaap:CommonStockMember 2017-06-30 0001607679 us-gaap:AdditionalPaidInCapitalMember 2017-04-01 2017-06-30 0001607679 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001607679 ADYNF:EquitytobeIssuedMember 2017-04-01 2017-06-30 0001607679 ADYNF:EquitytobeIssuedMember 2017-06-30 0001607679 us-gaap:RetainedEarningsMember 2017-04-01 2017-06-30 0001607679 us-gaap:RetainedEarningsMember 2017-06-30 0001607679 ADYNF:ConvertibleNoteMember 2017-06-20 2017-06-21 0001607679 2017-06-21 0001607679 ADYNF:ConvertibleNoteMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:ClaimMember 2017-10-23 2017-10-24 0001607679 ADYNF:ConvertibleNoteMember ADYNF:USDMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:BonifyMember 2017-08-06 2017-08-08 0001607679 us-gaap:SubsequentEventMember ADYNF:ThreeManagementPersonnelMember 2017-11-07 2017-11-08 0001607679 us-gaap:SubsequentEventMember ADYNF:MitacsAccelerateProgramMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:ConvertibleNoteMember ADYNF:USDMember 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:ConvertibleNotesMember 2017-04-01 2017-06-30 0001607679 us-gaap:SubsequentEventMember ADYNF:StockOptionsMember 2017-11-07 2017-11-08 0001607679 us-gaap:SubsequentEventMember ADYNF:ExternalCounselMember 2017-11-07 2017-11-08 xbrli:shares xbrli:pure iso4217:CAD iso4217:CAD xbrli:shares iso4217:USD xbrli:shares iso4217:USD Algae Dynamics Corp. 10-Q 2017-06-30 false --03-31 Smaller Reporting Company Q1 286792 416035 -804686 4313931 1016324 -6134941 -812588 4313931 1018406 86372 -6231297 Unlimited Unlimited 13337521 13337521 13337521 13337521 112466 341437 112466 66451 100000 50000 2318 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value at</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expiration Date</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Exercisable</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">of Vested Warrants &#8211; Liability</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2017</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">275,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 4%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160; &#160;0.04</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 19%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.05</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,050</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 17, 2022</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">900,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">900,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160; &#160;0.65</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.87</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">82,800</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 21, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160; 0.50</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.65</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,705</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,375,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,150,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.67</font></td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">115,555</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The activities in options outstanding are as noted below:</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, March 31, 2017</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">695,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.99</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, June 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">695,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.99</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The future commitments pursuant to this lease arrangement, including property taxes and operating expenses for the fiscal periods ending March 31 are:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018 (remaining)</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">20,133</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">17,896</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 10pt; line-height: 115%">Fair Value at</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="9" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">Fair Value Measurement Using</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; text-align: center">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">June 30, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">Level 1</font></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">Level 2</font></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">Level 3</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt; line-height: 115%">Derivative liability &#8211; conversion options</font></td> <td>&#160;</td> <td><font style="font-size: 10pt; line-height: 115%">$</font></td> <td style="text-align: right"><font style="font-size: 10pt; line-height: 115%">217,762</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt; line-height: 115%">$</font></td> <td style="text-align: right"><font style="font-size: 10pt; line-height: 115%">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt; line-height: 115%">$</font></td> <td style="text-align: right"><font style="font-size: 10pt; line-height: 115%">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt; line-height: 115%">$</font></td> <td style="text-align: right"><font style="font-size: 10pt; line-height: 115%">217,762</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 80pt"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 10pt; line-height: 115%">Fair Value at</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">Fair Value Measurement Using</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; text-align: center">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">June 30, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">Level 1</font></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">Level 2</font></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt; line-height: 115%">Level 3</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt; line-height: 115%">Derivative liability &#8211; Warrants</font></td> <td>&#160;</td> <td><font style="font-size: 10pt; line-height: 115%">$</font></td> <td style="text-align: right"><font style="font-size: 10pt; line-height: 115%">115,555</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt; line-height: 115%">$</font></td> <td style="text-align: right"><font style="font-size: 10pt; line-height: 115%">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt; line-height: 115%">$</font></td> <td style="text-align: right"><font style="font-size: 10pt; line-height: 115%">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt; line-height: 115%">$</font></td> <td style="text-align: right"><font style="font-size: 10pt; line-height: 115%">115,555</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> -16504 154755 25000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information relating to stock options outstanding and exercisable at June 30, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options Outstanding</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options Exercisable</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Life (Years)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Life (Years)</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 20%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.73</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">185,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.46</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">185,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.73</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.46</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.43</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">85,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.52</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">85,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.43</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.52</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.38</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">425,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.33</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">155,833</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.38</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.33</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.99</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">695,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.44</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">425,833</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.38</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.35</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth a summary of changes in the fair value of the Company&#8217;s Level 3 financial liabilities (convertible note derivative liability) for the periods ended June 30, 2017 and March 31, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 80pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="3" style="text-align: center"><font style="font-size: 10pt">Three months ended</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="3" style="text-align: center"><font style="font-size: 10pt">Year ended</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2017</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; text-align: justify"><font style="font-size: 10pt">Balance at beginning of period</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">260,677</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">Nil</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Derivative instruments issued</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">19,166</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">253,318</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Change in fair market value, recognized in operations as fair value change in derivative liability</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(62,081</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,359</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Balance at end of period</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">217,762</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">260,677</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth a summary of changes in the fair value of the Company&#8217;s Level 3 financial liabilities (warrant derivative liability) for the periods ended June 30, 2017 and March 31, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Three months</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">ended</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Year ended</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2017</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2017</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%"><font style="font-size: 10pt">Balance at beginning of year</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">236,200</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">27,479</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Derivative instruments granted or vested</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">27,152</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">633,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Derivative instruments exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(55,321</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Change in fair market value, recognized in operations as professional fees</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(147,797</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(368,958</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at end of period</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">115,555</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">236,200</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> -179358 21783 27152 27152 86372 86372 93000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>12.) Financial Instruments</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(a) Liquidity risk</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company&#8217;s liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company generates cash flow primarily from its financing activities and advances from shareholders. As at June 30, 2017, the Company had cash of $1,553 (March 31, 2017 - $87) to settle current liabilities of $946,122 (March 31, 2017 - $897,442). All of the Company&#8217;s financial liabilities other than the warrant liability of $115,555 (March 31, 2017 - $236,200), the term loan of $50,796 (March 31, 2017 - $48,894), the convertible notes of&#160;$67,952&#160;(March 31, 2017 - $26,076) a promissory note of $48,899 (March 31, 2017 - $16,456), and derivative liability of&#160;$217,763&#160;(March 31, 2017 - $260,677) have contractual maturities of less than 30 days and are subject to normal trade terms. The Company regularly evaluates its cash position to ensure preservation and security of capital as well as liquidity.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the normal course of business, management considers various alternatives to ensure that the Company can meet some of its operating cash flow requirements through financing activities, such as private placements of common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. Management may also consider strategic alternatives, including strategic investments and divestitures. As future operations may be financed out of funds generated from financing activities, the ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the&#160;cannabis&#160;industry and the Company&#8217;s securities in particular. Should the Company elect to satisfy its cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that the efforts to obtain such additional funding will be successful, or achieved on terms favorable to the Company or its existing shareholders. If adequate funds are not available on favorable terms, the Company may have to reduce substantially or eliminate expenditures or obtain funds through other sources such as divestiture or monetization of certain assets or sublicensing (where permitted) of certain rights to certain of the Company&#8217;s technologies or products.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(b) Concentration of credit risk</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits. Cash deposits with a major Canadian chartered bank are insured by the Canadian Deposit Insurance Corporation up to $100,000. As at June 30, 2017, the Company held $1,553 (March 31, 2017 - $87) with a major Canadian chartered bank.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(c) Foreign exchange risk</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company principally operates within Canada. The Company&#8217;s functional currency is the Canadian dollar and major purchases are transacted in Canadian dollars. Certain of the Company&#8217;s debt obligations are denominated in U.S. dollars. Management does not hedge its foreign exchange risk.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(d) Interest rate risk</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2017, the Company does not have any non-fixed interest-bearing debt.&#160;Management believes that the interest rate risk concentration with respect to financial instruments included in assets and liabilities has been reduced to the extent presently practicable.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(e) Derivative liability &#8211; warrant liability</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with consulting agreements, the Company granted warrants to purchase up to 1,175,000 common shares of the Company as disclosed in Note&#160;8(b). The warrants have an exercise price of USD$0.04&#160;($0.052)&#160;for Connectus warrants, USD$0.65 ($0.85) for Midtown warrants and USD$0.50 ($0.65) for the investment place in June 2017. The Connectus warrants are exercisable at any time prior to December 31, 2017, the Midtown warrants are exercisable at any time prior to January 16, 2022 and the warrants for the investment undertaken in June are exerciseable prior to June 21, 2022. The warrants are accounted for as derivative liabilities because the exercise price is denominated in a currency other than the Company&#8217;s functional currency.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value at</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value Measurement Using</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 39%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 2%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td style="width: 1%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 2%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td style="width: 1%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative liability &#8211; Warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">115,555</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">115,555</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b>&#160;</b>&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth a summary of changes in the fair value of the Company&#8217;s Level 3 financial liabilities (warrant derivative liability) for the periods ended June 30, 2017 and March 31, 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Three months</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ended</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Year ended</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2017</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at beginning of year</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">236,200</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,479</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative instruments granted or vested</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,152</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">633,000</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative instruments exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(55,321</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Change in fair market value, recognized in operations as professional fees</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(147,797</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(368,958</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at end of period</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">115,555</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">236,200</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 8 (b)</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(f) Derivative liability &#8211; conversion options</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Salamon promissory note&#160;and&#160;the convertible notes&#160;(Notes&#160;6(a), (b) and (c)), the Company has determined that the conversion features are considered derivative liabilities due to the variable conversion prices associated with the notes and the fact that the conversion price is denominated in US dollars whereas the functional currency of the Company is the Canadian dollar.&#160;See Note 7.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value at</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="9" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value Measurement Using</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 39%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 2%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td style="width: 1%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 2%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td style="width: 1%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative liability &#8211; conversion options</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">217,762</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">217,762</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 80pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth a summary of changes in the fair value of the Company&#8217;s Level 3 financial liabilities (convertible note derivative liability) for the periods ended June 30, 2017 and March 31, 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 80pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Three months ended</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="3" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Year ended</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 69%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at beginning of period</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">260,677</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative instruments issued</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">19,166</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">253,318</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Change in fair market value, recognized in operations as fair value change in derivative liability</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(62,081</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,359</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at end of period</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">217,762</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">260,677</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The continuity of warrants for the period ended June 30, 2017 as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">of Warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, March 31, 2017</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,197,500</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 4%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.68</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Issued</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.65</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expired, unexercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(22,500</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.12</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, June 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,375,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.67</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> ADYNF 0001607679 32878 74745 11963 13335 44928 89633 47828 43901 92756 133534 4313931 4313931 1016324 1018406 86372 73042 5897 1902 5897 33623 1741 87 1553 173 2900 1553 87 37932 50000 67595 13337521 13337521 100000 200000 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>2.)</b></font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Presentation of Financial Statements</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited condensed interim financial statements should be read in conjunction with the financial statements for the Company&#8217;s most recently completed fiscal year ended March 31, 2017. These unaudited condensed interim financial statements do not include all disclosures required in annual financial statements, but rather are prepared in accordance with recommendations for interim financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). These unaudited condensed interim financial statements have been prepared using the same accounting policies, and methods as those used by the Company in the annual financial statements for the year ended March 31, 2017, except when disclosed below.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed interim financial statements contain all adjustments (consisting of only normal recurring adjustments) which are necessary to present fairly the financial position of the Company as at June 30, 2017, and the results of its operations for the three month periods ended June 30, 2017 and 2016 and its cash flows for the three month periods ended June 30, 2017 and 2016. Note disclosures have been presented for material updates to the information previously reported in the annual financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Estimates</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of these unaudited condensed interim financial statements has required management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of the revenues and expenses during the reporting period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On an ongoing basis, the Company evaluates its estimates, including those related to provision for doubtful accounts, accrued liabilities and contingencies, and the valuation of income taxes, stock based compensation, warrants, convertible debt and intangible assets. The Company bases its estimates on historical experiences and on various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates. As adjustments become necessary, they are reported in earnings in the period in which they become known.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>New Accounting Pronouncements</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, was issued to simplify the classification of deferred taxes on the balance sheet. The new guidance would require that deferred taxes be classified as non-current assets and liabilities based on the tax paying jurisdiction. Application of the standard, which can be applied prospectively or retrospectively, is required for fiscal years beginning on or after December 15, 2016 and for interim periods within that year. The adoption of the amended guidance does not have a material impact on the Company&#8217;s consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU includes multiple provisions intended to simplify various aspects of the accounting for share-based payments. The areas of simplification in the update involve several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows, however, some of the areas for simplification apply only to non-public entities. This guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The guidance does not have a material impact on the Company&#8217;s financial statements.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>3.)</b></font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Equipment and Leasehold Improvements</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2017</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 39%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,558</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,607</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,558</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,530</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Production equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">67,367</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">37,249</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">67,367</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">35,663</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">42,290</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">29,458</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">42,290</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,194</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">113,215</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">69,314</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">113,215</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">65,387</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net carrying amount</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">43,901</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">47,828</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three month period ended June 30, 2017, the Company recorded total depreciation of $3,927 (2016 - $4,356) which was recorded to depreciation expense on the condensed interim statements of operations.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>8.)</b></font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Capital Stock</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(a) Common Shares</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Authorized</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue an unlimited number of common shares with no par value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Issued and Outstanding</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Equity to be issued</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 9, 2017 the Company signed a 12 month consulting agreement.&#160;The&#160;terms of the agreement include the provision of 100,000 restricted common shares on signing valued at USD$20,390 ($27,186). See Note10.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 8, 2017, the Company signed a consulting agreement with Carter, Terry &#38; Company.&#160;The&#160;terms of the agreement include a non-refundable equity retainer on signing of 150,000 restricted common shares valued at USD$33,000 ($45,197). See Note 10.&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of convertible notes issued on June 21, 2017 the Company agreed to issue 100,000&#160;restricted&#160;common shares as a commitment fee. See Note 6 (c). This commitment was valued at $13,989 based on the estimated fair market value of the shares as of the date of&#160;commitment.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Equity Purchase Agreement (&#8220;EPA&#8221;)</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 10,&#160;2015,&#160;the Company entered into the EPA. The holder of the EPA was committed to purchase up to USD$750,000 worth of the Company&#8217;s common shares (the &#8220;Put Shares&#8221;) over the 12-month term of the EPA. The Company paid to the holder of the EPA a commitment fee for entering into the EPA equal to 50,000 restricted common shares of the Company, valued at $67,195, based on the stock price in the most recent private placement as the Company&#8217;s shares had not yet begun to trade on a public market.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 23, 2016, the Company agreed in conjunction with RY Capital Group, LLC and GHS Investments, LLC to assign the EPA to GHS Investments, LLC.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has notified the holder of the EPA that&#160;the&#160;facility will not be utilized.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(b) Warrants</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2017, the following warrants were outstanding:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value at</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expiration Date</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Exercisable</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">of Vested Warrants &#8211; Liability</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2017</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">275,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 4%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160; &#160;0.04</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 19%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.05</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,050</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 17, 2022</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">900,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">900,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160; &#160;0.65</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.87</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">82,800</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 21, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160; 0.50</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.65</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,705</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,375,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,150,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.67</font></td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">115,555</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended June 30, 2017, the Company issued 200,000 warrants of the Company valued at $27,152 (USD$20,400), pursuant to the financing described in Note 6 (c). Each warrant entitles the holder to purchase one common share at an issue price of USD$0.50 ($0.65) for a period of 5 years after the date of issuance. The fair value of the warrants at the date of grant of $27,152 was estimated using the Black-Scholes option pricing model, based on the following weighted average assumptions: stock price of USD$0.11; expected dividend yield of 0%; risk free interest rate of 1.13%; expected volatility of 221%; and expected term of 5 years. The Company&#8217;s computation of expected volatility used to estimate the fair value of the warrants as at June 30, 2017 is based on the market close price of comparable public entities over the period equal to the expected remaining life of the warrants.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 815 &#8220;Derivatives and Hedging&#8221; indicates that warrants with exercise prices denominated in a currency other than an entity&#8217;s functional currency should not be classified as equity. As a result, warrants with a USD exercise price have been treated as derivatives and recorded as liabilities carried at their fair value, with period-to-period changes in the fair value recorded as a gain or loss in the statements of operations.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The continuity of warrants for the period ended June 30, 2017 as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">of Warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, March 31, 2017</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,197,500</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 4%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.68</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Issued</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.65</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expired, unexercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(22,500</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.12</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, June 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,375,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.67</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2017, the fair value of the 1,375,000 (March 31, 2017 &#8211; 1,175,000) warrants exercisable in US dollars was&#160;$139,180&#160;(March 31, 2017 - $298,700) which was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2017</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">175</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">229</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.33</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.03</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.97 years</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.85 years</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Of this amount,&#160;$115,555&#160;(March 31, 2017 - $236,200) was reflected as a liability as at June 30, 2017, representing the percentage of the fair value of the warrants that is equal to the percentage of the requisite service that has been rendered at June 30, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrant liability is classified as Level 3 within the fair value hierarchy (See Note 12). The Company&#8217;s computation of expected volatility during the&#160;three months&#160;ended June 30, 2017 and 2016 is based on the market close price of comparable public entities over the period equal to the expected life of the warrants. The Company&#8217;s computation of expected life is calculated using the contractual life.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(c) Stock-based compensation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s stock-based compensation program (the &#8220;Plan&#8221;) includes stock options in which some options vest based on continuous service. For those equity awards that vest based on continuous service, compensation expense is recorded over the service period from the date of grant.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The total number of options outstanding as at June 30, 2017 was 695,000 (2016 &#8211; 930,000). No options were granted during the three months ended June 30, 2017. The maximum number of options that may be issued under the plan is floating at an amount equivalent to 15% of the issued and outstanding common shares, or 2,000,628 as at June 30, 2017 (March 31, 2017 &#8211;&#160;2,000,628).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The activities in options outstanding are as noted below:</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, March 31, 2017</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">695,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.99</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, June 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">695,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.99</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information relating to stock options outstanding and exercisable at June 30, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options Outstanding</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options Exercisable</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Life (Years)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Life (Years)</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 20%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.73</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">185,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.46</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">185,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.73</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.46</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.43</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">85,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.52</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">85,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.43</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.52</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.38</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">425,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.33</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">155,833</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.38</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.33</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.99</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">695,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.44</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">425,833</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.38</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.35</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>9.) Income Taxes</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has no taxable income under Canadian Federal and provincial tax laws for the three month periods ended June 30, 2017 and 2016. The Company has non-capital loss carryforwards at June 30, 2017 totally approximately $3,702,500, which may be offset against future taxable income. If not used, the loss carryforwards will expire between 2019 and 2037.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>10.) Commitments and Contingencies</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a five year operating lease for office and production facilities. The lease commenced on December 1, 2013 and expires on November 30, 2018. The base monthly rental is $1,390 plus the Company&#8217;s estimated portion of property taxes and operating expenses which are currently $847 per month. The future commitments pursuant to this lease arrangement, including property taxes and operating expenses for the fiscal periods ending March 31 are:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018 (remaining)</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">20,133</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">17,896</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the&#160;three&#160;month period ended June 30, 2017, occupancy costs related to this lease were $6,711 (2016 &#8211; $6,525).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 11, 2014, and as amended on July 18, September 3, 2014, September 5, 2014, December 31, 2015 and again on December 20, 2016, the Company entered into a consulting agreement with Connectus, Inc. (&#8220;Connectus&#8221;) to assist and advise the Company in matters concerning corporate finance and the Company&#8217;s current and proposed financing activities for the period commencing April 1, 2014 and ending December 31, 2014. Pursuant to this agreement, the Company agreed to issue to Connectus, 625,000 warrants of the Company. Each warrant is exercisable at USD$0.04 ($0.054) per share for a period of three years. Of the warrants granted, 300,000 vested on September 3, 2014 with the unvested portion vesting pro-rata for each USD$250,000 ($335,675) raised in an offering, fully vesting upon USD$1,500,000 ($2,014,050) being raised. During the year ended March 31, 2015, the President of Connectus became a director of the Company. On December 31, 2015, the Company extended the contract to December 31, 2016. In consideration of the contract extension, the Company issued 93,000 common shares to Connectus as compensation, which has been recorded as professional fees on the statements of operations during the year ended March 31, 2016. On December 27, 2016, the Company extended the contract and expiry date of the warrants to December 31, 2017. On January 23, 2017 the Company approved the vesting of 100,000 warrants. Connectus assigned the warrants to Apollo Marketing, LLC.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 23, 2014, the Company entered into employment agreements with three officers of the Company effective July 1, 2014. The initial contracts contain minimum aggregate commitments of approximately $427,000 per year for three years and additional contingent payments of up to approximately $600,000 in aggregate upon the occurrence of a change of control. The employment agreements were amended whereby any salary from the commencement of the employment agreements has been waived until such a time when the Company is able to raise additional financing. Salaries will be earned and paid at the discretion of the Board.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 19, 2016, the Company signed a consulting agreement with an agent in connection with proposed placements of up to USD$10,000,000 ($13,427,000) in a combination of equity and or debt of the Company for a term of one year. Consideration payable under the consulting agreement include a non-refundable equity retainer of 100,000 common shares of the Company , a placement fee equal to 8% of the gross purchase price paid for equity of the Company, an administrative fee of 4% of the gross purchase price paid for equity, a placement fee of 4% of the gross purchase price paid for non-convertible debt and warrants to purchase common shares of the Company equal to 8% of the number of shares of common stock issuable by the Company upon exercise or conversion of any and all securities issued at each closing. On January 10, 2017, the Company entered into an addendum to the agreement signed on May 19, 2016 which provided for a grant of 900,000 warrants at an exercise price of USD$0.65 ($0.86) for a period of five years with a cashless exercise option. On August 15, 2017 the Company extended the contract for an additional year.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 23, 2017, the Company entered into a three year sponsored research contract with the University of Waterloo commencing on April 1, 2017. Under the terms of the agreement the Company will contribute $130,000 upon start date of the project, $130,000 on completion of Year 1 and $130,000 on completion of Year 2, plus the Company will make an in-kind contribution valued at $70,000 in each of the 3 years. Any patents initiated by the Company from the sponsored research will be assigned to the Company and in return the Company will pay the researcher $10,000 per patent filed, $40,000 per patent issued by the U.S. patent office, $50,000 per product after the first commercial sale and $50,000 per product&#160;once&#160;the gross sales exceed $1,000,000. As of June 30, 2017, the Company has not made any payments pursuant to this agreement. The payment schedule has been amended to match the cash flow from the capital raise being undertaken by the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 13, 2017, the Company entered into a four year sponsored research contract with the University of Western Ontario commencing on April 1, 2017. Under the terms of the agreement the Company will contribute $210,000 upon execution of the agreement, $210,000 on completion of Year 1, $210,000 on completion of Year 2 and $210,000 on completion of Year 3, plus the Company will make an in-kind contribution valued at $62,500 in each of the 4 years. Any patents initiated by the Company from the sponsored research will be assigned to the Company and in return the Company will pay the researcher $10,000 per patent filed, $40,000 per patent issued by the U.S. patent office, $50,000 per product after the first commercial sale and $50,000 per product&#160;once&#160;the gross sales exceed $1,000,000. As of June 30, 2017, the Company has not made any payments pursuant to this agreement. A payment of $50,000 was made on July 28, 2017. The payment schedule has been amended to match the cash flow from the capital raise being undertaken by the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 27, 2017, the Company entered into a&#160;one&#160;year agreement with Questrade, Inc. an Investment Dealer to provide guidance on the trading of the Company&#8217;s securities and guidance with respect to the promotion of the Company. The Company shall pay Questrade a monthly fee in an amount equal to USD$5,500 for consulting services rendered each month of the term. See Note 13.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 9, 2017, the Company signed a 12 month consulting agreement effective April 15, 2017 with an arm&#8217;s length organization, The Eversull Group Inc, to provide financial public relations, investor, shareholder, press relations and capital search consulting services. Terms of the agreement include the provision of 100,000 restricted shares annually, a minimum monthly retainer of USD$ 2,000 plus a 3% introduction fee for all sources of funding introduced by The Eversull Group, Inc. and accepted by the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 8, 2017, the Company signed a consulting agreement with Carter, Terry &#38; Company in connection with the proposed raising of capital in a combination of equity and/or debt of the Company for a term of two years. Terms of the agreement include the issuance of 150,000 restricted common shares on signing (see Note 8(a)) plus future consideration payable under the consulting agreement&#160;including&#160;a placement fee equal to 10% of the gross proceeds raised less than USD$1,000,000 and 8% for gross funds raised in excess of USD$1,000,000, plus the equivalent amount of restricted shares equal to 4% of the capital raised divided by the closing price of the stock on the date of close for a period of two years.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">See also Note 13 with respect to the Questrade, Inc. claim.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>11.) Related Party Transactions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amounts receivable from an officer in the amount of $3,270 was recovered during the three month period ended June 30, 2017, from an amount of $17,656 previously offset by an allowance for doubtful accounts, leaving a remaining balance in the doubtful account of $14,386.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>13.) Subsequent Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 19, 2017, the Company announced plans to form a joint venture corporation with Avanti Rx Analytics Inc. (ARA). The Company would own 96% of the joint venture and ARA would own 4%. As a result of signing the letter of Intent with Bonify on August 10, 2017 (details provided below) the Company will not be proceeding with the joint venture.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 10pt">During the quarter ended June 30, 2017, the Company commenced a financing of up to USD$500,000, see Note 6 (c</font><font style="font-size: 9pt">). </font><font style="font-size: 10pt">The convertible notes include a provision that if the Company raises additional funds under more favourable terms during the life of the convertible note, then the more favourable terms will apply. The Company did raise $358,000 under more favourable terms, see details below, convertible notes.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 8, 2017, the Company signed a non-binding Letter of Intent (LOI) with 6779264 Manitoba Ltd dba Bonify (&#8220;Bonify&#8221;). Bonify is a licensed producer, pursuant to the Access to Cannabis for Medical Purposes Regulations in Canada. In the LOI the Company and Bonify have outlined the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">i)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The purchase and installation of cannabis oil extraction equipment with an estimated cost of $1,450,000 to be jointly agreed upon by the Company and Bonify with the equipment being located in Bonify&#8217;s facility. At the end of the agreement, full right and title to the equipment would be assigned to Bonify;</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">ii)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The processing of cannabis material supplied by Bonify and other licensed producers in the oil extraction facility;</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">iii)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The supply of cannabis oil and algae omega-3 oils to The University of Waterloo and University of Western Ontario to support the sponsored research agreements that the Company has in place with the two universities (See Note 10);</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">iv)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The sharing of direct expenses, and, after adjustment for the market value of cannabis material supplied by Bonify and third parties, sharing of revenues from the sale of cannabis oil and algae-cannabis oil products; and</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">v)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The negotiation of a definitive agreement no later than September 30, 2017. The definitive agreement is still being negotiated.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Convertible Notes</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to June 30, 2017, the Company raised a total of USD$408,000 ($520,160) through the issue of convertible notes. The convertible notes, totalling USD$358,000 have a maturity of 60 days, an interest rate of 10%, a conversion price of USD$0.07 per share if the price on or around 15 days before maturity is less than US$0.10 or USD$0.10 per share if the closing price per share is USD$0.10 or above at the conversion dates. For the initial convertible note issued on July 25, 2017, of USD$50,000, the Company committed to issue 100,000 common shares as a commitment fee, the maturity is twelve months from the issue date, the interest rate is 12%, plus the Company granted 200,000 common share purchase warrants. . Each warrant is exercisable into one common share at USD$0.50 ($0.65) for a period of five years. See Note 6(c).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Part of the proceeds from the convertible notes has been used to repay the convertible notes payable to Salamon Partners LLC and GHS Investments. See Notes 6(a) and (b).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 10 for the $50,000 payment made to the University of Western Ontario.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 15, 2017, the Company engaged a Canadian firm, Kernaghan and Partners Ltd. (the Agent) a fully regulated full service brokerage firm to conduct a capital raise in the Canadian market. In consideration of the services to be rendered the Agents shall receive on the closing date of the offering;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">i)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">a work fee of $25,000; </font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">ii)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">cash commission (the <b>&#8220;</b>Agency Fee&#8221;) of 6% of the gross proceeds from the sale of common shares pursuant to the offering, except for sales to persons on the &#8220;President&#8217;s List&#8221;, in respect of which the commission shall be reduced to 2% of the gross proceeds received from such persons;</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">iii)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">broker warrants entitling the Agent to purchase, equal to the issue price, the number of common shares that is equal to 6% of the number of common shares sold pursuant to the offering, except for sales to persons on the &#8220;President&#8217;s List&#8221;, in respect of which the broker warrants shall entitle the Agent to purchase the number of common shares that is equal to 2% of the number of common shares sold to such persons. The broker warrants shall have a term of 2 years and an exercise price equal to the offering price of the common shares.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 24, 2017, the Company was named in Small Claims Court entitled Questrade, Inc. versus Algae Dynamics Corp. (the &#8220;Claim&#8221;).&#160; The Claim seeks payment of $25,000 for payments allegedly owed under a Consulting Agreement with the Company in which Questrade was to provide certain financial advisory services.&#160; The Company has filed a general denial of liability on the basis that services were not provided or alternately disputing the amount claimed. A hearing date of February 6, 2018 has been set.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant award</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, as the industry partner, is a participant in a Project Grant of up to $400,000 from the Mitacs Accelerate program, that will be delivered directly by Western University through eligible internships. The financial contribution by the Company which is $180,000 for this grant is part of the funding included in the research agreement the Company signed with the university and announced on March 13, 2017. To-date the Company has paid the initial of six installments to Mitacs, with the remaining installments being invoiced throughout the duration of the project. The balance of the $400,000 award ($220,000) will be provided by Mitacs. The project started on December 1, 2017 and is scheduled to operate for two (2) years. The extent of the announced award from Mitacs of $400,000 to be paid directly to the university is dependent on the funding provided by the Company and on the number of interns actually employed in the project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 8, 2017, the Board approved the grant of 850,000 stock options for common shares to directors and officers of the Company (800,000) and external counsel (50,000). In addition, the Board approved the award of an aggregate of 1,050,000 common shares to three management personnel for services rendered, plus the Board cancelled an aggregate of 600,000 common shares awarded in a prior period to the three management personnel.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2017</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 39%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,558</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,607</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,558</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,530</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Production equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">67,367</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">37,249</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">67,367</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">35,663</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">42,290</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">29,458</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">42,290</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,194</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">113,215</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">69,314</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">113,215</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">65,387</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net carrying amount</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">43,901</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">47,828</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 22347 29122 48894 50796 -6134941 -6231297 92756 133534 852514 856489 113215 113215 3558 67367 42290 3558 67367 42290 65387 69314 2530 35663 27194 2607 37249 29458 bridge financing with a relative of one of the officers of the Company. The holder of the note may, after a period of 180 days, at its sole option, convert the outstanding principal balance and accrued interest of 12% per annum, into the Company’s common shares at a market closing bid discount of 50% if converting at less than 5 days of the average trading volume, 60% if converting at more than 5 days of the average trading volume and 65% if converting at more than 10 days of the average trading volume at maturity. 2017-11-30 2017-08-18 2017-08-15 0.30 0.10 0.0499 0.20 1.25 1.35 0.12 1.44 0.12 .10 200000 56500 76382 65350 50000 0.0999 0.65 0.50 0.85 0.65 0.65 0.50 0.052 0.04 0.65 0.50 0.65 0.50 100000 100000 150000 50000 100000 150000 1000000 27186 20390 45197 33000 67195 750000 100000 0.00 0.00 0.00 1.75 2.29 2.21 0.0133 0.0103 0.0113 P3Y11M19D P3Y10M6D P5Y 298700 139180 236200 115555 695000 930000 185000 85000 425000 695000 0.15 2000628 2000628 1175000 1375000 275000 900000 200000 1150000 50000 900000 200000 0.67 -0.05 0.04 -0.87 0.65 0.50 -0.65 2014050 1500000 115555 5050 82800 27705 335675 250000 1197500 1375000 200000 -22500 0.68 0.67 0.65 1.12 200000 800000 1050000 850000 50000 1.73 2.43 0.38 0.99 0.99 0.99 P30D P2Y5M16D P3Y6M7D P4Y3M29D P3Y5M9D P5Y 2018-11-30 1390 847 6711 6525 900000 625000 0.054 0.04 0.86 .65 P5Y P5Y P3Y P5Y 300000 427000 50000 600000 13427000 10000000 P1Y P2Y 0.08 0.10 0.04 0.04 0.08 115555 27479 236200 217762 260677 -55321 -147797 -368958 .10 0.11 0.11 2.51 1.86 0.0091 0.0109 0.00 0.00 P1Y P2M12D <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>5.)</b></font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Term Loan</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 4, 2016, the Company agreed to a term loan of $40,000 for bridge financing with a relative of one of the officers of the Company. The loan matured&#160;on November 30, 2017 and the terms&#160;specified&#160;a 30% premium to be paid at that time. The 30% premium is recognized as an expense over the term of the loan and is amortized on the statements of operations. During the period ended June 30, 2017 the Company recorded accretion expense of $1,902 (2016 - $5,897). The loan was initially scheduled to mature on August 28, 2016 but an extension of three months, followed by a second extension of three months and followed by a further extension to February 28, 2018 was agreed to with the same terms.</p> 2018 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>7.)</b></font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Derivative Liability</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible notes discussed in Note 6 have variable conversion prices which results in the conversion feature being recorded as derivative liabilities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the derivative liabilities are recorded and shown separately under current liabilities. Changes in the fair value of the derivative liabilities are recorded in the statement of operations.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company used the Black-Scholes option pricing model with the following weighted average assumptions to estimate the fair value of the derivative liability at June 30, 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$0.10</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 84%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free rate</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 15%; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.09%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">186%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Conversion price</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$0.06</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life (in years)</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.20</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s computation of expected volatility used to estimate the fair value of the derivative liability as at June 30, 2017 is based on the&#160;quoted&#160;market close price of&#160;the Company&#8217;s shares&#160;over the period equal to the expected term of the conversion feature.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the Company&#8217;s derivative liabilities activity for the period ended June 30, 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Three months</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ended</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Year ended</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2017</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative liabilities balance, beginning of period</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">260,677</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Issuance of derivative liabilities during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">19,166</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">253,318</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Change in derivative liabilities during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(62,081</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,359</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative liabilities balance, end of period</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">217,762</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">260,677</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 0.06 0.25 0.25 0.07 0.10 260677 217762 19166 253318 -62081 7359 1175000 1375000 130000 130000 130000 70000 210000 210000 210000 210000 62500 10000 10000 418875 427000 5500 217762 217762 115555 115555 27152 633000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company used the Black-Scholes option pricing model with the following assumptions to estimate the fair value of the derivative liability at the date of issuance:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 21, 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$0.11</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 84%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free rate</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 15%; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.91%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">251%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Conversion/Exercise price</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$0.25</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term (in years)</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.0</font></td></tr> </table> <p style="margin: 0pt"></p> 0.96 0.04 500000 500000 520160 408000 358000 1.00 0.10 0.12 200000 P5Y P2Y 100000 13989 0.06 0.02 358000 897442 946122 236200 115555 48894 50796 26076 67953 16456 48899 260677 217762 100000 185000 85000 155833 425833 1.73 2.43 0.38 1.38 P2Y5M16D P3Y6M7D P4Y3M29D P3Y4M6D 47500 2500 0.25 0.30 0.35 135510 117807 19166 2.13 1.03 25978 0.38 40000 2016-08-28 3927 4356 expired in September 2016 3702500 expire between 2019 and 2037 40000 50000 40000 50000 1000000 50000 50000 1000000 1000000 1000000 13337521 112466 341437 5398 5025 3791 2857 18192 151105 85000 1075 2936 1607 8315 7982 -8125 2039 1045 5056 422 2486 -3270 3406 3247 112466 341437 0.01 0.04 13337521 9728634 86372 48651 3927 4356 41867 -3651 1372 -254 -43241 -90446 44707 93173 6775 50855 1466 2727 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>4.)</b></font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Advances from Shareholders</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2017, the Company had received cumulative net working capital advances in the amount of $29,122 (March 31, 2017 - $22,347) from two shareholders who are also officers and directors of the Company. The advances from shareholders are unsecured, non-interest bearing and payable upon demand.</p> 27152 20400 2000 0.03 0.08 0.04 14386 P45D Cash commission (the “Agency Fee”) of 6% of the gross proceeds from the sale of Common Shares pursuant to the offering, except for sales to persons on the “president’s list”, in respect of which the commission shall be reduced to 2% of the gross proceeds received from such persons; 400000 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>1.)</b></font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nature of the Business and Going Concern</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Algae Dynamics Corp. (the &#8220;Company&#8221;) was incorporated under the Canada Business Corporations Act on October 7, 2008 as Converted Carbon of Canada Corp. On November 19, 2010, the Company amended its Articles of Incorporation to change its name to Converted Carbon Technologies Corp. and a further amendment was approved by the shareholders on August 28, 2014 to change the name to Algae Dynamics Corp.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is conducting research through sponsored research agreements with two universities to support development of health products utilizing cannabis, hemp and algae oil. The Company&#8217;s planned principal operations are the sale of oil extracted from cannabis oils plus the sale of uniquely formulated health products utilizing cannabis oils, algae oils and hemp oils.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016, the Company signed a Letter of Engagement with Midtown Partners &#38; Co, LLC to raise additional equity capital to support the implementation of its business plan; an addendum to this agreement was signed on January 17, 2017 and the agreement was extended for one year in August 2017. See Note 10.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 8, 2017, the Company signed an additional consulting agreement with Carter, Terry &#38; Company in connection with the proposed capital raise in a combination of equity and/or debt of the Company for a term of two years. See Note 10.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2017, the Company signed a Letter of Intent (LOI) with an authorized&#160;licensed producer&#160;of cannabis for medical purposes.&#160;See Note 13</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s activities are subject to significant risks and uncertainties, including failing to obtain patents and failing to secure additional funding to operationalize the Company&#8217;s current technology before another company develops similar technology.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited condensed interim financial statements have been prepared on the basis of a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Company is in the development stage and has not yet realized profitable operations and has relied on non-operational sources to fund operations. The Company has suffered recurring losses and additional future losses are anticipated as the Company has not yet been able to generate revenue. In addition, as of June 30, 2017, the Company has a working capital deficiency of $856,489 (March 31, 2017 - $852,514) and an accumulated deficit of&#160;$6,231,297&#160;(March 31, 2017 - $6,134,941). The Company&#8217;s ability to continue as a going concern is dependent on successfully executing its business plan, which includes the raising of additional funds. The Company will continue to seek additional forms of debt or equity financing, but it cannot provide assurances that it will be successful in doing so. These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Such adjustments could be material.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>6.)</b></font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Convertible&#160;Notes</b></font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(a)</b></font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Promissory Note</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2017, the Company issued a promissory note to Salamon Partners LLC (&#8220;Salamon&#8221;), an arm&#8217;s length organization, for a principal amount of USD$50,000 ($65,350) at 12% per annum. The net proceeds were USD$47,500 which consisted of the principal amount, net of transaction cost of US$2,500. The principal amount&#160;became&#160;due on August 15, 2017. The outstanding amount may be prepaid at any time at the option of the Company. In the event of a prepayment the penalty rate shall be assessed as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">i.) if the prepayment occurs within 60 days of the loan issuance, the prepayment penalty will equal twenty-five (25%) of the principal amount prepaid</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ii.) If the prepayment occurs within 60 to 90 days of the loan issuance, the prepayment penalty will equal thirty percent (30%) of the principal amount prepaid</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">iii.) If the prepayment occurs within 90 to 120 days of the loan, the prepayment penalty will equal thirty-five (35%) of the principal amount.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The holder of the note may, after a period of 180 days, at its sole option, convert the outstanding principal balance and accrued interest of 12% per annum, into the Company&#8217;s common shares at a market closing bid discount of 50% if converting at less than 5 days of the average trading volume, 60% if converting at more than 5 days of the average trading volume and 65% if converting at more than 10 days of the average trading volume at maturity.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the variable conversion price associated with this promissory note and the fact that the conversion price is denominated in US dollars whereas the functional currency is the Canadian dollar, the Company has determined that the conversion feature is a derivative liability. The value of the embedded conversion feature at the date of issuance was estimated to be $135,510 (2016 - $Nil), which was recorded as a derivative liability as of the date of issuance. The debt discount is being amortized over the term of the promissory note.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The discount to the carrying value of the promissory note is being amortized as a non-cash interest expense over the term of the promissory note using the effective interest rate method, at a rate of 213%. During the period ended June 30, 2017, the Company accreted $33,623 (2016 - $Nil) in non-cash accretion expense in connection with the promissory note, which is included in accretion expense on the statements of operations.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the end of the quarter,&#160;the promissory note was fully paid at maturity, August 15, 2017. See Note 13.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: bottom; width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(b)</b></font></td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Securities Purchase Agreement and Convertible Note</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 18, 2016, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with GHS Investments, LLC (&#8220;GHS&#8221;). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, GHS shall purchase from the Company a senior convertible note with a principal amount of USD$56,500 ($76,382) for a purchase price of USD$50,000 ($67,595).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible note matures upon the earlier of successfully raising of at least USD$200,000 or August 18, 2017 and accrues interest at the rate of 10% per annum. The convertible note is convertible following ninety (90) days of the execution of the note, in whole or in part, at GHS&#8217; option into common shares of the Company&#8217;s capital stock at a variable conversion price equal to a 38% discount from the lowest trading price in the twenty (20) trading days prior to the day that GHS requests conversion. At no time will GHS be entitled to convert any portion of the convertible note to the extent that after such conversion, GHS (together with its affiliates) would beneficially own more than 4.99% of the outstanding common shares, although GHS can modify this limit to 9.99% of the outstanding common shares.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible note includes customary event of default provisions, and provides for a default interest rate of 20%. The Company&#160;had&#160;the right at any time prior to May 18, 2017 to redeem all, but not less than all, of the total outstanding amount then remaining under the convertible note in cash at a price ranging from 125% to 135% of the total amount of the convertible note then outstanding.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the variable conversion price associated with this convertible note, the Company has determined that the conversion feature is considered a derivative liability. The embedded conversion feature at the date of issuance was estimated to be $117,807 (2016 - $Nil), which was recorded as a derivative liability as of the date of issuance. The debt discount is being amortized over the term of the convertible note.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The discount to the carrying value of the convertible note is being amortized as a non-cash interest expense over the term of the convertible note using the effective interest rate method, at a rate of 144%. During the period ended June 30, 2017, the Company accreted&#160;$35,776&#160;(2016 - $Nil) in non-cash accretion expense in connection with the convertible note, which is included in accretion expense on the statements of operations.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to&#160;June 30, 2017&#160;the&#160;note was fully paid. See Note 13.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(c) Convertible Note</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 21, 2017, the Company commenced a financing of up to USD$500,000 of one-year 12% convertible notes. The notes are convertible at the option of the holder into common shares of the Company at a price of USD$0.25 per share, and are subject to mandatory conversion if the volume-weighted trading price of the common shares is greater than USD$1.00 per share for twenty consecutive trading days so long as the underlying shares may be resold in compliance with the registration requirements of the Securities Act of 1933, as amended. In addition, the Company shall issue pro rata to the purchasers of the first USD$100,000 of notes an aggregate of 200,000 common shares as a commitment fee. To June 30, 2017, the Company issued USD$50,000&#160;($66,451)&#160;of these notes. The Company also granted 200,000 common share purchase warrants to the holders of the USD$50,000 notes. Each warrant is exercisable into one common share at USD$0.50 ($0.65) for a period of five years.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the fact that the conversion price and the warrant exercise price are denominated in US dollars whereas the functional currency is the Canadian dollar, the Company has determined that the conversion feature and the warrant are derivative liabilities. The value of the embedded conversion feature at the date of issuance was estimated to be&#160;$19,166, which was recorded as a derivative liability as of the date of issuance. The value of the warrant at the date of the issuance was estimated at $27,152, which was recorded as a warrant liability as of the date of issuance. The debt discount is being amortized over the term of the note.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company used the Black-Scholes option pricing model with the following assumptions to estimate the fair value of the derivative liability at the date of issuance:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 21, 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$0.11</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 84%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free rate</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 15%; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.91%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">251%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Conversion/Exercise price</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$0.25</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term (in years)</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.0</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s computation of expected volatility is based on the quoted market close price of the Company&#8217;s shares over the period equal to the expected life of the convertible note. The Company&#8217;s computation of expected life is calculated using the contractual life.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The discount to the carrying value of the convertible note is being amortized as a non-cash interest expense over the term of the convertible note using the effective interest rate method, at a rate of 103%. During the period ended June 30, 2017, the Company accreted $1,741 in non-cash accretion expense in connection with the convertible note, which is included in accretion expense on the statements of operations.</p> 695000 695000 61047 129243 15294 40000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company used the Black-Scholes option pricing model with the following weighted average assumptions to estimate the fair value of the derivative liability at June 30, 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$0.10</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 84%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free rate</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 15%; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.09%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">186%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Conversion price</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">USD$0.06</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life (in years)</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.20</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the Company&#8217;s derivative liabilities activity for the period ended June 30, 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Three months</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ended</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Year ended</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2017</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative liabilities balance, beginning of period</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">260,677</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Issuance of derivative liabilities during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">19,166</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">253,318</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Change in derivative liabilities during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(62,081</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,359</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative liabilities balance, end of period</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">217,762</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">260,677</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2017, the fair value of the 1,375,000 (March 31, 2017 &#8211; 1,175,000) warrants exercisable in US dollars was&#160;$139,180&#160;(March 31, 2017 - $298,700) which was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2017</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">175</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">229</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.33</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.03</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.97 years</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.85 years</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 18192 18192 -16110 16110 -13898 0.50 0.65 17656 25000 2018-02-06 600000 50000 19166 253318 -62081 7359 1450000 50000 50000 200000 180000 400000 220000 EX-101.SCH 7 adynf-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Interim Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Interim Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Interim Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Interim Statements of Stockholders' Equity (Deficiency) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Interim Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of the Business and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Presentation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Equipment and Leasehold Improvements link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Advances from Shareholders link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Term Loan link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Equipment and Leasehold Improvements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Derivative Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Capital Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Nature of the Business and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Equipment and Leasehold Improvements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Equipment and Leasehold Improvements - Schedule of Equipment and Leasehold Improvements (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Advances from Shareholders (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Term Loan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Convertible Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Convertible Notes - Schedule of Assumptions Used to Estimate Fair Value of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Derivative Liability - Schedule of Weighted Average Assumptions Used for Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Derivative Liability - Schedule of Derivative Liability Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Capital Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Capital Stock - Summary of Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Capital Stock - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Capital Stock - Schedule of Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Capital Stock - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Capital Stock - Schedule of Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Financial Instruments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Financial Instruments - Summary of Fair Value of Financial Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Financial Instruments - Summary of Changes in the Fair Value of Level 3 Financial Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 adynf-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 adynf-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 adynf-20170630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Warrants [Member] Additional Paid-In Capital [Member] Equity to be Issued [Member] Accumulated Deficit [Member] Property, Plant and Equipment, Type [Axis] Computer Equipment [Member] Production Equipment [Member] Leasehold Improvements [Member] Range [Axis] Maximum [Member] Legal Entity [Axis] Canadian Deposit Insurance Corporation [Member] Fair Value, Hierarchy [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Currency [Axis] USD [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Consulting Agreement [Member] Related Party Transaction [Axis] Agent [Member] Employment Agreements [Member] Connectus, Inc. [Member] GHS Investments, LLC [Member] Debt Instrument [Axis] Convertible Note [Member] Securities Purchase Agreement [Member] Securities Purchase Agreement and Convertible Note [Member] Minimum [Member] Term Loan [Member] Promissory Note [Member] Salamon Partners LLC [Member] Award Type [Axis] With in 60 Days [Member] With in 60 to 90 Days [Member] With in 90 to 120 Days [Member] Warrants [Member] Liability Class [Axis] Warrant Liability [Member] Derivative Liability [Member] Three Year Sponsored Research Contract [Member] Scenario [Axis] Year One [Member] Year Two [Member] Year Three [Member] Four Year Sponsored Research Contract [Member] Year Three [Member] One Year Agreement [Member] Midtown Warrants [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Related Party [Axis] Joint Venture [Member] ARA [Member] U.S. Patent Office [Member] After First Commercial Sale [Member] Report Date [Axis] July 28, 2017 [Member] June 21, 2017 [Member] Restricted Common Stock [Member] Equity Purchase Agreement [Member] Stock Based Compensation [Member] Award Date [Axis] December 31, 2017 [Member] January 17, 2022 [Member] Option Indexed to Issuer's Equity, Type [Axis] Options [Member] Exercise Price One [Member] Exercise Price Two [Member] Exercise Price Three [Member] Exercise Price Four [Member] Consulting Agreements [Member] The Eversull Group Inc [Member] Carter, Terry & Company [Member] Title of Individual [Axis] Officer [Member] Credit Facility [Axis] Canadian Chartered Bank [Member] Connectus Warrants [Member] Convertible Note Derivative Warrant Liability [Member] Fixed Price Convertible Note [Member] Kernaghan and Partners Ltd. [Member] Directors And Officers [Member] Mitacs Accelerate Program [Member] Loss Contingency Nature [Axis] Claim [Member] Bonify [Member] Three Management Personnel [Member] Convertible Notes [Member] Stock Options [Member] External Counsel [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Prepaid expenses Amounts receivable, net Total Current Assets Equipment and leasehold improvements, net (Note 3) Total Assets LIABILITIES Current Liabilities Accounts payable and accrued liabilities Advances from shareholders and related parties (Note 4) Promissory note (Note 6a) Term loan (Note 5) Convertible notes (Note 6b and 6c) Derivative liability (Note 7) Warrant liability (Note 8b) Total Current Liabilities Going Concern (Note 1) Commitments and Contingencies (Note 10) STOCKHOLDERS' (DEFICIENCY) Common stock (Note 8a), no par value, unlimited amount authorized, 13,337,521 issued and outstanding as of June 30, 2017, (March 31, 2017 - 13,337,521) Additional paid in capital (Notes 8b and 8c) Equity to be issued (Note 8a) Accumulated deficit Total Stockholders' (Deficiency) Total Liabilities and Stockholders' (Deficiency) Common stock, no par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Accretion expenses (Notes 5 and 6) Application and membership fees Amortization expense (Note 3) Bad debt recovery (Note 11) Business development Fair value change in derivative liability (Note 7) Foreign exchange gain Interest Management fee (recovery) Occupancy costs Office and general Professional fees (recovery) (Notes 8a, 8b, 8c and 12e) Research and development Stock based compensation (Note 8c) Telephone and internet services Travel Total Operating Expenses Net loss before income taxes Deferred income tax recovery Net Loss for the Period Net loss per common share - basic and diluted Weighted average common shares outstanding - basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Warrants expired (Note 8b) Stock based compensation (Notes 8c) Shares issued to consultants as compensation for services rendered (Note 8a) Net loss for the period Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Amortization Change in warrant liability (Note 8b) Shares issued and to be issued for services (Note 8a) Accretion expense Professional fees Change in operating assets and liabilities Prepaid expenses Amounts receivable Accounts payable and accrued liabilities Net cash flows used in operating activities Cash flows from financing activities Advances from shareholders Term loan proceeds Convertible notes Warrant exercise proceeds Net cash flows from financing activities Net change in cash Cash position - beginning of period Cash position - end of period Supplemental Information: Income taxes paid Interest paid Accounting Policies [Abstract] Nature of the Business and Going Concern Organization, Consolidation and Presentation of Financial Statements [Abstract] Presentation of Financial Statements Property, Plant and Equipment [Abstract] Equipment and Leasehold Improvements Related Party Transactions [Abstract] Advances from Shareholders Debt Disclosure [Abstract] Term Loan Convertible Notes Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Liability Equity [Abstract] Capital Stock Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions Investments, All Other Investments [Abstract] Financial Instruments Subsequent Events [Abstract] Subsequent Events Schedule of Equipment and Leasehold Improvements Schedule of Assumptions Used to Estimate Fair Value of Derivative Liability Schedule of Weighted Average Assumptions Used for Fair Value Measurement Schedule of Derivative Liability Activity Summary of Warrants Outstanding Schedule of Warrant Activity Schedule of Weighted Average Assumptions Schedule of Option Activity Schedule of Stock Options Outstanding and Exercisable Schedule of Future Minimum Rental Payments for Operating Leases Summary of Fair Value of Financial Liabilities Summary of Changes in the Fair Value of Level 3 Financial Liabilities Working capital deficiency Accumulated deficit Depreciation expense Property and Equipment, Cost Accumulated Depreciation Property and Equipment, net Advances from shareholders Term loan bridge financing Loan description Loan maturity, date Premium interest percent Accretion expenses Loan initial maturity date Sale of Stock [Axis] Debt instrument principal amount Debt instrument interest rate Proceeds from promissory note Convertible note purchase price Debt transaction cost Debt maturity date Prepayment penalty percentage Debt instrument description Debt instrument embedded conversion feature Debt effective interest rate Convertible debt common stock outstanding, percentage Accreted accretion expense Conversion price equal to lower trading price, percentage Convertible note Common share exercisable price per share Common stock conversion price per share Common stock trading price per share Stock issued during period, value Stock issued during period, share Number of common stock granted Warrant to purchase of common stock Warrant exercisable price per share Warrant term Warrant liability Stock price Risk free rate Expected volatility Conversion/Exercise price Expected dividend rate Expected life (in years) Conversion price Derivative liabilities balance, beginning of period Issuance of derivative liabilities during the period Change in derivative liabilities during the period Derivative liabilities balance, end of period Restricted common shares Restricted common shares, value Number of restricted common shares issued for commitment fee Number of common shares issued for commitment fee, value Committed to purchase up to company's common shares Agreement expiration Number of common share purchase warrants issued Proceeds from issuance of warrants Common stock warrant exercise price per share Warrants term Fair value of warrants granted Dividend yield Risk-free interest rate Expected volatility Expected term Number of warrants exercisable Fair value of warrants exercisable Fair value of reflected as liability Number of options outstanding Percentage of amount equivalent of issued and outstanding common shares Number of common shares issued and outstanding Number of Warrants Number of Exercisable Warrants Weighted Average Exercise Price Grant Date Fair Value Equity Fair Value at June 30, 2017 of Vested Warrants - Liability Number of Warrants, Beginning Balance Number of Warrants, Issued Number of Warrants, Expired, unexercised Number of Warrants, Ending Balance Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Issued Weighted Average Exercise Price, Expired, unexercised Weighted Average Exercise Price, Ending Balance Expected dividend yield Risk free interest rate Shares Outstanding, Beginning Shares Outstanding, Granted Shares Outstanding, Ending Weighted Average Exercise Price, Beginning Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Ending Weighted Average Exercise Price Shares Outstanding Weighted Average Remaining Contractual Life (Years) Options Exercisable Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Taxable income under canadian Federal Net operating loss carry forwards Operating loss carryforward expiration Operating lease term Operating lease expiry date Payment for rent Property taxes operating expenses Rental expenses Number of warrants issued during the period Number of warrants exercisable per share Number of warrants granted vested, shares Unvested portion vesting pro-rata raised in offering value Vested offering costs Number of common stock shares issued for compensation Number of warrants vested during the period Payment for commitments Contingent payments Available for sale combination of equity and or debt Agreement term Number of restricted common shares Percentage of placement fee equal to gross purchase price paid for equity Percentage of administrative fee of gross purchase price paid for equity Percentage of placement fee Percentage of common stock shares issuable upon exercise of conversion of all securities Payment for contribution Payments to researcher Amount for patent Gross sales Issued invoice value Consulting fee Precentage of introduction fee Minimum monthly retainer Precentage of gross funds Precentage of captial raised Bad debt recovery Amount receivable from an officer Allowance for doubtful accounts Current liabilities Warrant liability Term loan Convertible note Promissory note Derivative liability Contractual maturities Cash deposits Warrants to purchase, shares Warrants exercise price Derivative liability - Warrants Balance at beginning of period Derivative instruments granted or vested Derivative instruments exercised Derivative instruments issued Change in fair market value, recognized in operations as professional fees Change in fair market value, recognized in operations as fair value change in derivative liability Balance at end of period Ownership percentage Amount of proceeds raised from placement Purchase and installation of oil equipment Proceeds from issuance of common stock Number of common stock issued during the period Number of common stock share issued for purchase warrants Debt interest rate Debt instrument, term Payment of convertible note Work fee Description on agency fee Percentage of placement fee is equal to gross proceeds Stock granted, value Financial contribution Payments for installments Grant award balance Grant amount total Claim payment amount Claim hearing date Number of options granted, shares Number of cancelled common share Proceeds from convertible notes Agent [Member] custom:AgreementAxis Application and membership fees. Canadian Deposit Insurance Corporation [Member] Compensation For Services [Member] Connectus Inc [Member] Consultant In Settlement Of Debt [Member] Consultant [Member] Consulting Agreement [Member] Consulting Firm [Member] Convertible Note [Member] December 31, 2017 [Member] Directors Officers [Member] Employment Agreement [Member] Equity Purchase Agreement [Member] Equity to be issued. Equity to be Issued [Member] Equity to be Issued [Member] Exercise Price Four [Member] Exercise Price [Member] Exercise Price Three [Member] Exercise Price [Member] GHS Investments, LLC [Member] June 6, 2017 [Member] 90 Days [Member] Non-Refundable Retainer [Member] Officers And Consultants [Member] Production Equipment [Member] Proposed Placements [Member] Scenario [Member] Scenario [Member] Scenario [Member] Scenario [Member] Scenario [Member] Scenario [Member] Scenario [Member] Scenario [Member] Scenario [Member] Schedule of Warrant Activity [Table Text Block] Securities Purchase Agreement [Member] Stock Based Compensation [Member] Term Loan [Member] Two Directors And Officers [Member] Two Directors [Member] Two Officers And Directors [Member] USD [Member] Promissory Note [Member] Working capital deficiency. Loan initial maturity date. Salamon Partners LLC [Member] With In 60 Days [Member] With In 60 to 90 Days [Member] With In 90 to 120 Days [Member] Prepayment penalty percentage. Fair value of warrants exercisable. Fair value of reflected as liability. Percentage of amount equivalent of issued and outstanding common shares. Number of common shares issued and outstanding . January 17, 2022 [Member] Weighted average exercise price. Unvested portion vesting pro-rata raised in offering value. ShareBased Compensation Arrangement By ShareBased Payment Award NonOption Outstanding Exercise Price Rage Number of Share. Weighted Average Exercise Price, Issued. ShareBased Compensation Arrangement by ShareBased Payment Award Non Option Forfeited Or Expired in Period Exercise Price. Shares Outstanding. Operating lease term. Number of warrants issued during the period. Warrants term. Payment for commitments. Contingent payments. Agreement term. Percentage of placement fee equal to gross purchase price paid for equity. Percentage of administrative fee of gross purchase price paid for equity Percentage of placement fee. Percentage of common stock shares issuable upon exercise of conversion of all securities. Warrants [Member] April 1, 2017 [Member] Warrant liability. February 14, 2017 [Member] November 18, 2016 [Member] Derivative Liability [Member] Warrant Liability [Member] Conversion price equal to lower trading price, percentage. Securities Purchase Agreement and Convertible Note [Member] Issuance of derivative liability during the year. Change in derivative liabilities during the year. Consulting Agreements [Member] Offering [Member] Number of warrants exercisable. Payment for contribution. Year One [Member] Year Two [Member] Year Three [Member] Four Year Sponsored Research Contract [Member] Three Year Sponsored Research Contract [Member] Year Three [Member] One Year Agreement [Member] Director and Officer [Member] Derivative instruments granted or vested. Derivative instruments issued. Change in fair market value, recognized in operations as fair value change in derivative liability. Joint Venture [Member] ARA [Member] Percentage of placement fee is equal to gross proceeds. Number of common share purchase warrants issued. Warrant term. Notes [Member] Schedule of Assumptions Used to Measure Fair Value of Derivative Liability. Agreement expiration. Employees and Directors Share-based Payments [Member] Non-employee Awards [Member] Operating loss carryforward expiration. 2029 [Member] 2030 [Member] 2031 [Member] 2032 [Member] 2033 [Member] 2034 [Member] 2035 [Member] 2036 [Member] 2037 [Member] Amount for patent. U.S. Patent Office [Member] After First Commercial Sale [Member] Issued invoice value. July 28, 2017 [Member] September 1, 2017 [Member] December 1, 2017 [Member] March 1, 2018 [Member] April 1, 2018 and ending on January 1, 2021 [Member] Advances from Shareholders [Text Block] June 21, 2017 [Member] December 31, 2017 [Member] Precentage of introduction fee. Minimum monthly retainer. The Eversull Group Inc [Member] Carter, Terry & Company [Member] Precentage of gross funds. Precentage of captial raised. Canadian Chartered Bank [Member] Midtown Warrants [Member] Connectus Warrants [Member] Convertible Note Derivative Warrant Liability [Member] Fixed Price Convertible Note [Member] Kernaghan and Partners Ltd. [Member] Description on agency fee. Management Personnel One [Member] Management Personnel Three [Member] Management Personnel Two [Member] Going Concern. Amount of increase in additional paid in capital (APIC) resulting from warrants expired. A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Common share exercisable price per share. Mitacs Accelerate Program [Member] Claim [Member] Claim hearing date. Directors And Officers [Member] Warrant to purchase of common stock. Bonify [Member] Three Management Personnel [Member] Financial contribution. Grant award balance. Grant amount total. Convertible Notes [Member] Payments for installments. Stock Options [Member] External Counsel [Member] WarrantsMember YearFourMember Assets, Current Assets Stockholders' Equity Attributable to Parent Liabilities and Equity Derivative, Gain (Loss) on Derivative, Net Foreign Currency Transaction Gain (Loss), before Tax Operating Expenses Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net Deferred Income Tax Expense (Benefit) Net Income (Loss) Attributable to Parent Shares, Outstanding Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) Derivative Liability [Default Label] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisePriceRageNumberOfShare SharesOutstandingBeginning Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value EX-101.PRE 11 adynf-20170630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
3 Months Ended
Jun. 30, 2017
Jan. 02, 2018
Document And Entity Information    
Entity Registrant Name Algae Dynamics Corp.  
Entity Central Index Key 0001607679  
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Amendment Flag false  
Current Fiscal Year End Date --03-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   13,337,521
Trading Symbol ADYNF  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2018  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Interim Balance Sheets (Unaudited) - CAD
Jun. 30, 2017
Mar. 31, 2017
Current Assets    
Cash CAD 1,553 CAD 87
Prepaid expenses 74,745 32,878
Amounts receivable, net 13,335 11,963
Total Current Assets 89,633 44,928
Equipment and leasehold improvements, net (Note 3) 43,901 47,828
Total Assets 133,534 92,756
Current Liabilities    
Accounts payable and accrued liabilities 416,035 286,792
Advances from shareholders and related parties (Note 4) 29,122 22,347
Promissory note (Note 6a) 48,899 16,456
Term loan (Note 5) 50,796 48,894
Convertible notes (Note 6b and 6c) 67,953 26,076
Derivative liability (Note 7) 217,762 260,677
Warrant liability (Note 8b) 115,555 236,200
Total Current Liabilities 946,122 897,442
Going Concern (Note 1)
Commitments and Contingencies (Note 10)
STOCKHOLDERS' (DEFICIENCY)    
Common stock (Note 8a), no par value, unlimited amount authorized, 13,337,521 issued and outstanding as of June 30, 2017, (March 31, 2017 - 13,337,521) 4,313,931 4,313,931
Additional paid in capital (Notes 8b and 8c) 1,018,406 1,016,324
Equity to be issued (Note 8a) 86,372
Accumulated deficit (6,231,297) (6,134,941)
Total Stockholders' (Deficiency) (812,588) (804,686)
Total Liabilities and Stockholders' (Deficiency) CAD 133,534 CAD 92,756
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Interim Balance Sheets (Parenthetical) - CAD / shares
3 Months Ended 12 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Statement of Financial Position [Abstract]    
Common stock, no par value
Common stock, shares authorized Unlimited Unlimited
Common stock, shares issued 13,337,521 13,337,521
Common stock, shares outstanding 13,337,521 13,337,521
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Interim Statements of Operations (Unaudited) - CAD
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
OPERATING EXPENSES    
Accretion expenses (Notes 5 and 6) CAD 73,042 CAD 5,897
Application and membership fees 3,406 3,247
Amortization expense (Note 3) 3,927 4,356
Bad debt recovery (Note 11) (3,270)
Business development 422 2,486
Fair value change in derivative liability (Note 7) (61,047)
Foreign exchange gain (5,056)
Interest 2,039 1,045
Management fee (recovery) (8,125)
Occupancy costs 8,315 7,982
Office and general 2,936 1,607
Professional fees (recovery) (Notes 8a, 8b, 8c and 12e) (16,504) 154,755
Research and development 85,000 1,075
Stock based compensation (Note 8c) 18,192 151,105
Telephone and internet services 3,791 2,857
Travel 5,398 5,025
Total Operating Expenses 112,466 341,437
Net loss before income taxes 112,466 341,437
Deferred income tax recovery
Net Loss for the Period CAD 112,466 CAD 341,437
Net loss per common share - basic and diluted CAD 0.01 CAD 0.04
Weighted average common shares outstanding - basic and diluted 13,337,521 9,728,634
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Interim Statements of Stockholders' Equity (Deficiency) (Unaudited) - 3 months ended Jun. 30, 2017 - CAD
Common Stock [Member]
Additional Paid-In Capital [Member]
Equity to be Issued [Member]
Accumulated Deficit [Member]
Total
Balance at Mar. 31, 2017 CAD 4,313,931 CAD 1,016,324 CAD (6,134,941) CAD (804,686)
Balance, shares at Mar. 31, 2017 13,337,521        
Warrants expired (Note 8b) (16,110) 16,110
Stock based compensation (Notes 8c) 18,192 18,192
Shares issued to consultants as compensation for services rendered (Note 8a) 86,372 86,372
Net loss for the period (112,466) (112,466)
Balance at Jun. 30, 2017 CAD 4,313,931 CAD 1,018,406 CAD 86,372 CAD (6,231,297) CAD (812,588)
Balance, shares at Jun. 30, 2017 13,337,521        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Interim Statements of Cash Flows (Unaudited) - CAD
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash flows from operating activities    
Net loss for the period CAD (112,466) CAD (341,437)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization 3,927 4,356
Stock based compensation (Note 8c) 18,192 151,105
Change in warrant liability (Note 8b) (179,358) 21,783
Shares issued and to be issued for services (Note 8a) 86,372 48,651
Accretion expense 73,042 5,897
Foreign exchange gain (5,056)
Professional fees (13,898)
Change in operating assets and liabilities    
Prepaid expenses (41,867) 3,651
Amounts receivable (1,372) 254
Accounts payable and accrued liabilities 129,243 15,294
Net cash flows used in operating activities (43,241) (90,446)
Cash flows from financing activities    
Advances from shareholders 6,775 50,855
Term loan proceeds 40,000
Convertible notes 37,932
Warrant exercise proceeds 2,318
Net cash flows from financing activities 44,707 93,173
Net change in cash 1,466 2,727
Cash position - beginning of period 87 173
Cash position - end of period 1,553 2,900
Supplemental Information:    
Income taxes paid
Interest paid
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of the Business and Going Concern
3 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Nature of the Business and Going Concern

1.) Nature of the Business and Going Concern

 

Algae Dynamics Corp. (the “Company”) was incorporated under the Canada Business Corporations Act on October 7, 2008 as Converted Carbon of Canada Corp. On November 19, 2010, the Company amended its Articles of Incorporation to change its name to Converted Carbon Technologies Corp. and a further amendment was approved by the shareholders on August 28, 2014 to change the name to Algae Dynamics Corp.

 

The Company is conducting research through sponsored research agreements with two universities to support development of health products utilizing cannabis, hemp and algae oil. The Company’s planned principal operations are the sale of oil extracted from cannabis oils plus the sale of uniquely formulated health products utilizing cannabis oils, algae oils and hemp oils.

 

In May 2016, the Company signed a Letter of Engagement with Midtown Partners & Co, LLC to raise additional equity capital to support the implementation of its business plan; an addendum to this agreement was signed on January 17, 2017 and the agreement was extended for one year in August 2017. See Note 10.

 

On May 8, 2017, the Company signed an additional consulting agreement with Carter, Terry & Company in connection with the proposed capital raise in a combination of equity and/or debt of the Company for a term of two years. See Note 10.

 

In August 2017, the Company signed a Letter of Intent (LOI) with an authorized licensed producer of cannabis for medical purposes. See Note 13

 

The Company’s activities are subject to significant risks and uncertainties, including failing to obtain patents and failing to secure additional funding to operationalize the Company’s current technology before another company develops similar technology.

 

These unaudited condensed interim financial statements have been prepared on the basis of a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Company is in the development stage and has not yet realized profitable operations and has relied on non-operational sources to fund operations. The Company has suffered recurring losses and additional future losses are anticipated as the Company has not yet been able to generate revenue. In addition, as of June 30, 2017, the Company has a working capital deficiency of $856,489 (March 31, 2017 - $852,514) and an accumulated deficit of $6,231,297 (March 31, 2017 - $6,134,941). The Company’s ability to continue as a going concern is dependent on successfully executing its business plan, which includes the raising of additional funds. The Company will continue to seek additional forms of debt or equity financing, but it cannot provide assurances that it will be successful in doing so. These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Such adjustments could be material.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Presentation of Financial Statements
3 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Presentation of Financial Statements

2.) Presentation of Financial Statements

 

Basis of Presentation

 

These unaudited condensed interim financial statements should be read in conjunction with the financial statements for the Company’s most recently completed fiscal year ended March 31, 2017. These unaudited condensed interim financial statements do not include all disclosures required in annual financial statements, but rather are prepared in accordance with recommendations for interim financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These unaudited condensed interim financial statements have been prepared using the same accounting policies, and methods as those used by the Company in the annual financial statements for the year ended March 31, 2017, except when disclosed below.

 

The unaudited condensed interim financial statements contain all adjustments (consisting of only normal recurring adjustments) which are necessary to present fairly the financial position of the Company as at June 30, 2017, and the results of its operations for the three month periods ended June 30, 2017 and 2016 and its cash flows for the three month periods ended June 30, 2017 and 2016. Note disclosures have been presented for material updates to the information previously reported in the annual financial statements.

 

Estimates

 

The preparation of these unaudited condensed interim financial statements has required management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of the revenues and expenses during the reporting period.

 

On an ongoing basis, the Company evaluates its estimates, including those related to provision for doubtful accounts, accrued liabilities and contingencies, and the valuation of income taxes, stock based compensation, warrants, convertible debt and intangible assets. The Company bases its estimates on historical experiences and on various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates. As adjustments become necessary, they are reported in earnings in the period in which they become known.

 

New Accounting Pronouncements

 

ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, was issued to simplify the classification of deferred taxes on the balance sheet. The new guidance would require that deferred taxes be classified as non-current assets and liabilities based on the tax paying jurisdiction. Application of the standard, which can be applied prospectively or retrospectively, is required for fiscal years beginning on or after December 15, 2016 and for interim periods within that year. The adoption of the amended guidance does not have a material impact on the Company’s consolidated financial statements.

 

ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU includes multiple provisions intended to simplify various aspects of the accounting for share-based payments. The areas of simplification in the update involve several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows, however, some of the areas for simplification apply only to non-public entities. This guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The guidance does not have a material impact on the Company’s financial statements.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equipment and Leasehold Improvements
3 Months Ended
Jun. 30, 2017
Property, Plant and Equipment [Abstract]  
Equipment and Leasehold Improvements

3.) Equipment and Leasehold Improvements

 

    June 30, 2017     March 31, 2017  
          Accumulated           Accumulated  
    Cost     Depreciation     Cost     Depreciation  
Computer equipment   $ 3,558     $ 2,607     $ 3,558     $ 2,530  
Production equipment     67,367       37,249       67,367       35,663  
Leasehold improvements     42,290       29,458       42,290       27,194  
Total   $ 113,215     $ 69,314     $ 113,215     $ 65,387  
Net carrying amount           $ 43,901             $ 47,828  

 

During the three month period ended June 30, 2017, the Company recorded total depreciation of $3,927 (2016 - $4,356) which was recorded to depreciation expense on the condensed interim statements of operations.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Advances from Shareholders
3 Months Ended
Jun. 30, 2017
Related Party Transactions [Abstract]  
Advances from Shareholders

4.) Advances from Shareholders

 

As at June 30, 2017, the Company had received cumulative net working capital advances in the amount of $29,122 (March 31, 2017 - $22,347) from two shareholders who are also officers and directors of the Company. The advances from shareholders are unsecured, non-interest bearing and payable upon demand.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Term Loan
3 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Term Loan

5.) Term Loan

 

On May 4, 2016, the Company agreed to a term loan of $40,000 for bridge financing with a relative of one of the officers of the Company. The loan matured on November 30, 2017 and the terms specified a 30% premium to be paid at that time. The 30% premium is recognized as an expense over the term of the loan and is amortized on the statements of operations. During the period ended June 30, 2017 the Company recorded accretion expense of $1,902 (2016 - $5,897). The loan was initially scheduled to mature on August 28, 2016 but an extension of three months, followed by a second extension of three months and followed by a further extension to February 28, 2018 was agreed to with the same terms.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Convertible Notes
3 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Convertible Notes

6.) Convertible Notes
   
(a) Promissory Note

 

On February 14, 2017, the Company issued a promissory note to Salamon Partners LLC (“Salamon”), an arm’s length organization, for a principal amount of USD$50,000 ($65,350) at 12% per annum. The net proceeds were USD$47,500 which consisted of the principal amount, net of transaction cost of US$2,500. The principal amount became due on August 15, 2017. The outstanding amount may be prepaid at any time at the option of the Company. In the event of a prepayment the penalty rate shall be assessed as follows:

   

i.) if the prepayment occurs within 60 days of the loan issuance, the prepayment penalty will equal twenty-five (25%) of the principal amount prepaid

 

ii.) If the prepayment occurs within 60 to 90 days of the loan issuance, the prepayment penalty will equal thirty percent (30%) of the principal amount prepaid

 

iii.) If the prepayment occurs within 90 to 120 days of the loan, the prepayment penalty will equal thirty-five (35%) of the principal amount.

 

The holder of the note may, after a period of 180 days, at its sole option, convert the outstanding principal balance and accrued interest of 12% per annum, into the Company’s common shares at a market closing bid discount of 50% if converting at less than 5 days of the average trading volume, 60% if converting at more than 5 days of the average trading volume and 65% if converting at more than 10 days of the average trading volume at maturity.

 

Due to the variable conversion price associated with this promissory note and the fact that the conversion price is denominated in US dollars whereas the functional currency is the Canadian dollar, the Company has determined that the conversion feature is a derivative liability. The value of the embedded conversion feature at the date of issuance was estimated to be $135,510 (2016 - $Nil), which was recorded as a derivative liability as of the date of issuance. The debt discount is being amortized over the term of the promissory note.

 

The discount to the carrying value of the promissory note is being amortized as a non-cash interest expense over the term of the promissory note using the effective interest rate method, at a rate of 213%. During the period ended June 30, 2017, the Company accreted $33,623 (2016 - $Nil) in non-cash accretion expense in connection with the promissory note, which is included in accretion expense on the statements of operations.

 

Subsequent to the end of the quarter, the promissory note was fully paid at maturity, August 15, 2017. See Note 13.

 

(b) Securities Purchase Agreement and Convertible Note

 

On November 18, 2016, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with GHS Investments, LLC (“GHS”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, GHS shall purchase from the Company a senior convertible note with a principal amount of USD$56,500 ($76,382) for a purchase price of USD$50,000 ($67,595).

 

The convertible note matures upon the earlier of successfully raising of at least USD$200,000 or August 18, 2017 and accrues interest at the rate of 10% per annum. The convertible note is convertible following ninety (90) days of the execution of the note, in whole or in part, at GHS’ option into common shares of the Company’s capital stock at a variable conversion price equal to a 38% discount from the lowest trading price in the twenty (20) trading days prior to the day that GHS requests conversion. At no time will GHS be entitled to convert any portion of the convertible note to the extent that after such conversion, GHS (together with its affiliates) would beneficially own more than 4.99% of the outstanding common shares, although GHS can modify this limit to 9.99% of the outstanding common shares.

 

The convertible note includes customary event of default provisions, and provides for a default interest rate of 20%. The Company had the right at any time prior to May 18, 2017 to redeem all, but not less than all, of the total outstanding amount then remaining under the convertible note in cash at a price ranging from 125% to 135% of the total amount of the convertible note then outstanding.

 

Due to the variable conversion price associated with this convertible note, the Company has determined that the conversion feature is considered a derivative liability. The embedded conversion feature at the date of issuance was estimated to be $117,807 (2016 - $Nil), which was recorded as a derivative liability as of the date of issuance. The debt discount is being amortized over the term of the convertible note.

 

The discount to the carrying value of the convertible note is being amortized as a non-cash interest expense over the term of the convertible note using the effective interest rate method, at a rate of 144%. During the period ended June 30, 2017, the Company accreted $35,776 (2016 - $Nil) in non-cash accretion expense in connection with the convertible note, which is included in accretion expense on the statements of operations.

 

Subsequent to June 30, 2017 the note was fully paid. See Note 13.

 

(c) Convertible Note

 

On June 21, 2017, the Company commenced a financing of up to USD$500,000 of one-year 12% convertible notes. The notes are convertible at the option of the holder into common shares of the Company at a price of USD$0.25 per share, and are subject to mandatory conversion if the volume-weighted trading price of the common shares is greater than USD$1.00 per share for twenty consecutive trading days so long as the underlying shares may be resold in compliance with the registration requirements of the Securities Act of 1933, as amended. In addition, the Company shall issue pro rata to the purchasers of the first USD$100,000 of notes an aggregate of 200,000 common shares as a commitment fee. To June 30, 2017, the Company issued USD$50,000 ($66,451) of these notes. The Company also granted 200,000 common share purchase warrants to the holders of the USD$50,000 notes. Each warrant is exercisable into one common share at USD$0.50 ($0.65) for a period of five years.

  

Due to the fact that the conversion price and the warrant exercise price are denominated in US dollars whereas the functional currency is the Canadian dollar, the Company has determined that the conversion feature and the warrant are derivative liabilities. The value of the embedded conversion feature at the date of issuance was estimated to be $19,166, which was recorded as a derivative liability as of the date of issuance. The value of the warrant at the date of the issuance was estimated at $27,152, which was recorded as a warrant liability as of the date of issuance. The debt discount is being amortized over the term of the note.

 

The Company used the Black-Scholes option pricing model with the following assumptions to estimate the fair value of the derivative liability at the date of issuance:

 

    June 21, 2017
Stock price   USD$0.11
Risk free rate   0.91%
Expected volatility   251%
Conversion/Exercise price   USD$0.25
Expected dividend rate   0%
Expected term (in years)   1.0

 

The Company’s computation of expected volatility is based on the quoted market close price of the Company’s shares over the period equal to the expected life of the convertible note. The Company’s computation of expected life is calculated using the contractual life.

 

The discount to the carrying value of the convertible note is being amortized as a non-cash interest expense over the term of the convertible note using the effective interest rate method, at a rate of 103%. During the period ended June 30, 2017, the Company accreted $1,741 in non-cash accretion expense in connection with the convertible note, which is included in accretion expense on the statements of operations.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Liability
3 Months Ended
Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Liability

7.) Derivative Liability

 

The convertible notes discussed in Note 6 have variable conversion prices which results in the conversion feature being recorded as derivative liabilities.

 

The fair value of the derivative liabilities are recorded and shown separately under current liabilities. Changes in the fair value of the derivative liabilities are recorded in the statement of operations.

 

The Company used the Black-Scholes option pricing model with the following weighted average assumptions to estimate the fair value of the derivative liability at June 30, 2017:

 

    June 30, 2017
Stock price   USD$0.10
Risk free rate   1.09%
Expected volatility   186%
Conversion price   USD$0.06
Expected dividend rate   0%
Expected life (in years)   0.20

 

The Company’s computation of expected volatility used to estimate the fair value of the derivative liability as at June 30, 2017 is based on the quoted market close price of the Company’s shares over the period equal to the expected term of the conversion feature.

 

The following table represents the Company’s derivative liabilities activity for the period ended June 30, 2017:

 

    Three months        
    ended     Year ended  
    June 30, 2017     March 31, 2017  
             
Derivative liabilities balance, beginning of period   $ 260,677     $ -  
Issuance of derivative liabilities during the period     19,166       253,318  
Change in derivative liabilities during the period     (62,081 )     7,359  
Derivative liabilities balance, end of period   $ 217,762     $ 260,677  

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Stock
3 Months Ended
Jun. 30, 2017
Equity [Abstract]  
Capital Stock

8.) Capital Stock

 

(a) Common Shares

 

Authorized

 

The Company is authorized to issue an unlimited number of common shares with no par value.

 

Issued and Outstanding

  

Equity to be issued

 

On April 9, 2017 the Company signed a 12 month consulting agreement. The terms of the agreement include the provision of 100,000 restricted common shares on signing valued at USD$20,390 ($27,186). See Note10.

 

On May 8, 2017, the Company signed a consulting agreement with Carter, Terry & Company. The terms of the agreement include a non-refundable equity retainer on signing of 150,000 restricted common shares valued at USD$33,000 ($45,197). See Note 10. 

 

Under the terms of convertible notes issued on June 21, 2017 the Company agreed to issue 100,000 restricted common shares as a commitment fee. See Note 6 (c). This commitment was valued at $13,989 based on the estimated fair market value of the shares as of the date of commitment.

  

Equity Purchase Agreement (“EPA”)

 

On September 10, 2015, the Company entered into the EPA. The holder of the EPA was committed to purchase up to USD$750,000 worth of the Company’s common shares (the “Put Shares”) over the 12-month term of the EPA. The Company paid to the holder of the EPA a commitment fee for entering into the EPA equal to 50,000 restricted common shares of the Company, valued at $67,195, based on the stock price in the most recent private placement as the Company’s shares had not yet begun to trade on a public market.

 

On June 23, 2016, the Company agreed in conjunction with RY Capital Group, LLC and GHS Investments, LLC to assign the EPA to GHS Investments, LLC.

 

The Company has notified the holder of the EPA that the facility will not be utilized.

 

(b) Warrants

 

As at June 30, 2017, the following warrants were outstanding:

 

                          Fair Value at  
          Number of     Weighted         June 30, 2017  
Expiration Date   Number of
Warrants
    Warrants
Exercisable
    Average
Exercise Price
        of Vested Warrants – Liability  
December 31, 2017     275,000       50,000     USD$    0.04              
                    $ (0.05 )       $ 5,050  
January 17, 2022     900,000       900,000     USD$    0.65              
                    $ (0.87 )       $ 82,800  
June 21, 2017     200,000       200,000     USD$   0.50              
                    $ (0.65 )       $ 27,705  
      1,375,000       1,150,000     $ 0.67         $ 115,555  

 

During the period ended June 30, 2017, the Company issued 200,000 warrants of the Company valued at $27,152 (USD$20,400), pursuant to the financing described in Note 6 (c). Each warrant entitles the holder to purchase one common share at an issue price of USD$0.50 ($0.65) for a period of 5 years after the date of issuance. The fair value of the warrants at the date of grant of $27,152 was estimated using the Black-Scholes option pricing model, based on the following weighted average assumptions: stock price of USD$0.11; expected dividend yield of 0%; risk free interest rate of 1.13%; expected volatility of 221%; and expected term of 5 years. The Company’s computation of expected volatility used to estimate the fair value of the warrants as at June 30, 2017 is based on the market close price of comparable public entities over the period equal to the expected remaining life of the warrants.

 

ASC 815 “Derivatives and Hedging” indicates that warrants with exercise prices denominated in a currency other than an entity’s functional currency should not be classified as equity. As a result, warrants with a USD exercise price have been treated as derivatives and recorded as liabilities carried at their fair value, with period-to-period changes in the fair value recorded as a gain or loss in the statements of operations.

 

The continuity of warrants for the period ended June 30, 2017 as follows:

 

    Number     Weighted Average  
    of Warrants     Exercise Price  
Balance, March 31, 2017     1,197,500     $ 0.68  
Issued     200,000     $ 0.65  
Expired, unexercised     (22,500 )   $ 1.12  
Balance, June 30, 2017     1,375,000     $ 0.67  

 

As at June 30, 2017, the fair value of the 1,375,000 (March 31, 2017 – 1,175,000) warrants exercisable in US dollars was $139,180 (March 31, 2017 - $298,700) which was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:

 

    June 30, 2017     March 31, 2017  
Expected dividend yield     0 %     0 %
Expected volatility     175 %     229 %
Risk free interest rate     1.33 %     1.03 %
Expected term     3.97 years       3.85 years  

  

Of this amount, $115,555 (March 31, 2017 - $236,200) was reflected as a liability as at June 30, 2017, representing the percentage of the fair value of the warrants that is equal to the percentage of the requisite service that has been rendered at June 30, 2017.

 

The warrant liability is classified as Level 3 within the fair value hierarchy (See Note 12). The Company’s computation of expected volatility during the three months ended June 30, 2017 and 2016 is based on the market close price of comparable public entities over the period equal to the expected life of the warrants. The Company’s computation of expected life is calculated using the contractual life.

 

(c) Stock-based compensation

 

The Company’s stock-based compensation program (the “Plan”) includes stock options in which some options vest based on continuous service. For those equity awards that vest based on continuous service, compensation expense is recorded over the service period from the date of grant.

 

The total number of options outstanding as at June 30, 2017 was 695,000 (2016 – 930,000). No options were granted during the three months ended June 30, 2017. The maximum number of options that may be issued under the plan is floating at an amount equivalent to 15% of the issued and outstanding common shares, or 2,000,628 as at June 30, 2017 (March 31, 2017 – 2,000,628).

 

The activities in options outstanding are as noted below:

    Number of     Weighted Average  
    Options     Exercise Price  
Balance, March 31, 2017     695,000     $ 0.99  
Granted     -     $ -  
Balance, June 30, 2017     695,000     $ 0.99  

 

The following table presents information relating to stock options outstanding and exercisable at June 30, 2017.

 

      Options Outstanding     Options Exercisable  
            Weighted                 Weighted  
            Average           Weighted     Average  
            Remaining           Average     Remaining  
      Number of     Contractual     Number of     Exercise     Contractual  
Exercise Price     Options     Life (Years)     Options     Price     Life (Years)  
$ 1.73       185,000       2.46       185,000     $ 1.73       2.46  
$ 2.43       85,000       3.52       85,000     $ 2.43       3.52  
$ 0.38       425,000       4.33       155,833     $ 0.38       4.33  
$ 0.99       695,000       3.44       425,833     $ 1.38       3.35  

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
3 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes

9.) Income Taxes

 

The Company has no taxable income under Canadian Federal and provincial tax laws for the three month periods ended June 30, 2017 and 2016. The Company has non-capital loss carryforwards at June 30, 2017 totally approximately $3,702,500, which may be offset against future taxable income. If not used, the loss carryforwards will expire between 2019 and 2037.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
3 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

10.) Commitments and Contingencies

 

The Company entered into a five year operating lease for office and production facilities. The lease commenced on December 1, 2013 and expires on November 30, 2018. The base monthly rental is $1,390 plus the Company’s estimated portion of property taxes and operating expenses which are currently $847 per month. The future commitments pursuant to this lease arrangement, including property taxes and operating expenses for the fiscal periods ending March 31 are:

 

2018 (remaining)   $ 20,133  
2019   $ 17,896  

 

For the three month period ended June 30, 2017, occupancy costs related to this lease were $6,711 (2016 – $6,525).

 

On March 11, 2014, and as amended on July 18, September 3, 2014, September 5, 2014, December 31, 2015 and again on December 20, 2016, the Company entered into a consulting agreement with Connectus, Inc. (“Connectus”) to assist and advise the Company in matters concerning corporate finance and the Company’s current and proposed financing activities for the period commencing April 1, 2014 and ending December 31, 2014. Pursuant to this agreement, the Company agreed to issue to Connectus, 625,000 warrants of the Company. Each warrant is exercisable at USD$0.04 ($0.054) per share for a period of three years. Of the warrants granted, 300,000 vested on September 3, 2014 with the unvested portion vesting pro-rata for each USD$250,000 ($335,675) raised in an offering, fully vesting upon USD$1,500,000 ($2,014,050) being raised. During the year ended March 31, 2015, the President of Connectus became a director of the Company. On December 31, 2015, the Company extended the contract to December 31, 2016. In consideration of the contract extension, the Company issued 93,000 common shares to Connectus as compensation, which has been recorded as professional fees on the statements of operations during the year ended March 31, 2016. On December 27, 2016, the Company extended the contract and expiry date of the warrants to December 31, 2017. On January 23, 2017 the Company approved the vesting of 100,000 warrants. Connectus assigned the warrants to Apollo Marketing, LLC.

 

On April 23, 2014, the Company entered into employment agreements with three officers of the Company effective July 1, 2014. The initial contracts contain minimum aggregate commitments of approximately $427,000 per year for three years and additional contingent payments of up to approximately $600,000 in aggregate upon the occurrence of a change of control. The employment agreements were amended whereby any salary from the commencement of the employment agreements has been waived until such a time when the Company is able to raise additional financing. Salaries will be earned and paid at the discretion of the Board.

 

On May 19, 2016, the Company signed a consulting agreement with an agent in connection with proposed placements of up to USD$10,000,000 ($13,427,000) in a combination of equity and or debt of the Company for a term of one year. Consideration payable under the consulting agreement include a non-refundable equity retainer of 100,000 common shares of the Company , a placement fee equal to 8% of the gross purchase price paid for equity of the Company, an administrative fee of 4% of the gross purchase price paid for equity, a placement fee of 4% of the gross purchase price paid for non-convertible debt and warrants to purchase common shares of the Company equal to 8% of the number of shares of common stock issuable by the Company upon exercise or conversion of any and all securities issued at each closing. On January 10, 2017, the Company entered into an addendum to the agreement signed on May 19, 2016 which provided for a grant of 900,000 warrants at an exercise price of USD$0.65 ($0.86) for a period of five years with a cashless exercise option. On August 15, 2017 the Company extended the contract for an additional year.

  

On February 23, 2017, the Company entered into a three year sponsored research contract with the University of Waterloo commencing on April 1, 2017. Under the terms of the agreement the Company will contribute $130,000 upon start date of the project, $130,000 on completion of Year 1 and $130,000 on completion of Year 2, plus the Company will make an in-kind contribution valued at $70,000 in each of the 3 years. Any patents initiated by the Company from the sponsored research will be assigned to the Company and in return the Company will pay the researcher $10,000 per patent filed, $40,000 per patent issued by the U.S. patent office, $50,000 per product after the first commercial sale and $50,000 per product once the gross sales exceed $1,000,000. As of June 30, 2017, the Company has not made any payments pursuant to this agreement. The payment schedule has been amended to match the cash flow from the capital raise being undertaken by the Company.

 

On March 13, 2017, the Company entered into a four year sponsored research contract with the University of Western Ontario commencing on April 1, 2017. Under the terms of the agreement the Company will contribute $210,000 upon execution of the agreement, $210,000 on completion of Year 1, $210,000 on completion of Year 2 and $210,000 on completion of Year 3, plus the Company will make an in-kind contribution valued at $62,500 in each of the 4 years. Any patents initiated by the Company from the sponsored research will be assigned to the Company and in return the Company will pay the researcher $10,000 per patent filed, $40,000 per patent issued by the U.S. patent office, $50,000 per product after the first commercial sale and $50,000 per product once the gross sales exceed $1,000,000. As of June 30, 2017, the Company has not made any payments pursuant to this agreement. A payment of $50,000 was made on July 28, 2017. The payment schedule has been amended to match the cash flow from the capital raise being undertaken by the Company.

 

On March 27, 2017, the Company entered into a one year agreement with Questrade, Inc. an Investment Dealer to provide guidance on the trading of the Company’s securities and guidance with respect to the promotion of the Company. The Company shall pay Questrade a monthly fee in an amount equal to USD$5,500 for consulting services rendered each month of the term. See Note 13.

 

On April 9, 2017, the Company signed a 12 month consulting agreement effective April 15, 2017 with an arm’s length organization, The Eversull Group Inc, to provide financial public relations, investor, shareholder, press relations and capital search consulting services. Terms of the agreement include the provision of 100,000 restricted shares annually, a minimum monthly retainer of USD$ 2,000 plus a 3% introduction fee for all sources of funding introduced by The Eversull Group, Inc. and accepted by the Company.

 

On May 8, 2017, the Company signed a consulting agreement with Carter, Terry & Company in connection with the proposed raising of capital in a combination of equity and/or debt of the Company for a term of two years. Terms of the agreement include the issuance of 150,000 restricted common shares on signing (see Note 8(a)) plus future consideration payable under the consulting agreement including a placement fee equal to 10% of the gross proceeds raised less than USD$1,000,000 and 8% for gross funds raised in excess of USD$1,000,000, plus the equivalent amount of restricted shares equal to 4% of the capital raised divided by the closing price of the stock on the date of close for a period of two years.

 

See also Note 13 with respect to the Questrade, Inc. claim.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions
3 Months Ended
Jun. 30, 2017
Related Party Transactions [Abstract]  
Related Party Transactions

11.) Related Party Transactions

 

Amounts receivable from an officer in the amount of $3,270 was recovered during the three month period ended June 30, 2017, from an amount of $17,656 previously offset by an allowance for doubtful accounts, leaving a remaining balance in the doubtful account of $14,386.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financial Instruments
3 Months Ended
Jun. 30, 2017
Investments, All Other Investments [Abstract]  
Financial Instruments

12.) Financial Instruments

 

(a) Liquidity risk

 

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company’s liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company generates cash flow primarily from its financing activities and advances from shareholders. As at June 30, 2017, the Company had cash of $1,553 (March 31, 2017 - $87) to settle current liabilities of $946,122 (March 31, 2017 - $897,442). All of the Company’s financial liabilities other than the warrant liability of $115,555 (March 31, 2017 - $236,200), the term loan of $50,796 (March 31, 2017 - $48,894), the convertible notes of $67,952 (March 31, 2017 - $26,076) a promissory note of $48,899 (March 31, 2017 - $16,456), and derivative liability of $217,763 (March 31, 2017 - $260,677) have contractual maturities of less than 30 days and are subject to normal trade terms. The Company regularly evaluates its cash position to ensure preservation and security of capital as well as liquidity.

 

In the normal course of business, management considers various alternatives to ensure that the Company can meet some of its operating cash flow requirements through financing activities, such as private placements of common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. Management may also consider strategic alternatives, including strategic investments and divestitures. As future operations may be financed out of funds generated from financing activities, the ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the cannabis industry and the Company’s securities in particular. Should the Company elect to satisfy its cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that the efforts to obtain such additional funding will be successful, or achieved on terms favorable to the Company or its existing shareholders. If adequate funds are not available on favorable terms, the Company may have to reduce substantially or eliminate expenditures or obtain funds through other sources such as divestiture or monetization of certain assets or sublicensing (where permitted) of certain rights to certain of the Company’s technologies or products.

  

(b) Concentration of credit risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits. Cash deposits with a major Canadian chartered bank are insured by the Canadian Deposit Insurance Corporation up to $100,000. As at June 30, 2017, the Company held $1,553 (March 31, 2017 - $87) with a major Canadian chartered bank.

 

(c) Foreign exchange risk

 

The Company principally operates within Canada. The Company’s functional currency is the Canadian dollar and major purchases are transacted in Canadian dollars. Certain of the Company’s debt obligations are denominated in U.S. dollars. Management does not hedge its foreign exchange risk.

 

(d) Interest rate risk

 

As at June 30, 2017, the Company does not have any non-fixed interest-bearing debt. Management believes that the interest rate risk concentration with respect to financial instruments included in assets and liabilities has been reduced to the extent presently practicable.

 

(e) Derivative liability – warrant liability

 

In connection with consulting agreements, the Company granted warrants to purchase up to 1,175,000 common shares of the Company as disclosed in Note 8(b). The warrants have an exercise price of USD$0.04 ($0.052) for Connectus warrants, USD$0.65 ($0.85) for Midtown warrants and USD$0.50 ($0.65) for the investment place in June 2017. The Connectus warrants are exercisable at any time prior to December 31, 2017, the Midtown warrants are exercisable at any time prior to January 16, 2022 and the warrants for the investment undertaken in June are exerciseable prior to June 21, 2022. The warrants are accounted for as derivative liabilities because the exercise price is denominated in a currency other than the Company’s functional currency.

 

      Fair Value at       Fair Value Measurement Using
      June 30, 2017       Level 1       Level 2       Level 3  
Derivative liability – Warrants   $ 115,555     $ -     $ -     $ 115,555  

   

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (warrant derivative liability) for the periods ended June 30, 2017 and March 31, 2017:

 

    Three months        
    ended     Year ended  
    June 30, 2017     March 31, 2017  
Balance at beginning of year   $ 236,200     $ 27,479  
Derivative instruments granted or vested     27,152       633,000  
Derivative instruments exercised     -       (55,321 )
Change in fair market value, recognized in operations as professional fees     (147,797 )     (368,958 )
Balance at end of period   $ 115,555     $ 236,200  

 

See Note 8 (b)

  

(f) Derivative liability – conversion options

 

In connection with the Salamon promissory note and the convertible notes (Notes 6(a), (b) and (c)), the Company has determined that the conversion features are considered derivative liabilities due to the variable conversion prices associated with the notes and the fact that the conversion price is denominated in US dollars whereas the functional currency of the Company is the Canadian dollar. See Note 7.

 

      Fair Value at       Fair Value Measurement Using  
      June 30, 2017       Level 1       Level 2       Level 3  
Derivative liability – conversion options   $ 217,762     $ -     $ -     $ 217,762  

 

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (convertible note derivative liability) for the periods ended June 30, 2017 and March 31, 2017:

 

    Three months ended     Year ended
    June 30, 2017     March 31, 2017
Balance at beginning of period   $ 260,677       $ Nil  
Derivative instruments issued     19,166         253,318  
Change in fair market value, recognized in operations as fair value change in derivative liability     (62,081 )       7,359  
Balance at end of period   $ 217,762       $ 260,677  

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events
3 Months Ended
Jun. 30, 2017
Subsequent Events [Abstract]  
Subsequent Events

13.) Subsequent Events

 

On April 19, 2017, the Company announced plans to form a joint venture corporation with Avanti Rx Analytics Inc. (ARA). The Company would own 96% of the joint venture and ARA would own 4%. As a result of signing the letter of Intent with Bonify on August 10, 2017 (details provided below) the Company will not be proceeding with the joint venture.

 

During the quarter ended June 30, 2017, the Company commenced a financing of up to USD$500,000, see Note 6 (c). The convertible notes include a provision that if the Company raises additional funds under more favourable terms during the life of the convertible note, then the more favourable terms will apply. The Company did raise $358,000 under more favourable terms, see details below, convertible notes.

 

On August 8, 2017, the Company signed a non-binding Letter of Intent (LOI) with 6779264 Manitoba Ltd dba Bonify (“Bonify”). Bonify is a licensed producer, pursuant to the Access to Cannabis for Medical Purposes Regulations in Canada. In the LOI the Company and Bonify have outlined the following:

 

i) The purchase and installation of cannabis oil extraction equipment with an estimated cost of $1,450,000 to be jointly agreed upon by the Company and Bonify with the equipment being located in Bonify’s facility. At the end of the agreement, full right and title to the equipment would be assigned to Bonify;
   
ii) The processing of cannabis material supplied by Bonify and other licensed producers in the oil extraction facility;
   
iii) The supply of cannabis oil and algae omega-3 oils to The University of Waterloo and University of Western Ontario to support the sponsored research agreements that the Company has in place with the two universities (See Note 10);
   
iv) The sharing of direct expenses, and, after adjustment for the market value of cannabis material supplied by Bonify and third parties, sharing of revenues from the sale of cannabis oil and algae-cannabis oil products; and
   
v) The negotiation of a definitive agreement no later than September 30, 2017. The definitive agreement is still being negotiated.

 

Convertible Notes

 

Subsequent to June 30, 2017, the Company raised a total of USD$408,000 ($520,160) through the issue of convertible notes. The convertible notes, totalling USD$358,000 have a maturity of 60 days, an interest rate of 10%, a conversion price of USD$0.07 per share if the price on or around 15 days before maturity is less than US$0.10 or USD$0.10 per share if the closing price per share is USD$0.10 or above at the conversion dates. For the initial convertible note issued on July 25, 2017, of USD$50,000, the Company committed to issue 100,000 common shares as a commitment fee, the maturity is twelve months from the issue date, the interest rate is 12%, plus the Company granted 200,000 common share purchase warrants. . Each warrant is exercisable into one common share at USD$0.50 ($0.65) for a period of five years. See Note 6(c).

 

Part of the proceeds from the convertible notes has been used to repay the convertible notes payable to Salamon Partners LLC and GHS Investments. See Notes 6(a) and (b).

 

See Note 10 for the $50,000 payment made to the University of Western Ontario. 

 

On August 15, 2017, the Company engaged a Canadian firm, Kernaghan and Partners Ltd. (the Agent) a fully regulated full service brokerage firm to conduct a capital raise in the Canadian market. In consideration of the services to be rendered the Agents shall receive on the closing date of the offering;

 

i) a work fee of $25,000;
   
ii) cash commission (the Agency Fee”) of 6% of the gross proceeds from the sale of common shares pursuant to the offering, except for sales to persons on the “President’s List”, in respect of which the commission shall be reduced to 2% of the gross proceeds received from such persons;
   
iii) broker warrants entitling the Agent to purchase, equal to the issue price, the number of common shares that is equal to 6% of the number of common shares sold pursuant to the offering, except for sales to persons on the “President’s List”, in respect of which the broker warrants shall entitle the Agent to purchase the number of common shares that is equal to 2% of the number of common shares sold to such persons. The broker warrants shall have a term of 2 years and an exercise price equal to the offering price of the common shares.

 

On October 24, 2017, the Company was named in Small Claims Court entitled Questrade, Inc. versus Algae Dynamics Corp. (the “Claim”).  The Claim seeks payment of $25,000 for payments allegedly owed under a Consulting Agreement with the Company in which Questrade was to provide certain financial advisory services.  The Company has filed a general denial of liability on the basis that services were not provided or alternately disputing the amount claimed. A hearing date of February 6, 2018 has been set.

 

Grant award

 

The Company, as the industry partner, is a participant in a Project Grant of up to $400,000 from the Mitacs Accelerate program, that will be delivered directly by Western University through eligible internships. The financial contribution by the Company which is $180,000 for this grant is part of the funding included in the research agreement the Company signed with the university and announced on March 13, 2017. To-date the Company has paid the initial of six installments to Mitacs, with the remaining installments being invoiced throughout the duration of the project. The balance of the $400,000 award ($220,000) will be provided by Mitacs. The project started on December 1, 2017 and is scheduled to operate for two (2) years. The extent of the announced award from Mitacs of $400,000 to be paid directly to the university is dependent on the funding provided by the Company and on the number of interns actually employed in the project.

 

On November 8, 2017, the Board approved the grant of 850,000 stock options for common shares to directors and officers of the Company (800,000) and external counsel (50,000). In addition, the Board approved the award of an aggregate of 1,050,000 common shares to three management personnel for services rendered, plus the Board cancelled an aggregate of 600,000 common shares awarded in a prior period to the three management personnel.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equipment and Leasehold Improvements (Tables)
3 Months Ended
Jun. 30, 2017
Property, Plant and Equipment [Abstract]  
Schedule of Equipment and Leasehold Improvements

    June 30, 2017     March 31, 2017  
          Accumulated           Accumulated  
    Cost     Depreciation     Cost     Depreciation  
Computer equipment   $ 3,558     $ 2,607     $ 3,558     $ 2,530  
Production equipment     67,367       37,249       67,367       35,663  
Leasehold improvements     42,290       29,458       42,290       27,194  
Total   $ 113,215     $ 69,314     $ 113,215     $ 65,387  
Net carrying amount           $ 43,901             $ 47,828  

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Convertible Notes (Tables)
3 Months Ended
Jun. 30, 2017
June 21, 2017 [Member]  
Schedule of Assumptions Used to Estimate Fair Value of Derivative Liability

The Company used the Black-Scholes option pricing model with the following assumptions to estimate the fair value of the derivative liability at the date of issuance:

 

    June 21, 2017
Stock price   USD$0.11
Risk free rate   0.91%
Expected volatility   251%
Conversion/Exercise price   USD$0.25
Expected dividend rate   0%
Expected term (in years)   1.0

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Liability (Tables)
3 Months Ended
Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Weighted Average Assumptions Used for Fair Value Measurement

The Company used the Black-Scholes option pricing model with the following weighted average assumptions to estimate the fair value of the derivative liability at June 30, 2017:

 

    June 30, 2017
Stock price   USD$0.10
Risk free rate   1.09%
Expected volatility   186%
Conversion price   USD$0.06
Expected dividend rate   0%
Expected life (in years)   0.20

Schedule of Derivative Liability Activity

The following table represents the Company’s derivative liabilities activity for the period ended June 30, 2017:

 

    Three months        
    ended     Year ended  
    June 30, 2017     March 31, 2017  
             
Derivative liabilities balance, beginning of period   $ 260,677     $ -  
Issuance of derivative liabilities during the period     19,166       253,318  
Change in derivative liabilities during the period     (62,081 )     7,359  
Derivative liabilities balance, end of period   $ 217,762     $ 260,677  

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Stock (Tables)
3 Months Ended
Jun. 30, 2017
Equity [Abstract]  
Summary of Warrants Outstanding

                          Fair Value at  
          Number of     Weighted         June 30, 2017  
Expiration Date   Number of
Warrants
    Warrants
Exercisable
    Average
Exercise Price
        of Vested Warrants – Liability  
December 31, 2017     275,000       50,000     USD$    0.04              
                    $ (0.05 )       $ 5,050  
January 17, 2022     900,000       900,000     USD$    0.65              
                    $ (0.87 )       $ 82,800  
June 21, 2017     200,000       200,000     USD$   0.50              
                    $ (0.65 )       $ 27,705  
      1,375,000       1,150,000     $ 0.67         $ 115,555  

Schedule of Warrant Activity

The continuity of warrants for the period ended June 30, 2017 as follows:

 

    Number     Weighted Average  
    of Warrants     Exercise Price  
Balance, March 31, 2017     1,197,500     $ 0.68  
Issued     200,000     $ 0.65  
Expired, unexercised     (22,500 )   $ 1.12  
Balance, June 30, 2017     1,375,000     $ 0.67  

Schedule of Weighted Average Assumptions

As at June 30, 2017, the fair value of the 1,375,000 (March 31, 2017 – 1,175,000) warrants exercisable in US dollars was $139,180 (March 31, 2017 - $298,700) which was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:

 

    June 30, 2017     March 31, 2017  
Expected dividend yield     0 %     0 %
Expected volatility     175 %     229 %
Risk free interest rate     1.33 %     1.03 %
Expected term     3.97 years       3.85 years  

Schedule of Option Activity

The activities in options outstanding are as noted below:

    Number of     Weighted Average  
    Options     Exercise Price  
Balance, March 31, 2017     695,000     $ 0.99  
Granted     -     $ -  
Balance, June 30, 2017     695,000     $ 0.99  

Schedule of Stock Options Outstanding and Exercisable

The following table presents information relating to stock options outstanding and exercisable at June 30, 2017.

 

      Options Outstanding     Options Exercisable  
            Weighted                 Weighted  
            Average           Weighted     Average  
            Remaining           Average     Remaining  
      Number of     Contractual     Number of     Exercise     Contractual  
Exercise Price     Options     Life (Years)     Options     Price     Life (Years)  
$ 1.73       185,000       2.46       185,000     $ 1.73       2.46  
$ 2.43       85,000       3.52       85,000     $ 2.43       3.52  
$ 0.38       425,000       4.33       155,833     $ 0.38       4.33  
$ 0.99       695,000       3.44       425,833     $ 1.38       3.35  

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Tables)
3 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases

The future commitments pursuant to this lease arrangement, including property taxes and operating expenses for the fiscal periods ending March 31 are:

 

2018 (remaining)   $ 20,133  
2019   $ 17,896  

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financial Instruments (Tables)
3 Months Ended
Jun. 30, 2017
Summary of Fair Value of Financial Liabilities

      Fair Value at       Fair Value Measurement Using  
      June 30, 2017       Level 1       Level 2       Level 3  
Derivative liability – conversion options   $ 217,762     $ -     $ -     $ 217,762  

Summary of Changes in the Fair Value of Level 3 Financial Liabilities

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (convertible note derivative liability) for the periods ended June 30, 2017 and March 31, 2017:

 

    Three months ended     Year ended
    June 30, 2017     March 31, 2017
Balance at beginning of period   $ 260,677       $ Nil  
Derivative instruments issued     19,166         253,318  
Change in fair market value, recognized in operations as fair value change in derivative liability     (62,081 )       7,359  
Balance at end of period   $ 217,762       $ 260,677  

Warrant Liability [Member]  
Summary of Fair Value of Financial Liabilities

      Fair Value at       Fair Value Measurement Using
      June 30, 2017       Level 1       Level 2       Level 3  
Derivative liability – Warrants   $ 115,555     $ -     $ -     $ 115,555  

Summary of Changes in the Fair Value of Level 3 Financial Liabilities

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (warrant derivative liability) for the periods ended June 30, 2017 and March 31, 2017:

 

    Three months        
    ended     Year ended  
    June 30, 2017     March 31, 2017  
Balance at beginning of year   $ 236,200     $ 27,479  
Derivative instruments granted or vested     27,152       633,000  
Derivative instruments exercised     -       (55,321 )
Change in fair market value, recognized in operations as professional fees     (147,797 )     (368,958 )
Balance at end of period   $ 115,555     $ 236,200  

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of the Business and Going Concern (Details Narrative) - CAD
Jun. 30, 2017
Mar. 31, 2017
Accounting Policies [Abstract]    
Working capital deficiency CAD 856,489 CAD 852,514
Accumulated deficit CAD 6,231,297 CAD 6,134,941
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equipment and Leasehold Improvements (Details Narrative) - CAD
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Property, Plant and Equipment [Abstract]    
Depreciation expense CAD 3,927 CAD 4,356
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equipment and Leasehold Improvements - Schedule of Equipment and Leasehold Improvements (Details) - CAD
Jun. 30, 2017
Mar. 31, 2017
Property and Equipment, Cost CAD 113,215 CAD 113,215
Accumulated Depreciation 69,314 65,387
Property and Equipment, net 43,901 47,828
Computer Equipment [Member]    
Property and Equipment, Cost 3,558 3,558
Accumulated Depreciation 2,607 2,530
Production Equipment [Member]    
Property and Equipment, Cost 67,367 67,367
Accumulated Depreciation 37,249 35,663
Leasehold Improvements [Member]    
Property and Equipment, Cost 42,290 42,290
Accumulated Depreciation CAD 29,458 CAD 27,194
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Advances from Shareholders (Details Narrative) - CAD
Jun. 30, 2017
Mar. 31, 2017
Related Party Transactions [Abstract]    
Advances from shareholders CAD 29,122 CAD 22,347
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Term Loan (Details Narrative) - CAD
3 Months Ended
May 04, 2016
Jun. 30, 2017
Jun. 30, 2016
Term loan bridge financing CAD 40,000    
Loan description bridge financing with a relative of one of the officers of the Company.    
Loan maturity, date Nov. 30, 2017    
Premium interest percent 30.00%    
Accretion expenses   CAD 73,042 CAD 5,897
Loan initial maturity date Aug. 28, 2016    
Term Loan [Member]      
Accretion expenses   CAD 1,902 CAD 5,897
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Convertible Notes (Details Narrative)
3 Months Ended
Jun. 21, 2017
CAD
CAD / shares
Jun. 21, 2017
USD ($)
shares
Feb. 14, 2017
USD ($)
Nov. 18, 2016
CAD
Nov. 18, 2016
USD ($)
May 04, 2016
Jun. 30, 2017
CAD
CAD / shares
shares
Jun. 30, 2017
USD ($)
shares
Jun. 30, 2016
CAD
Jun. 30, 2017
$ / shares
Jun. 21, 2017
$ / shares
Feb. 14, 2017
CAD
Feb. 14, 2017
USD ($)
Nov. 18, 2016
USD ($)
Debt instrument interest rate           30.00%                
Convertible note purchase price             CAD 37,932            
Debt maturity date           Nov. 30, 2017                
Debt instrument description           bridge financing with a relative of one of the officers of the Company.                
Debt effective interest rate                       213.00% 213.00%  
Accretion expenses             73,042   5,897          
Common share exercisable price per share | CAD / shares CAD 0.65                          
Warrant liability             CAD (179,358)   21,783          
Securities Purchase Agreement and Convertible Note [Member]                            
Debt instrument interest rate       20.00%     144.00%             20.00%
Debt instrument embedded conversion feature             CAD 117,807            
Accreted accretion expense             25,978            
Securities Purchase Agreement and Convertible Note [Member] | Maximum [Member]                            
Debt instrument interest rate       135.00%                   135.00%
Securities Purchase Agreement and Convertible Note [Member] | Minimum [Member]                            
Debt instrument interest rate       125.00%                   125.00%
Promissory Note [Member]                            
Debt instrument embedded conversion feature             135,510            
Accretion expenses             33,623            
Convertible Note [Member]                            
Debt instrument embedded conversion feature             CAD 19,166              
Debt effective interest rate             103.00%              
Accretion expenses             CAD 1,741              
Stock issued during period, value             CAD 66,451              
Stock issued during period, share | shares   200,000                        
Number of common stock granted | shares             200,000 200,000            
Warrant to purchase of common stock             CAD 50,000              
Warrant exercisable price per share | CAD / shares             CAD 0.65              
Warrant term             5 years 5 years            
Warrant liability             CAD 27,152              
USD [Member]                            
Debt instrument interest rate 12.00%                          
Convertible note CAD 500,000                          
Common share exercisable price per share | CAD / shares CAD 0.50                          
Common stock conversion price per share | $ / shares                     $ 0.25      
USD [Member] | Promissory Note [Member] | Securities Purchase Agreement and Convertible Note [Member]                            
Common stock conversion price per share | $ / shares                     $ 0.25      
USD [Member] | Convertible Note [Member]                            
Common stock trading price per share | CAD / shares CAD 1.00                          
Stock issued during period, value | $   $ 100,000           $ 50,000            
Warrant exercisable price per share | $ / shares                   $ 0.50        
Salamon Partners LLC [Member]                            
Debt instrument principal amount                       CAD 65,350    
Debt instrument interest rate                       12.00% 12.00%  
Debt maturity date     Aug. 15, 2017                      
Debt instrument description     The holder of the note may, after a period of 180 days, at its sole option, convert the outstanding principal balance and accrued interest of 12% per annum, into the Company’s common shares at a market closing bid discount of 50% if converting at less than 5 days of the average trading volume, 60% if converting at more than 5 days of the average trading volume and 65% if converting at more than 10 days of the average trading volume at maturity.                      
Salamon Partners LLC [Member] | With in 60 Days [Member]                            
Prepayment penalty percentage                       25.00% 25.00%  
Salamon Partners LLC [Member] | With in 60 to 90 Days [Member]                            
Prepayment penalty percentage                       30.00% 30.00%  
Salamon Partners LLC [Member] | With in 90 to 120 Days [Member]                            
Prepayment penalty percentage                       35.00% 35.00%  
Salamon Partners LLC [Member] | USD [Member]                            
Debt instrument principal amount | $                         $ 50,000  
Proceeds from promissory note | $     $ 47,500                      
Debt transaction cost | $     $ 2,500                      
GHS Investments, LLC [Member] | Maximum [Member]                            
Debt instrument interest rate       4.99%                   4.99%
GHS Investments, LLC [Member] | Securities Purchase Agreement [Member]                            
Debt instrument principal amount       CAD 76,382                    
Convertible note purchase price       67,595                    
GHS Investments, LLC [Member] | Convertible Note [Member]                            
Debt instrument principal amount       CAD 200,000                    
Debt instrument interest rate       10.00%                   10.00%
Debt maturity date       Aug. 18, 2017 Aug. 18, 2017                  
Convertible debt common stock outstanding, percentage       9.99% 9.99%                  
Conversion price equal to lower trading price, percentage       38.00% 38.00%                  
GHS Investments, LLC [Member] | USD [Member] | Securities Purchase Agreement [Member]                            
Debt instrument principal amount | $                           $ 56,500
Convertible note purchase price | $         $ 50,000                  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Convertible Notes - Schedule of Assumptions Used to Estimate Fair Value of Derivative Liability (Details)
Jun. 21, 2017
$ / shares
USD [Member]  
Conversion/Exercise price $ 0.25
Promissory Note [Member] | Securities Purchase Agreement and Convertible Note [Member]  
Risk free rate 0.91%
Expected volatility 251.00%
Expected dividend rate 0.00%
Expected life (in years) 1 year
Promissory Note [Member] | USD [Member] | Securities Purchase Agreement and Convertible Note [Member]  
Stock price $ 0.11
Conversion/Exercise price $ 0.25
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Liability - Schedule of Weighted Average Assumptions Used for Fair Value Measurement (Details)
3 Months Ended
Jun. 30, 2017
CAD / shares
Jun. 30, 2017
$ / shares
Jun. 21, 2017
$ / shares
USD [Member]      
Conversion price     $ 0.25
Derivative Liability [Member]      
Risk free rate 1.09%    
Expected volatility 186.00%    
Expected dividend rate 0.00%    
Expected life (in years) 2 months 12 days    
Derivative Liability [Member] | USD [Member]      
Stock price | CAD / shares CAD .10    
Conversion price   $ 0.06  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Liability - Schedule of Derivative Liability Activity (Details) - CAD
3 Months Ended 12 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Derivative liabilities balance, beginning of period CAD 260,677
Issuance of derivative liabilities during the period 19,166 253,318
Change in derivative liabilities during the period (62,081) 7,359
Derivative liabilities balance, end of period CAD 217,762 CAD 260,677
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Stock (Details Narrative)
3 Months Ended 12 Months Ended
May 08, 2017
CAD
shares
Apr. 09, 2017
CAD
shares
Apr. 09, 2017
USD ($)
shares
Jan. 10, 2017
Sep. 10, 2015
CAD
shares
Sep. 10, 2015
USD ($)
shares
Jun. 30, 2017
CAD
CAD / shares
shares
Jun. 30, 2016
CAD
shares
Mar. 31, 2017
CAD
shares
Fair value of warrants granted             CAD (179,358) CAD 21,783  
Dividend yield             0.00%   0.00%
Risk-free interest rate             1.33%   1.03%
Expected volatility             175.00%   229.00%
Expected term             3 years 11 months 19 days   3 years 10 months 6 days
Warrants [Member]                  
Number of common share purchase warrants issued | shares             200,000    
Proceeds from issuance of warrants             CAD 27,152    
Common stock warrant exercise price per share | CAD / shares             CAD 0.65    
Warrants term             5 years    
Fair value of warrants granted             CAD 27,152    
Dividend yield             0.00%    
Risk-free interest rate             1.13%    
Expected volatility             221.00%    
Expected term             5 years    
Number of warrants exercisable | shares             1,375,000   1,175,000
Fair value of reflected as liability             CAD 115,555   CAD 236,200
Stock Based Compensation [Member]                  
Number of options outstanding | shares             695,000 930,000  
Percentage of amount equivalent of issued and outstanding common shares             15.00%    
Number of common shares issued and outstanding | shares             2,000,628   2,000,628
USD [Member] | Warrants [Member]                  
Proceeds from issuance of warrants             CAD 20,400    
Common stock warrant exercise price per share | CAD / shares             CAD 0.50    
Stock price | CAD / shares             CAD 0.11    
Fair value of warrants exercisable             CAD 139,180   CAD 298,700
Consulting Agreement [Member]                  
Restricted common shares | shares   100,000 100,000            
Restricted common shares, value   CAD 27,186              
Common stock warrant exercise price per share | CAD / shares             CAD 0.65    
Warrants term       5 years          
Consulting Agreement [Member] | Restricted Common Stock [Member]                  
Restricted common shares | shares 150,000                
Restricted common shares, value CAD 45,197                
Number of restricted common shares issued for commitment fee | shares 100,000                
Consulting Agreement [Member] | USD [Member]                  
Restricted common shares, value CAD 33,000   $ 20,390            
Number of common shares issued for commitment fee, value CAD 13,989                
Common stock warrant exercise price per share | CAD / shares             CAD 0.50    
Equity Purchase Agreement [Member] | USD [Member]                  
Restricted common shares | shares         50,000 50,000      
Restricted common shares, value         CAD 67,195        
Committed to purchase up to company's common shares | $           $ 750,000      
Agreement expiration         expired in September 2016 expired in September 2016      
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Stock - Summary of Warrants Outstanding (Details)
3 Months Ended
Sep. 03, 2014
CAD
Sep. 03, 2014
USD ($)
Jun. 30, 2017
CAD
CAD / shares
shares
Warrants [Member]      
Number of Warrants | shares     1,375,000
Number of Exercisable Warrants | shares     1,150,000
Weighted Average Exercise Price | CAD / shares     CAD 0.67
Grant Date Fair Value Equity | CAD    
Fair Value at June 30, 2017 of Vested Warrants - Liability | CAD CAD 2,014,050   CAD 115,555
USD [Member] | Warrants [Member]      
Fair Value at June 30, 2017 of Vested Warrants - Liability | $   $ 1,500,000  
December 31, 2017 [Member]      
Number of Warrants | shares     275,000
Number of Exercisable Warrants | shares     50,000
Weighted Average Exercise Price | CAD / shares     CAD (0.05)
Grant Date Fair Value Equity | CAD    
Fair Value at June 30, 2017 of Vested Warrants - Liability | CAD     CAD 5,050
December 31, 2017 [Member] | USD [Member]      
Weighted Average Exercise Price | CAD / shares     CAD 0.04
January 17, 2022 [Member]      
Number of Warrants | shares     900,000
Number of Exercisable Warrants | shares     900,000
Weighted Average Exercise Price | CAD / shares     CAD (0.87)
Grant Date Fair Value Equity | CAD    
Fair Value at June 30, 2017 of Vested Warrants - Liability | CAD     CAD 82,800
January 17, 2022 [Member] | USD [Member]      
Weighted Average Exercise Price | CAD / shares     CAD 0.65
June 21, 2017 [Member]      
Number of Warrants | shares     200,000
Number of Exercisable Warrants | shares     200,000
Weighted Average Exercise Price | CAD / shares     CAD 0.50
Grant Date Fair Value Equity | CAD    
Fair Value at June 30, 2017 of Vested Warrants - Liability | CAD     CAD 27,705
June 21, 2017 [Member] | USD [Member]      
Weighted Average Exercise Price | CAD / shares     CAD (0.65)
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Stock - Schedule of Warrant Activity (Details) - Warrants [Member]
3 Months Ended
Jun. 30, 2017
CAD / shares
shares
Number of Warrants, Beginning Balance | shares 1,197,500
Number of Warrants, Issued | shares 200,000
Number of Warrants, Expired, unexercised | shares (22,500)
Number of Warrants, Ending Balance | shares 1,375,000
Weighted Average Exercise Price, Beginning Balance | CAD / shares CAD 0.68
Weighted Average Exercise Price, Issued | CAD / shares 0.65
Weighted Average Exercise Price, Expired, unexercised | CAD / shares 1.12
Weighted Average Exercise Price, Ending Balance | CAD / shares CAD 0.67
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Stock - Schedule of Weighted Average Assumptions (Details)
3 Months Ended 12 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Equity [Abstract]    
Expected dividend yield 0.00% 0.00%
Expected volatility 175.00% 229.00%
Risk free interest rate 1.33% 1.03%
Expected term 3 years 11 months 19 days 3 years 10 months 6 days
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Stock - Schedule of Option Activity (Details) - Options [Member]
3 Months Ended
Jun. 30, 2017
CAD / shares
shares
Shares Outstanding, Beginning | shares 695,000
Shares Outstanding, Granted | shares
Shares Outstanding, Ending | shares 695,000
Weighted Average Exercise Price, Beginning | CAD / shares CAD 0.99
Weighted Average Exercise Price, Granted | CAD / shares
Weighted Average Exercise Price, Ending | CAD / shares CAD 0.99
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Stock - Schedule of Stock Options Outstanding and Exercisable (Details)
3 Months Ended
Jun. 30, 2017
CAD / shares
shares
Exercise Price One [Member]  
Weighted Average Exercise Price | CAD / shares CAD 1.73
Shares Outstanding | shares 185,000
Weighted Average Remaining Contractual Life (Years) 2 years 5 months 16 days
Options Exercisable | shares 185,000
Weighted Average Exercise Price | CAD / shares CAD 1.73
Weighted Average Remaining Contractual Life (Years) 2 years 5 months 16 days
Exercise Price Two [Member]  
Weighted Average Exercise Price | CAD / shares CAD 2.43
Shares Outstanding | shares 85,000
Weighted Average Remaining Contractual Life (Years) 3 years 6 months 7 days
Options Exercisable | shares 85,000
Weighted Average Exercise Price | CAD / shares CAD 2.43
Weighted Average Remaining Contractual Life (Years) 3 years 6 months 7 days
Exercise Price Three [Member]  
Weighted Average Exercise Price | CAD / shares CAD 0.38
Shares Outstanding | shares 425,000
Weighted Average Remaining Contractual Life (Years) 4 years 3 months 29 days
Options Exercisable | shares 155,833
Weighted Average Exercise Price | CAD / shares CAD 0.38
Weighted Average Remaining Contractual Life (Years) 4 years 3 months 29 days
Exercise Price Four [Member]  
Weighted Average Exercise Price | CAD / shares CAD 0.99
Shares Outstanding | shares 695,000
Weighted Average Remaining Contractual Life (Years) 3 years 5 months 9 days
Options Exercisable | shares 425,833
Weighted Average Exercise Price | CAD / shares CAD 1.38
Weighted Average Remaining Contractual Life (Years) 3 years 4 months 6 days
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details Narrative) - CAD
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Income Tax Disclosure [Abstract]    
Taxable income under canadian Federal
Net operating loss carry forwards CAD 3,702,500  
Operating loss carryforward expiration expire between 2019 and 2037  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details Narrative)
3 Months Ended 12 Months Ended
May 08, 2017
CAD
shares
Apr. 09, 2017
CAD
shares
Mar. 27, 2017
CAD
Mar. 13, 2017
CAD
Feb. 23, 2017
CAD
Jan. 23, 2017
shares
Jan. 10, 2017
CAD / shares
shares
May 19, 2016
CAD
shares
Sep. 03, 2014
CAD
shares
Sep. 03, 2014
USD ($)
shares
Apr. 23, 2014
CAD
Dec. 02, 2013
Jun. 30, 2017
CAD
shares
Jun. 30, 2016
CAD
Mar. 31, 2016
shares
Mar. 31, 2017
CAD / shares
Mar. 31, 2017
$ / shares
Jan. 10, 2017
$ / shares
May 19, 2016
USD ($)
Operating lease term                       5 years              
Operating lease expiry date                       Nov. 30, 2018              
Payment for rent                         CAD 1,390            
Property taxes operating expenses                         847            
Rental expenses                         6,711 CAD 6,525          
Gross sales                         1,000,000            
Consulting fee                         CAD 418,875 CAD 427,000          
Connectus, Inc. [Member]                                      
Number of common stock shares issued for compensation | shares                             93,000        
The Eversull Group Inc [Member]                                      
Number of restricted common shares | shares   100,000                                  
Precentage of introduction fee   3.00%                                  
Carter, Terry & Company [Member]                                      
Agreement term 2 years                                    
Number of restricted common shares | shares 150,000                                    
Percentage of placement fee equal to gross purchase price paid for equity 10.00%                                    
Precentage of gross funds 8.00%                                    
Precentage of captial raised 4.00%                                    
USD [Member] | The Eversull Group Inc [Member]                                      
Minimum monthly retainer   CAD 2,000                                  
USD [Member] | Carter, Terry & Company [Member]                                      
Gross sales CAD 1,000,000                                    
USD [Member] | Carter, Terry & Company [Member] | Maximum [Member]                                      
Number of restricted common shares | shares 1,000,000                                    
Warrants [Member]                                      
Number of warrants exercisable per share | CAD / shares                               CAD 0.054      
Warrants term                         5 years            
Number of warrants granted vested, shares | shares                 300,000 300,000                  
Unvested portion vesting pro-rata raised in offering value                 CAD 335,675                    
Vested offering costs                 CAD 2,014,050       CAD 115,555            
Warrants [Member] | Connectus, Inc. [Member]                                      
Number of warrants vested during the period | shares           100,000                          
Warrants [Member] | USD [Member]                                      
Number of warrants exercisable per share | $ / shares                                 $ 0.04    
Unvested portion vesting pro-rata raised in offering value | $                   $ 250,000                  
Vested offering costs | $                   $ 1,500,000                  
Consulting Agreements [Member] | Warrants [Member]                                      
Number of warrants issued during the period | shares                         625,000            
Warrants term                         3 years            
Employment Agreements [Member]                                      
Payment for commitments                     CAD 427,000                
Contingent payments                     CAD 600,000                
Consulting Agreement [Member]                                      
Number of warrants issued during the period | shares             900,000                        
Number of warrants exercisable per share | CAD / shares             CAD 0.86                        
Warrants term             5 years                        
Number of restricted common shares | shares   100,000                                  
Consulting Agreement [Member] | Agent [Member]                                      
Available for sale combination of equity and or debt               CAD 13,427,000                      
Agreement term               1 year                      
Number of restricted common shares | shares               100,000                      
Percentage of placement fee equal to gross purchase price paid for equity               8.00%                     8.00%
Percentage of administrative fee of gross purchase price paid for equity               4.00%                     4.00%
Percentage of placement fee               4.00%                     4.00%
Percentage of common stock shares issuable upon exercise of conversion of all securities               8.00%                     8.00%
Consulting Agreement [Member] | USD [Member]                                      
Number of warrants exercisable per share | $ / shares                                   $ .65  
Consulting Agreement [Member] | USD [Member] | Agent [Member]                                      
Available for sale combination of equity and or debt | $                                     $ 10,000,000
Three Year Sponsored Research Contract [Member]                                      
Payment for contribution         CAD 130,000                            
Payments to researcher         10,000                            
Gross sales         50,000                            
Three Year Sponsored Research Contract [Member] | Maximum [Member]                                      
Gross sales         1,000,000                            
Three Year Sponsored Research Contract [Member] | After First Commercial Sale [Member]                                      
Amount for patent         50,000                            
Three Year Sponsored Research Contract [Member] | Year One [Member]                                      
Payment for contribution         130,000                            
Three Year Sponsored Research Contract [Member] | Year Two [Member]                                      
Payment for contribution         130,000                            
Three Year Sponsored Research Contract [Member] | Year Three [Member]                                      
Payment for contribution         70,000                            
Three Year Sponsored Research Contract [Member] | U.S. Patent Office [Member]                                      
Amount for patent         CAD 40,000                            
Four Year Sponsored Research Contract [Member]                                      
Payment for contribution       CAD 210,000                              
Payments to researcher       10,000                              
Gross sales       50,000                              
Four Year Sponsored Research Contract [Member] | July 28, 2017 [Member]                                      
Payment for commitments                         CAD 50,000            
Four Year Sponsored Research Contract [Member] | Maximum [Member]                                      
Gross sales       1,000,000                              
Four Year Sponsored Research Contract [Member] | After First Commercial Sale [Member]                                      
Amount for patent       50,000                              
Four Year Sponsored Research Contract [Member] | Year One [Member]                                      
Payment for contribution       210,000                              
Four Year Sponsored Research Contract [Member] | Year Two [Member]                                      
Payment for contribution       210,000                              
Four Year Sponsored Research Contract [Member] | Year Three [Member]                                      
Payment for contribution       210,000                              
Four Year Sponsored Research Contract [Member] | U.S. Patent Office [Member]                                      
Amount for patent       40,000                              
Four Year Sponsored Research Contract [Member] | Year Three [Member]                                      
Payment for contribution       CAD 62,500                              
One Year Agreement [Member]                                      
Consulting fee     CAD 5,500                                
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions (Details Narrative) - CAD
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Bad debt recovery CAD 3,270
Officer [Member]    
Amount receivable from an officer 17,656  
Allowance for doubtful accounts CAD 14,386  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financial Instruments (Details Narrative) - CAD
12 Months Ended
Mar. 31, 2017
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2016
Cash CAD 87 CAD 1,553 CAD 2,900 CAD 173
Current liabilities 897,442 946,122    
Warrant liability 236,200 115,555    
Term loan 48,894 50,796    
Convertible note 26,076 67,953    
Promissory note 16,456 48,899    
Derivative liability 260,677 CAD 217,762    
Consulting Agreement [Member]        
Warrants to purchase, shares   1,175,000    
Warrants exercise price   CAD 0.65    
Consulting Agreement [Member] | Connectus Warrants [Member]        
Warrants exercise price   0.052    
Consulting Agreement [Member] | Midtown Warrants [Member]        
Warrants exercise price   0.85    
Consulting Agreement [Member] | USD [Member]        
Warrants exercise price   0.50    
Consulting Agreement [Member] | USD [Member] | Connectus Warrants [Member]        
Warrants exercise price   0.04    
Consulting Agreement [Member] | USD [Member] | Midtown Warrants [Member]        
Warrants exercise price   CAD 0.65    
Canadian Chartered Bank [Member]        
Cash CAD 87 CAD 1,553    
Canadian Deposit Insurance Corporation [Member]        
Cash deposits   CAD 100,000    
Maximum [Member]        
Contractual maturities 30 days      
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financial Instruments - Summary of Fair Value of Financial Liabilities (Details)
Jun. 30, 2017
CAD
Derivative liability - Warrants CAD 217,762
Warrant Liability [Member]  
Derivative liability - Warrants 115,555
Level 1 [Member]  
Derivative liability - Warrants
Level 1 [Member] | Warrant Liability [Member]  
Derivative liability - Warrants
Level 2 [Member]  
Derivative liability - Warrants
Level 2 [Member] | Warrant Liability [Member]  
Derivative liability - Warrants
Level 3 [Member]  
Derivative liability - Warrants 217,762
Level 3 [Member] | Warrant Liability [Member]  
Derivative liability - Warrants CAD 115,555
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financial Instruments - Summary of Changes in the Fair Value of Level 3 Financial Liabilities (Details) - CAD
3 Months Ended 12 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Warrant Liability [Member]    
Balance at beginning of period CAD 236,200 CAD 27,479
Derivative instruments granted or vested 27,152 633,000
Derivative instruments exercised (55,321)
Change in fair market value, recognized in operations as professional fees (147,797) (368,958)
Balance at end of period 115,555 236,200
Convertible Note Derivative Warrant Liability [Member]    
Balance at beginning of period 260,677
Derivative instruments issued 19,166 253,318
Change in fair market value, recognized in operations as fair value change in derivative liability (62,081) 7,359
Balance at end of period CAD 217,762 CAD 260,677
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events (Details Narrative)
3 Months Ended
Nov. 08, 2017
shares
Oct. 24, 2017
CAD
Aug. 15, 2017
CAD
Aug. 08, 2017
CAD
Jun. 21, 2017
CAD
CAD / shares
shares
Jun. 30, 2017
CAD
CAD / shares
shares
Jun. 30, 2017
USD ($)
shares
Jun. 30, 2016
CAD
Jun. 30, 2017
$ / shares
Jun. 21, 2017
$ / shares
Apr. 19, 2017
May 04, 2016
Debt interest rate                       30.00%
Work fee           CAD (16,504)   CAD 154,755        
Proceeds from convertible notes           CAD 37,932          
Convertible Note [Member]                        
Number of common stock issued during the period | shares         200,000              
Warrant exercisable price per share | CAD / shares           CAD 0.65            
Warrant term           5 years 5 years          
Number of options granted, shares | shares           200,000 200,000          
USD [Member]                        
Convertible note         CAD 500,000              
Debt interest rate         12.00%              
Common stock conversion price per share | $ / shares                   $ 0.25    
USD [Member] | Convertible Note [Member]                        
Warrant exercisable price per share | $ / shares                 $ 0.50      
Common stock trading price per share | CAD / shares         CAD 1.00              
Subsequent Event [Member] | Directors And Officers [Member]                        
Number of options granted, shares | shares 800,000                      
Subsequent Event [Member] | External Counsel [Member]                        
Number of options granted, shares | shares 50,000                      
Subsequent Event [Member] | Three Management Personnel [Member]                        
Number of options granted, shares | shares 1,050,000                      
Number of cancelled common share | shares 600,000                      
Subsequent Event [Member] | Stock Options [Member]                        
Number of options granted, shares | shares 850,000                      
Subsequent Event [Member] | Mitacs Accelerate Program [Member]                        
Stock granted, value     CAD 400,000                  
Financial contribution           CAD 180,000            
Grant award balance           400,000            
Grant amount total           220,000            
Subsequent Event [Member] | Claim [Member]                        
Claim payment amount   CAD 25,000                    
Claim hearing date   Feb. 06, 2018                    
Subsequent Event [Member] | Fixed Price Convertible Note [Member]                        
Convertible note           CAD 520,160            
Number of common stock issued during the period | shares           100,000 100,000          
Number of common stock share issued for purchase warrants | shares           200,000            
Warrant exercisable price per share | CAD / shares           CAD 0.65            
Warrants term           5 years 5 years          
Debt interest rate           10.00%            
Debt instrument, term           45 days 45 days          
Payment of convertible note           CAD 50,000            
Subsequent Event [Member] | Convertible Notes [Member]                        
Common stock trading price per share | CAD / shares           CAD 0.12            
Subsequent Event [Member] | Bonify [Member]                        
Purchase and installation of oil equipment       CAD 1,450,000                
Subsequent Event [Member] | Kernaghan and Partners Ltd. [Member]                        
Work fee     CAD 25,000                  
Description on agency fee     Cash commission (the “Agency Fee”) of 6% of the gross proceeds from the sale of Common Shares pursuant to the offering, except for sales to persons on the “president’s list”, in respect of which the commission shall be reduced to 2% of the gross proceeds received from such persons;                  
Warrant term     2 years                  
Percentage of placement fee is equal to gross proceeds     6.00%                  
Subsequent Event [Member] | Kernaghan and Partners Ltd. [Member] | Minimum [Member]                        
Percentage of placement fee is equal to gross proceeds     2.00%                  
Subsequent Event [Member] | USD [Member]                        
Convertible note           CAD 500,000            
Amount of proceeds raised from placement           358,000            
Subsequent Event [Member] | USD [Member] | Fixed Price Convertible Note [Member]                        
Convertible note           CAD 408,000            
Proceeds from issuance of common stock | $             $ 50,000          
Warrant exercisable price per share | $ / shares                 0.50      
Common stock trading price per share | CAD / shares           CAD 0.10            
Subsequent Event [Member] | USD [Member] | Fixed Price Convertible Note [Member] | Minimum [Member]                        
Common stock conversion price per share | $ / shares                 $ 0.07      
Subsequent Event [Member] | USD [Member] | Fixed Price Convertible Note [Member] | Maximum [Member]                        
Common stock conversion price per share | CAD / shares           CAD 0.10            
Subsequent Event [Member] | USD [Member] | Convertible Note [Member]                        
Convertible note           CAD 358,000            
Subsequent Event [Member] | Joint Venture [Member]                        
Ownership percentage                     96.00%  
Subsequent Event [Member] | ARA [Member]                        
Ownership percentage                     4.00%  
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 60 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 190 234 1 false 75 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://algaedynamics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Interim Balance Sheets (Unaudited) Sheet http://algaedynamics.com/role/InterimBalanceSheets Condensed Interim Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Interim Balance Sheets (Parenthetical) Sheet http://algaedynamics.com/role/InterimBalanceSheetsParenthetical Condensed Interim Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Interim Statements of Operations (Unaudited) Sheet http://algaedynamics.com/role/InterimStatementsOfOperations Condensed Interim Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Interim Statements of Stockholders' Equity (Deficiency) (Unaudited) Sheet http://algaedynamics.com/role/InterimStatementsOfStockholdersEquityDeficiency Condensed Interim Statements of Stockholders' Equity (Deficiency) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Interim Statements of Cash Flows (Unaudited) Sheet http://algaedynamics.com/role/InterimStatementsOfCashFlows Condensed Interim Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of the Business and Going Concern Sheet http://algaedynamics.com/role/NatureOfBusinessAndGoingConcern Nature of the Business and Going Concern Notes 7 false false R8.htm 00000008 - Disclosure - Presentation of Financial Statements Sheet http://algaedynamics.com/role/PresentationOfFinancialStatements Presentation of Financial Statements Notes 8 false false R9.htm 00000009 - Disclosure - Equipment and Leasehold Improvements Sheet http://algaedynamics.com/role/EquipmentAndLeaseholdImprovements Equipment and Leasehold Improvements Notes 9 false false R10.htm 00000010 - Disclosure - Advances from Shareholders Sheet http://algaedynamics.com/role/AdvancesFromShareholders Advances from Shareholders Notes 10 false false R11.htm 00000011 - Disclosure - Term Loan Sheet http://algaedynamics.com/role/TermLoan Term Loan Notes 11 false false R12.htm 00000012 - Disclosure - Convertible Notes Notes http://algaedynamics.com/role/ConvertibleNotes Convertible Notes Notes 12 false false R13.htm 00000013 - Disclosure - Derivative Liability Sheet http://algaedynamics.com/role/DerivativeLiability Derivative Liability Notes 13 false false R14.htm 00000014 - Disclosure - Capital Stock Sheet http://algaedynamics.com/role/CapitalStock Capital Stock Notes 14 false false R15.htm 00000015 - Disclosure - Income Taxes Sheet http://algaedynamics.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://algaedynamics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Related Party Transactions Sheet http://algaedynamics.com/role/RelatedPartyTransactions Related Party Transactions Notes 17 false false R18.htm 00000018 - Disclosure - Financial Instruments Sheet http://algaedynamics.com/role/FinancialInstruments Financial Instruments Notes 18 false false R19.htm 00000019 - Disclosure - Subsequent Events Sheet http://algaedynamics.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - Equipment and Leasehold Improvements (Tables) Sheet http://algaedynamics.com/role/EquipmentAndLeaseholdImprovementsTables Equipment and Leasehold Improvements (Tables) Tables http://algaedynamics.com/role/EquipmentAndLeaseholdImprovements 20 false false R21.htm 00000021 - Disclosure - Convertible Notes (Tables) Notes http://algaedynamics.com/role/ConvertibleNotesTables Convertible Notes (Tables) Tables http://algaedynamics.com/role/ConvertibleNotes 21 false false R22.htm 00000022 - Disclosure - Derivative Liability (Tables) Sheet http://algaedynamics.com/role/DerivativeLiabilityTables Derivative Liability (Tables) Tables http://algaedynamics.com/role/DerivativeLiability 22 false false R23.htm 00000023 - Disclosure - Capital Stock (Tables) Sheet http://algaedynamics.com/role/CapitalStockTables Capital Stock (Tables) Tables http://algaedynamics.com/role/CapitalStock 23 false false R24.htm 00000024 - Disclosure - Commitments and Contingencies (Tables) Sheet http://algaedynamics.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://algaedynamics.com/role/CommitmentsAndContingencies 24 false false R25.htm 00000025 - Disclosure - Financial Instruments (Tables) Sheet http://algaedynamics.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://algaedynamics.com/role/FinancialInstruments 25 false false R26.htm 00000026 - Disclosure - Nature of the Business and Going Concern (Details Narrative) Sheet http://algaedynamics.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative Nature of the Business and Going Concern (Details Narrative) Details http://algaedynamics.com/role/NatureOfBusinessAndGoingConcern 26 false false R27.htm 00000027 - Disclosure - Equipment and Leasehold Improvements (Details Narrative) Sheet http://algaedynamics.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative Equipment and Leasehold Improvements (Details Narrative) Details http://algaedynamics.com/role/EquipmentAndLeaseholdImprovementsTables 27 false false R28.htm 00000028 - Disclosure - Equipment and Leasehold Improvements - Schedule of Equipment and Leasehold Improvements (Details) Sheet http://algaedynamics.com/role/EquipmentAndLeaseholdImprovements-ScheduleOfEquipmentAndLeaseholdImprovementsDetails Equipment and Leasehold Improvements - Schedule of Equipment and Leasehold Improvements (Details) Details 28 false false R29.htm 00000029 - Disclosure - Advances from Shareholders (Details Narrative) Sheet http://algaedynamics.com/role/AdvancesFromShareholdersDetailsNarrative Advances from Shareholders (Details Narrative) Details http://algaedynamics.com/role/AdvancesFromShareholders 29 false false R30.htm 00000030 - Disclosure - Term Loan (Details Narrative) Sheet http://algaedynamics.com/role/TermLoanDetailsNarrative Term Loan (Details Narrative) Details http://algaedynamics.com/role/TermLoan 30 false false R31.htm 00000031 - Disclosure - Convertible Notes (Details Narrative) Notes http://algaedynamics.com/role/ConvertibleNotesDetailsNarrative Convertible Notes (Details Narrative) Details http://algaedynamics.com/role/ConvertibleNotesTables 31 false false R32.htm 00000032 - Disclosure - Convertible Notes - Schedule of Assumptions Used to Estimate Fair Value of Derivative Liability (Details) Notes http://algaedynamics.com/role/ConvertibleNotes-ScheduleOfAssumptionsUsedToEstimateFairValueOfDerivativeLiabilityDetails Convertible Notes - Schedule of Assumptions Used to Estimate Fair Value of Derivative Liability (Details) Details 32 false false R33.htm 00000033 - Disclosure - Derivative Liability - Schedule of Weighted Average Assumptions Used for Fair Value Measurement (Details) Sheet http://algaedynamics.com/role/DerivativeLiability-ScheduleOfWeightedAverageAssumptionsUsedForFairValueMeasurementDetails Derivative Liability - Schedule of Weighted Average Assumptions Used for Fair Value Measurement (Details) Details 33 false false R34.htm 00000034 - Disclosure - Derivative Liability - Schedule of Derivative Liability Activity (Details) Sheet http://algaedynamics.com/role/DerivativeLiability-ScheduleOfDerivativeLiabilityActivityDetails Derivative Liability - Schedule of Derivative Liability Activity (Details) Details 34 false false R35.htm 00000035 - Disclosure - Capital Stock (Details Narrative) Sheet http://algaedynamics.com/role/CapitalStockDetailsNarrative Capital Stock (Details Narrative) Details http://algaedynamics.com/role/CapitalStockTables 35 false false R36.htm 00000036 - Disclosure - Capital Stock - Summary of Warrants Outstanding (Details) Sheet http://algaedynamics.com/role/CapitalStock-SummaryOfWarrantsOutstandingDetails Capital Stock - Summary of Warrants Outstanding (Details) Details 36 false false R37.htm 00000037 - Disclosure - Capital Stock - Schedule of Warrant Activity (Details) Sheet http://algaedynamics.com/role/CapitalStock-ScheduleOfWarrantActivityDetails Capital Stock - Schedule of Warrant Activity (Details) Details 37 false false R38.htm 00000038 - Disclosure - Capital Stock - Schedule of Weighted Average Assumptions (Details) Sheet http://algaedynamics.com/role/CapitalStock-ScheduleOfWeightedAverageAssumptionsDetails Capital Stock - Schedule of Weighted Average Assumptions (Details) Details 38 false false R39.htm 00000039 - Disclosure - Capital Stock - Schedule of Option Activity (Details) Sheet http://algaedynamics.com/role/CapitalStock-ScheduleOfOptionActivityDetails Capital Stock - Schedule of Option Activity (Details) Details 39 false false R40.htm 00000040 - Disclosure - Capital Stock - Schedule of Stock Options Outstanding and Exercisable (Details) Sheet http://algaedynamics.com/role/CapitalStock-ScheduleOfStockOptionsOutstandingAndExercisableDetails Capital Stock - Schedule of Stock Options Outstanding and Exercisable (Details) Details 40 false false R41.htm 00000041 - Disclosure - Income Taxes (Details Narrative) Sheet http://algaedynamics.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://algaedynamics.com/role/IncomeTaxes 41 false false R42.htm 00000042 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://algaedynamics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://algaedynamics.com/role/CommitmentsAndContingenciesTables 42 false false R43.htm 00000043 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://algaedynamics.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://algaedynamics.com/role/RelatedPartyTransactions 43 false false R44.htm 00000044 - Disclosure - Financial Instruments (Details Narrative) Sheet http://algaedynamics.com/role/FinancialInstrumentsDetailsNarrative Financial Instruments (Details Narrative) Details http://algaedynamics.com/role/FinancialInstrumentsTables 44 false false R45.htm 00000045 - Disclosure - Financial Instruments - Summary of Fair Value of Financial Liabilities (Details) Sheet http://algaedynamics.com/role/FinancialInstruments-SummaryOfFairValueOfFinancialLiabilitiesDetails Financial Instruments - Summary of Fair Value of Financial Liabilities (Details) Details 45 false false R46.htm 00000046 - Disclosure - Financial Instruments - Summary of Changes in the Fair Value of Level 3 Financial Liabilities (Details) Sheet http://algaedynamics.com/role/FinancialInstruments-SummaryOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails Financial Instruments - Summary of Changes in the Fair Value of Level 3 Financial Liabilities (Details) Details 46 false false R47.htm 00000047 - Disclosure - Subsequent Events (Details Narrative) Sheet http://algaedynamics.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://algaedynamics.com/role/SubsequentEvents 47 false false All Reports Book All Reports adynf-20170630.xml adynf-20170630.xsd adynf-20170630_cal.xml adynf-20170630_def.xml adynf-20170630_lab.xml adynf-20170630_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/currency/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 65 0001493152-18-000410-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-000410-xbrl.zip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end

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